| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
BioMarin Pharmaceutical Inc.$59.12
-0.76 (-1.27%)
B 75Pipeline Score Undervalued Biotech · Commercial
Market Cap
10.45 B
EPS
1.40
P/E Ratio
39.47 $
Value Trade
123.66 M
SEC Financials
Q1 2026Dilution Risk
Revenue
766.21 M
R&D Expenses
178.80 M
Operating CF
220.65 M
Total Assets
8.59 B
Total Liabilities
2.38 B
Equity
6.21 B
D/E Ratio
12,345
1.27 %
Week
-1.47 %
1 Month
-14.27 %
3 Month
2.6 %
6 Month
-31.51 %
5 Year
260.6 %
All Time
Cash Data
Cash Position
2.22 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 5, 2026
Overview
Volume
1.56 M
52 Week Range
49.26 - 66.28
% held by Insiders
1.61 %
% held by Institutions
100.59 %
Enterprise Value
9.68 B
Total Shares
193.32 M
Short %
7.25 %
Float Shares
191.97 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for BioMarin Pharmaceutical Inc.
1558Total events
17Upcoming
454Tier-1 (high impact)
2010 – 2034Coverage
Upcoming catalysts 17
Event history 1541
Q3 2026
◆NDA SubmissionvosoritideApprovedRegulatory Filing
Planned submission of VOXZOGO data to health authorities for hypochondroplasia approval
hypochondroplasiasource ↗
Q3 2026
●FDA Filing AcceptedvosoritideApprovedRegulatory Filing
Expects to be notified of sNDA acceptance for achondroplasia by Q3 2026
achondroplasiasource ↗
Jun 16, 2026
▲Topline ReadoutvosoritideApprovedClinical Data
Positive topline results from Phase 3 CANOPY-HCH-3 study of VOXZOGO in hypochondroplasia
hypochondroplasiasource ↗
Jun 15, 2026
▲Oral PresentationvosoritideApprovedPresentation
Three-year results from Phase 2 extension trial of VOXZOGO in hypochondroplasia presented at ENDO 2026
hypochondroplasiasource ↗
Jun 14, 2026
▲Poster PresentationPresentation
Phase 1 results of BMN 333 supporting weekly dosing presented at ENDO 2026
achondroplasiasource ↗
Jun 2, 2026
◆Management ChangeCorporate
Ian T. Clark elected Chair of the Board, subject to election at Annual Meeting
May 20, 2026
▲Primary Endpoint MetvosoritideApprovedClinical Data
Phase 3 CANOPY-HCH-3 study met primary endpoint with statistically significant improvement in annualized growth velocity
hypochondroplasiasource ↗
May 20, 2026
▲Secondary Endpoint DatavosoritideApprovedClinical Data
Statistically significant improvement in arm span at week 52
hypochondroplasiasource ↗
May 18, 2026
▼Topline ReadoutClinical Data
ENERGY 3 topline results: met PPi co-primary endpoint, missed RGI-C co-primary endpoint
ENPP1 deficiencysource ↗
May 4, 2026
●Enrollment MilestoneTrial
12 mg/kg dose cohort continues to enroll
Duchenne muscular dystrophysource ↗
Drug Pipeline Intelligence
B75
Pipeline Score $12.2B
Pipeline ValueUndervalued
Valuation Signal24
Drugs Scored3.9x
rNPV / MCap Top 96%
Mid Cap (rank 37 of 911)
Percentile RankBioMarin Pharmaceutical Inc. holds a solid B-grade pipeline (75/100), with $14.4B risk-adjusted pipeline value, led by 6R BH4 in Kidney Disease (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6R BH4 Small molecule | Kidney Disease | Phase 2 | NCT00625820 | 31% | $6.1B | COMPLETED | 17 | - | - | Sep 1, 2008 | - | Oct 18, 2016 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
VOXZOGO | hypochondroplasia | Phase 2 | 2026-06-16 | Mean height SDS improved by 0.72 SD over three years of treatment; mean AGV increased from 4.27 cm/year at baseline to 7.24 cm/year at year one (p<0.001) Read More | BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced new data from studies of VOXZOGO® (vosoritide) in children with hypochondroplasia and the... Read More | |
VOXZOGO | hypochondroplasia | Phase 2 | 2026-06-16 | Mean height SDS improved by 0.72 SD over three years of treatment; mean AGV increased from 4.27 cm/year at baseline to 7.24 cm/year at year one (p<0.001) Read More | BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced new data from studies of VOXZOGO® (vosoritide) in children with hypochondroplasia and the... Read More | |
VOXZOGO | hypochondroplasia | Phase 2 | 2026-06-16 | Mean height SDS improved by 0.72 SD over three years of treatment; mean AGV increased from 4.27 cm/year at baseline to 7.24 cm/year at year one (p<0.001) Read More | BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced new data from studies of VOXZOGO® (vosoritide) in children with hypochondroplasia and the... Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BMRN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BMRN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BMRNWhy Do I Pheel This Way? Episode 3: Finding Strength Through Sports While Living with Phenylketonuria
In the third episode of 'Why Do I Pheel This Way?', co-hosts Connor and Londyn discuss the challenges and rewards of participating in sports while managing phenylketonuria (PKU). They highlight the need for careful planning and support from teammates and coaches. Both express how sports have positively influenced their confidence and mental health.
Read more →BMRNFrom Unexpected Turns to Purposeful Impact
Devesh Radhakrishnan's career journey reflects a series of unexpected pivots, from law to biopharma. His passion for chemistry and bioprocess engineering led him to BioMarin, where he focuses on enhancing manufacturing processes and fostering inclusive teams. Devesh emphasizes the significance of connection and collaboration in driving impactful solutions for patients.
Read more →BMRNBioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced new data from studies of VOXZOGO® (vosoritide) in children with hypochondroplasia and the...
BioMarin Pharmaceutical Inc. announced promising new data on their treatments VOXZOGO and BMN 333 at ENDO 2026. The results from a three-year study indicate significant growth improvements in children with hypochondroplasia receiving VOXZOGO. Additionally, Phase 1 data for BMN 333 demonstrated favorable pharmacokinetics, supporting its advancement into later-stage trials. These findings reinforce BioMarin's commitment to developing effective therapies for skeletal dysplasias.
Read more →BMRNWhy Do I Pheel This Way? Episode 2 Explores Social Life, Support and Self-Advocacy for Teens with Phenylketonuria
The second episode of 'Why Do I Pheel This Way?' discusses the social challenges faced by teens with phenylketonuria (PKU). Co-hosts Connor and Londyn share their experiences managing relationships while dealing with the condition. They emphasize the importance of understanding friends and family support, as well as self-advocacy in navigating daily life with PKU.
Read more →BMRNKim Warner Builds Pathways for Early-Career Professionals Seeking Mission-Driven Opportunities
Kim Warner leads BioMarin's Early Talent Program, which is set to welcome over 130 interns globally. Her journey from a temporary role to a leadership position highlights her commitment to inclusion and community building. Warner emphasizes the importance of connection and belonging in the workplace, aiming to create pathways for diverse early-career professionals in the biopharma industry.
Read more →BMRNWhy Do I Pheel This Way? New Video Podcast Series Sheds Light on Navigating Adolescence with Phenylketonuria
A new video podcast series titled 'Why Do I Pheel This Way?' aims to support teenagers living with phenylketonuria (PKU) by sharing their experiences. Co-hosted by Connor and Londyn, the series features discussions on daily life with PKU, including challenges related to diet and emotional health. The first episode includes insights from a clinical psychologist and aims to inspire others navigating similar challenges.
Read more →BMRN▲ +7.8%on this news
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
BioMarin announced positive results from its Phase 3 CANOPY-HCH-3 study for VOXZOGO (vosoritide) in children with hypochondroplasia. The study demonstrated a statistically significant increase in annualized growth velocity, standing height, and arm span compared to placebo. Safety findings were consistent with the established profile, and a supplemental New Drug Application is planned for submission to the FDA in Q3 2026.
Read more →BMRNBioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced results from the pivotal Phase 3 ENERGY 3 trial evaluating BMN 401 in children aged 1-12...
BioMarin Pharmaceutical announced partial results from the Phase 3 ENERGY 3 trial for BMN 401, a treatment for children aged 1-12 with ENPP1 deficiency. The trial successfully increased plasma inorganic pyrophosphate (PPi) levels, meeting one co-primary endpoint, but did not improve Radiographic Global Impression of Change (RGI-C) scores, the other co-primary endpoint. The lack of improvement in secondary endpoints raised concerns regarding the treatment's overall efficacy. The company is now evaluating the data to plan next steps following these mixed results.
Read more →BMRNCrossing Paths: How the National MPS Society Reaches Families Where They Are
The National MPS Society's Crossing Paths initiative aims to connect families affected by mucopolysaccharidosis (MPS) and mucolipidosis (ML) through community outreach. By hosting informal gatherings in underserved areas, the program seeks to break down barriers to care and foster relationships among families. Over three years, the initiative has successfully engaged more families, promoting equity and understanding within the community.
Read more →BMRNFinding a Way Forward: How the National MPS Society’s Pathways Program Supports Families at Diagnosis
The National MPS Society's Pathways Program offers vital support to families diagnosed with mucopolysaccharidosis (MPS) and mucolipidosis (ML). Launched in 2018, the program provides free, personalized guidance and resources to families in the first year following diagnosis. It emphasizes emotional support and community connection, helping families navigate the challenges of rare genetic conditions.
Read more →BMRNBioMarin Reports First Quarter 2026 Financial and Operating Results
BioMarin Pharmaceutical Inc. reported a strong financial performance for the first quarter of 2026, with total revenues reaching $766 million, reflecting a year-over-year increase. The company has raised its full-year revenue guidance, anticipating between $3.825 billion and $3.925 billion. The acquisition of Amicus Therapeutics has enhanced BioMarin's portfolio with new therapies for Fabry and Pompe diseases, positioning the company for accelerated growth.
Read more →BMRNBioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society’s 2026 Annual Meeting
BioMarin presented new data on VOXZOGO at the Pediatric Endocrine Society's 2026 Annual Meeting, highlighting its positive effects on arm span and bone health in children with achondroplasia. The research indicates significant improvements in health measures beyond height, with long-term treatment showing sustained benefits. Additionally, new studies on hypochondroplasia are expected to yield pivotal Phase 3 results in 2026.
Read more →BMRNInvestors Media Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports First Quarter 2026 Financial and Operating Results First Quarter
BioMarin Pharmaceutical Inc. reported its first quarter 2026 financial results, highlighting a year-over-year increase in total revenues to $766 million. The company raised its full-year revenue guidance, reflecting an accelerated growth driven by new product additions, including GALAFOLD and POMBILITI + OPFOLDA. While BioMarin anticipates strong future performance, it faced challenges, including a decrease in net income and increased operational costs related to the Amicus acquisition. Upcoming data readouts from ongoing clinical trials are expected to further inform investors on the company's growth trajectory.
Read more →BMRNBioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new research from studies of VOXZOGO® (vosoritide) in children with achondroplasia...
BioMarin Pharmaceuticals announced new findings regarding its drug VOXZOGO (vosoritide) for treating achondroplasia in children. The research, which will be presented at the Pediatric Endocrine Society's 2026 Annual Meeting, highlights significant positive effects on arm span, bone density, and overall growth metrics, showing substantial benefits for children receiving long-term treatment. Data from clinical trials suggests that early intervention with VOXZOGO leads to meaningful improvements in health outcomes compared to untreated cohorts. The company also plans to share upcoming Phase 3 data on VOXZOGO's impact on another condition, hypochondroplasia, later in 2026.
Read more →BMRNMonica Mann Reflects on a Life Dedicated to Healthcare Transformation
Monica Mann, Vice President at BioMarin, reflects on her journey shaped by personal loss and her commitment to transforming healthcare for patients with rare conditions. At the Pediatric Endocrine Society Annual Meeting, she will present advancements in research for achondroplasia and hypochondroplasia. Her work emphasizes the importance of community engagement and innovative approaches to improve patient outcomes.
Read more →BMRNTommaso Corio Discusses His Journey from BioMarin Internship to International Impact
Tommaso Corio shares his inspiring journey from an intern at BioMarin to Operations Manager for Western Europe and Canada. Driven by a desire to impact patient lives, he transitioned from pharmaceutical chemistry to marketing. His experiences at BioMarin have reinforced his commitment to the company's mission of improving quality of life for patients, particularly children.
Read more →BMRNBioMarin Completes Acquisition of Amicus Therapeutics
BioMarin Pharmaceutical Inc. has completed its acquisition of Amicus Therapeutics for $4.8 billion, enhancing its portfolio with Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease. The acquisition aligns with BioMarin's strategy to diversify its offerings in rare disease treatments. The company plans to provide updated financial guidance during its upcoming earnings call.
Read more →BMRNBioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
BioMarin Pharmaceutical Inc. has announced a conference call scheduled for May 4, 2026, at 4:30 p.m. ET. The call will be hosted by CEO Alexander Hardy to discuss the company's first quarter financial results and provide a business update. Interested parties can access the live webcast through BioMarin's investor website.
Read more →BMRNInvestors Media Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 218-7111 BioMarin Completes Acquisition of Amicus Therapeutics Acquisition Adds Galafold
BioMarin Pharmaceutical Inc. has completed its acquisition of Amicus Therapeutics for approximately $4.8 billion. This acquisition adds two significant treatments to BioMarin's portfolio, namely Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease. The company aims to leverage its established resources to enhance the availability of these treatments worldwide. Additionally, BioMarin plans to provide updated financial guidance during its upcoming earnings call.
Read more →BMRNJake Birecki Makes Space for Passion, Purpose and Play
Jake Birecki, a 21-year-old living with achondroplasia, shares his journey of pursuing passions like soccer and outdoor activities. He emphasizes personal growth and positivity, aiming to inspire others with disabilities. Through his work with the United Adaptive Soccer Association, he advocates for inclusive sports opportunities for adaptive athletes. Jake's story highlights the importance of community and shared experiences.
Read more →BMRNBioMarin Announces Board Leadership Transition
BioMarin Pharmaceutical Inc. has appointed Ian T. Clark as the new Chair of the Board, succeeding Richard A. Meier, who is retiring after 20 years. Clark, who joined the Board in 2025, expressed excitement about leading the company into its next growth phase. Meier noted the company's strong performance and strategic clarity as it transitions to new leadership.
Read more →BMRNBridget Yates on the Power of Purpose: Cultivating Impact Through Scientific Discovery
Bridget Yates reflects on her journey in biopharma, inspired by personal loss and a commitment to patient advocacy. Celebrating 12 years at BioMarin, she leads research on enzyme replacement therapies for rare genetic conditions. Yates emphasizes the importance of connection with patients and communities to drive impactful research and innovation.
Read more →BMRNAn Open Letter to the Pompe and Fabry Communities
BioMarin has announced its plans to acquire Amicus Therapeutics, aiming for completion in Q2 2026. The letter emphasizes BioMarin's commitment to the Pompe and Fabry communities, highlighting their history in rare disease treatment. The company expresses eagerness to engage with these communities and learn from their experiences.
Read more →BMRNThe Heart of the Matter: BioMarin Scientists Reflect on Experiences Meeting Patients
BioMarin employees reflect on the inspiring experiences of meeting patients, emphasizing the importance of these interactions in understanding the real-world impact of their work. The visits create opportunities for scientists to connect with patients and families, fostering meaningful dialogue and reinforcing the company's mission. Personal stories shared by patients highlight the significance of innovation in addressing rare diseases.
Read more →BMRNBioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
BioMarin presented new data at the 2026 ACMG Annual Clinical Genetics Meeting, highlighting the positive effects of early treatment with VOXZOGO (vosoritide) in children with achondroplasia. The findings indicate that initiating treatment before age 2 results in significant improvements in growth metrics such as proportionality and arm span. The data builds on over 10,000 patient-years of evidence supporting VOXZOGO's efficacy and safety.
Read more →BMRNU.S. Food and Drug Administration Approves BioMarin’s PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
BioMarin Pharmaceutical Inc. announced that the FDA has approved PALYNZIQ (pegvaliase-pqpz) for adolescents aged 12 and older with phenylketonuria (PKU). This approval is based on the Phase 3 PEGASUS study, which demonstrated significant reductions in blood phenylalanine levels compared to diet alone. PALYNZIQ is unique as it allows for dietary freedom while managing PKU effectively. The company is also pursuing approval in the European Union.
Read more →BMRNU.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
BioMarin has received FDA approval for PALYNZIQ (pegvaliase-pqpz) to treat adolescents aged 12 and older with phenylketonuria (PKU). This enzyme substitution therapy significantly lowers blood phenylalanine levels compared to diet alone, offering a new management option for adolescents. The approval is based on positive results from the Phase 3 PEGASUS study, which demonstrated substantial efficacy and safety.
Read more →BMRNBioMarin to Participate in Four Upcoming Investor Conferences in March
BioMarin Pharmaceutical Inc. has announced its participation in four investor conferences scheduled for March 2026. These events include the TD Cowen 46th Annual Health Care Conference, the Leerink 2026 Global Healthcare Conference, the Jefferies 2026 Biotech on the Bay Summit, and the Barclays 28th Annual Global Healthcare Conference. The company will provide live webcasts of the discussions, which will also be available for replay on their website.
Read more →BMRNBioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
BioMarin Pharmaceutical Inc. reported a 13% increase in total revenues for 2025, reaching $3.2 billion, driven by growth in enzyme therapies and VOXZOGO. The company announced a definitive agreement to acquire Amicus Therapeutics, which is expected to enhance its revenue diversification. BioMarin also provided optimistic guidance for 2026, anticipating continued strong financial performance.
Read more →BMRNChieze Ibeneche-Nnewihe Reflects on Her Journey from Amateur Scientist to Business Development Leader
Chieze Ibeneche-Nnewihe shares her inspiring journey from childhood science experiments to a leadership role in business development at BioMarin. Her experiences highlight her commitment to improving patient outcomes through innovative healthcare solutions. She emphasizes the importance of teamwork and connection within the organization, which fuels her passion for making a meaningful impact in the biopharma industry.
Read more →BMRNBioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a...
BioMarin Pharmaceutical Inc. has announced a conference call and webcast scheduled for February 23, 2026, to discuss its fourth quarter and full-year 2025 financial results. Alexander Hardy, the CEO, will provide updates on the company's performance and business. The call will be accessible for live listening and will include a replay available for one week after the event. BioMarin is recognized for its commitment to developing therapies for rare genetic conditions.
Read more →BMRNBioMarin Announces Closing of Private Offering of Senior Notes
BioMarin Pharmaceutical Inc. has successfully closed an $850 million offering of senior unsecured notes due in 2034. The proceeds will be used to finance the acquisition of Amicus Therapeutics and related expenses. The company has also established new secured credit facilities to support this acquisition. However, if the acquisition is not completed by December 2026, the notes will need to be redeemed.
Read more →BMRNInvestors Media Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Erin Rau BioMarin Pharmaceutical Inc. (925) 683-9622 BioMarin Announces Closing of Private Offering of Senior Notes
BioMarin Pharmaceutical Inc. has completed an offering of $850 million in senior unsecured notes to finance its pending acquisition of Amicus Therapeutics. The company will utilize a combination of these proceeds, term loan facilities, and cash on hand to support the acquisition and related expenses. However, if the acquisition does not close by the set deadline, BioMarin faces obligations to redeem the notes at the issue price. The funding strategy reflects BioMarin's commitment to expanding its portfolio in the rare disease market.
Read more →BMRN‘We’re Fighters’: How One Family is Advocating for Progress in ENPP1 Deficiency
Christine O'Brien and her family advocate for awareness and support for ENPP1 deficiency, a rare genetic condition affecting their children. They founded the Brighter Hope Foundation to connect families and raise awareness, particularly through GACI/ARHR2 Awareness Day. Despite the challenges posed by the condition, the family remains hopeful for future treatments and emphasizes the importance of community support.
Read more →BMRNBioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
BioMarin Pharmaceutical Inc. has priced its offering of $850 million in senior unsecured notes due 2034, expected to close on February 12, 2026. This move is part of a broader financial strategy that includes a $2 billion senior secured term loan facility to fund the acquisition of Amicus Therapeutics. The company aims to use the proceeds from these offerings to cover acquisition costs and related expenses.
Read more →BMRNInvestors Media Traci McCarty Erin Rau BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (925) 683-9622 BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Sy
BioMarin Pharmaceutical Inc. has announced the pricing of an $850 million offering of senior unsecured notes, set to close on February 12, 2026, subject to customary conditions. This financing is part of a broader strategy, supporting BioMarin's planned acquisition of Amicus Therapeutics, Inc., which also includes a new $2 billion senior secured term loan facility. The company intends to use the proceeds from this offering and additional borrowings to cover acquisition costs and related fees.
Read more →BMRNBioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility
BioMarin Pharmaceutical Inc. announced a proposed offering of $850 million in senior unsecured notes due 2034 and the syndication of a new $2 billion senior secured term loan facility. These financial moves are intended to fund the acquisition of Amicus Therapeutics and related expenses. The notes will be guaranteed by certain subsidiaries and are subject to specific covenants and conditions.
Read more →BMRNFinding His Rhythm in Science: Andrew’s Journey to Bioanalytical Sciences Leadership
Andrew Melton's career path in biopharma began unexpectedly in a music studio, but a challenge from a professor sparked his interest in science. Now a Senior Director at BioMarin, he emphasizes the importance of teamwork and scientific rigor in drug development. His contributions have led to multiple approved therapies, showcasing his commitment to improving patient outcomes.
Read more →BMRNInvestors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Erin Rau BioMarin Pharmaceutical Inc. (925) 683-9622 BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New
BioMarin Pharmaceutical Inc. announced its intention to offer $850 million in senior unsecured notes due in 2034. This offering is part of funding for the acquisition of Amicus Therapeutics, for which BioMarin is also launching a $2 billion senior secured term loan facility. The proceeds from these offerings will help cover the acquisition costs and related expenses. However, completion of the offering and acquisition is dependent on market conditions, creating some risk for investors.
Read more →BMRNBioMarin Appoints Arpit Davé Chief Digital and Information Officer
BioMarin Pharmaceutical has appointed Arpit Davé as Chief Digital and Information Officer. With over 20 years of experience in the biopharmaceutical industry, Davé will lead the company's digital transformation and technology strategy. His previous roles include significant positions at Amgen, Bristol Myers Squibb, and Merck, focusing on AI and data science to enhance business operations.
Read more →BMRNth Annual J.P. Morgan Healthcare Conference Alexander Hardy Greg Friberg Chief Executive Officer Chief R&D Officer BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. provided forward-looking statements during the 2026 J.P. Morgan Healthcare Conference, revealing expected financial results for the year ending December 31, 2025. Key highlights included anticipated revenue growth driven by product sales and a proposed acquisition of Amicus Therapeutics. Additionally, BioMarin plans to enhance its treatment portfolio, specifically for skeletal conditions and enzyme therapies. However, the company acknowledged potential risks that could affect future performance, including the complexities surrounding the acquisition and financial reporting procedures.
Read more →BMRNBioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
BioMarin Pharmaceutical Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Alexander Hardy will share insights and preliminary financial results for the year ended December 31, 2025. The event will be accessible via a live audio webcast, with an archived version available later.
Read more →BMRNDonnie Mackenzie: Rising to the Challenge to Deliver Transformative Therapies
Donnie Mackenzie, an Associate Director at BioMarin, shares his commitment to developing therapies for rare genetic conditions. He emphasizes the importance of working smart in drug development, inspired by patient advocates. Mackenzie and his team focus on innovative research for conditions like achondroplasia and ENPP1-deficiency, driven by a dedication to meet patient needs.
Read more →BMRNA Family Legacy: Marie-Josee Toutounji Following in Her Parents’ Footsteps
Marie-Josee Toutounji, the Medical Director at BioMarin in Canada, shares her journey influenced by her parents' careers in pharmaceuticals. Initially resistant to the idea of following in their footsteps, she eventually embraced a career in biopharma. Toutounji emphasizes the importance of relationships and collaboration in her work, aiming to improve patient access to innovative therapies.
Read more →BMRNBioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
BioMarin Pharmaceutical Inc. has announced its acquisition of Amicus Therapeutics for approximately $4.8 billion. This strategic move will enhance BioMarin's portfolio with two marketed products for rare diseases, Galafold and Pombiliti + Opfolda, which generated significant revenue in the past year. The transaction is expected to close in the second quarter of 2026, pending regulatory approvals and stockholder consent.
Read more →BMRN▲ +17.7%on this newsshared move
BioMarin Contacts Amicus Contacts Traci McCarty, Investors BioMarin Pharmaceutical Inc. (415) 455-7558 Andrew Faughnan, Investors Amicus Therapeutics (609) 662-3809 Marni Kottle, Media BioMarin Pharmaceutical Inc. (415)
BioMarin Pharmaceutical Inc. has announced a definitive agreement to acquire Amicus Therapeutics for approximately $4.8 billion, which will strengthen its portfolio in rare disease treatments. The acquisition of products Galafold and Pombiliti, among others, not only diversifies BioMarin's offerings but is expected to accelerate revenue growth. The deal has received unanimous approval from both companies' boards and is subject to customary regulatory approvals. This strategic move positions BioMarin to better serve patients with rare diseases globally, enhancing its financial outlook and market presence.
Read more →BMRN▲ +17.7%on this newsshared move
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding ...
BioMarin Pharmaceutical Inc. has announced a definitive agreement to acquire Amicus Therapeutics for approximately $4.8 billion, paying $14.50 per share in cash. This acquisition aims to enhance BioMarin's position within the rare diseases market by adding high-growth products like Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease. The deal is expected to be immediately accretive to BioMarin's earnings and expand access to these therapies in new markets. Closing is anticipated in the second quarter of 2026, pending regulatory approval and stockholder vote.
Read more →BMRNJoyanna Hansen: A Journey from the Clinic to BioMarin
Joyanna Hansen, a registered dietitian and PKU Medical Science Liaison at BioMarin, shares her journey from clinical practice to the biopharma industry. Her experience with families affected by phenylketonuria (PKU) drives her commitment to improving patient care. At BioMarin, she focuses on providing education to clinicians and translating research into practical guidance for managing PKU.
Read more →BMRNRoberto McLean Turns Military Discipline into Impact for Patients
Roberto McLean, an Operational Readiness Planner at BioMarin, utilizes his military discipline to ensure efficient delivery of life-changing therapies. His journey from military service to biopharma highlights the importance of teamwork and operational readiness. McLean emphasizes the significance of collaboration and aims to make a tangible impact on patient communities through his work.
Read more →BMRNCamp Ellellbee Creates Space for Connection, Joy and Open Conversations About Skeletal Conditions
Camp Ellellbee, founded by Kristen DeAndrade, successfully brought together over 60 families from the U.S. dwarfism community for a weekend of connection and support. The camp aims to create an inclusive environment for individuals with skeletal conditions and their families, encouraging open dialogue about their experiences. Attendees appreciated the opportunity to bond and share insights, highlighting the camp's role as a catalyst for change in the community.
Read more →BMRNBioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England
BioMarin Pharmaceutical Inc. will present at the Jefferies Global Healthcare Conference on November 18, 2025, at 10:30 AM GMT in London. The event will feature a live audio webcast, which will later be archived on the company's website. BioMarin continues to emphasize its dedication to developing treatments for rare genetic conditions.
Read more →BMRNChristina Pao on Charting a New Course for Children with Hypochondroplasia
Christina Pao, Senior Director of Medical Affairs at BioMarin, is dedicated to improving care for children with hypochondroplasia. She emphasizes the importance of early diagnosis and education for healthcare providers about the condition. Pao's team is implementing a four-pronged approach to enhance patient care and has already seen positive results from their educational programs.
Read more →BMRNFDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
BioMarin Pharmaceutical has announced that the FDA has accepted its supplemental Biologics License Application for PALYNZIQ (pegvaliase-pqpz) to expand its use to adolescents aged 12-17 with phenylketonuria (PKU). The application is based on positive outcomes from the Phase 3 PEGASUS study, which demonstrated significant reductions in blood phenylalanine levels. The FDA has set a target action date of February 28, 2026, for this application.
Read more →BMRNBioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
BioMarin Pharmaceutical Inc. reported a 11% increase in total revenues for the third quarter of 2025, driven by strong growth in its PALYNZIQ and VOXZOGO products. The company is pursuing options to divest ROCTAVIAN while reaffirming its full-year revenue guidance. Despite a reported GAAP net loss, BioMarin remains optimistic about its strategic focus and growth potential.
Read more →BMRNBioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET
BioMarin Pharmaceutical Inc. will host a conference call on October 27, 2025, at 4:30 p.m. ET to discuss its third quarter financial results and provide a business update. CEO Alexander Hardy will lead the call, which can be accessed via the company's investor website. A replay will be available for one week following the event.
Read more →BMRNFrom Patient to Policy Advocate: A Journey Rooted in Urgency and Hope
Lynsey Chediak, BioMarin's Associate Director of Government Affairs, shares her journey from being a patient with arthrogryposis to a passionate advocate for rare disease policies. Her lived experience motivates her efforts to improve access to treatments and support for children with genetic conditions. Lynsey's initiatives include launching coalitions and advocating for legislative changes to enhance patient care.
Read more →BMRNFrom Healthcare to Computer Science and Law, RARE Scholars Draw on Lived Experiences to Pursue Their Dreams
The RARE Scholars program by BioMarin provides financial support to U.S. college students with rare genetic conditions. This year's cohort includes five students who share their inspiring journeys and aspirations in healthcare, technology, and law. The program has awarded over $175,000 since its inception, empowering students to advocate for themselves and others in their fields.
Read more →BMRNTerri Klein on How Her Personal Experience Has Shaped the National MPS Society’s Groundbreaking Programs for Families
Terri Klein, President of the National MPS Society, shares how her daughter's diagnosis of mucolipidosis inspired the creation of supportive programs for families. The Society's Pathways program offers essential guidance during the first year post-diagnosis, while the new Crossing Paths initiative aims to connect with underserved families. Klein emphasizes the importance of newborn screening and ongoing advocacy for broader inclusion of MPS conditions.
Read more →BMRNJavier Femenia Helps Turn Promising Molecules into Breakthrough Medicines
Javier Femenia, head of BioMarin's BioProcess Development team, shares his inspiring journey in developing breakthrough medicines. His work focuses on transforming promising molecules into effective treatments, particularly for rare diseases. The motivation stems from the impact on patients' lives, as illustrated by personal stories of hope. The team faces unique challenges in creating first-in-class therapies.
Read more →BMRNLeading with Heart: Letticia Atkins Brings the Spirit of Family to Her Work at BioMarin
Letticia Atkins, head of BioMarin's Field Based Clinical Support team, shares her journey and commitment to supporting families with rare genetic conditions. She emphasizes the importance of personal connections with patients and the dedication of her team to provide exceptional care. Letticia's background in a large family shapes her approach to teamwork and patient interactions, aiming to create a supportive environment.
Read more →BMRNCampfires and Connections: How Summer Camp Brings Families with PKU Together
The flok Family Camp brings together families affected by phenylketonuria (PKU), fostering community and support. Attendees participate in traditional camp activities while learning about metabolic science. Children like Elijah and Maddy find connection and independence, with families hopeful for future advancements in PKU treatment that may ease dietary restrictions.
Read more →BMRNBioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting
BioMarin Pharmaceutical Inc. presented new data at the ASBMR Annual Meeting, highlighting the positive impact of VOXZOGO on spinal morphology and growth in children with achondroplasia. The findings from 14 studies demonstrate VOXZOGO's efficacy even after puberty onset. Additionally, BioMarin is advancing BMN 401 for ENPP1 deficiency, with pivotal data expected in 2026.
Read more →BMRNBioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
BioMarin announced positive results from the Phase 3 PEGASUS study for PALYNZIQ in adolescents with phenylketonuria (PKU). The study demonstrated a 49.7% decrease in mean blood Phe levels, with nearly half of participants achieving significant reductions. The company plans to submit these findings to global health authorities in the second half of 2025 to expand PALYNZIQ's indication to adolescents.
Read more →BMRNTravis Wilson’s Steadying Presence Ensures Stability in Operations
Travis Wilson, a leader at BioMarin, shares his journey from a Navy mechanic to a key role in biopharma. He emphasizes the importance of operational excellence, mentorship, and building strong relationships with colleagues and patients. His commitment to enhancing infrastructure and supporting team members aligns with BioMarin's mission to deliver critical therapies.
Read more →BMRNBioMarin to Participate in Upcoming Investor Conferences
BioMarin Pharmaceutical Inc. has announced its participation in upcoming investor conferences in September. Management will present, and an audio webcast will be available live, with an archived version accessible later. The company emphasizes its commitment to developing innovative therapies for rare genetic conditions.
Read more →BMRNBioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS
BioMarin Pharmaceutical Inc. reported strong financial results for the second quarter of 2025, with total revenues reaching $825 million, a 16% increase year-over-year. The company also reported a significant rise in GAAP diluted earnings per share, which increased by 124% compared to the previous year. Additionally, BioMarin completed the acquisition of Inozyme, enhancing its product pipeline. The company anticipates further growth with the upcoming pivotal study of BMN 333 in pediatric achondroplasia.
Read more →BMRNBioMarin Announces Appointment of Ian T. Clark to Board of Directors
BioMarin Pharmaceutical Inc. has appointed Ian T. Clark to its Board of Directors, effective August 1, 2025. Clark, former CEO of Genentech, has a rich background in the biopharmaceutical industry, having launched numerous drugs. His experience is expected to provide valuable insights as BioMarin continues to develop therapies for genetically defined conditions.
Read more →BMRNConnection to Purpose Defines Carolina Coelho’s Experience at BioMarin
Carolina Coelho, Senior Director at BioMarin, shares her inspiring career journey from law to biopharma. Motivated by a desire to impact patient lives, she emphasizes the importance of connection and collaboration in her role. Coelho expresses gratitude for her supportive colleagues and the meaningful relationships that enhance her work experience.
Read more →BMRNBioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a...
BioMarin Pharmaceutical Inc. has announced a conference call and webcast set for August 4, 2025, at 4:30 p.m. ET, where CEO Alexander Hardy will discuss the company's financial results for the second quarter of 2025. The live audio webcast will be accessible through BioMarin's investor website, and a replay will be available for one week post-call. BioMarin continues to position itself as a leader in developing treatments for genetic conditions, emphasized by its robust pipeline and history of innovation.
Read more →BMRNBioMarin Announces Completion of Acquisition of Inozyme BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (Nasdaq:...
BioMarin Pharmaceutical Inc. has completed its acquisition of Inozyme Pharma, Inc. for $270 million, paying $4.00 per share in cash. This acquisition is expected to enhance BioMarin's enzyme therapies portfolio by adding INZ-701, a late-stage treatment for ENPP1 Deficiency, a rare genetic condition. The tender offer saw a significant response, with approximately 70% of Inozyme's outstanding shares being validly tendered. Following the acquisition, Inozyme's shares will be delisted from the Nasdaq Global Select Market.
Read more →BMRNPushing the Boundaries of Living with PKU: Karlye’s Story
Karlye Vonderwell shares her journey living with phenylketonuria (PKU), reflecting on the progress made in managing the condition. She highlights the support from her family and the PKU community, as well as her experiences with new dietary options. Karlye expresses optimism for the future of PKU treatment and her desire to connect more with the community.
Read more →BMRNFate Played a Large Role in Shola Fafunso’s Career Journey
Shola Fafunso, the U.S. country lead for BioMarin's Skeletal Conditions unit, shares his career journey and dedication to improving health outcomes for children with skeletal conditions. He emphasizes the importance of connection, mentorship, and an inclusive culture at BioMarin. His personal experiences have shaped his commitment to the biopharma industry and the mission to serve patients.
Read more →BMRNBioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data underscoring the long-term efficacy and safety of ROCTAVIAN® (valoctocogene...
BioMarin Pharmaceutical Inc. presented new five-year data on ROCTAVIAN (valoctocogene roxaparvovec-rvox) at the ISTH Congress, confirming its long-term efficacy and safety for severe hemophilia A. The Phase 3 GENEr8-1 trial showed that patients maintain sustained FVIII expression and durable bleed control, with 81.3% of individuals off prophylaxis after five years. Importantly, no new safety signals were detected, nor were there thromboembolic events or malignancies during the study period. This reinforces ROCTAVIAN's potential role in alleviating the chronic burden of hemophilia A treatment.
Read more →BMRNSabrina Sun Embraces Competitive Spirit to Make a Difference for Patients
Sabrina Sun, Associate Director of Corporate Intelligence at BioMarin, shares her journey and aspirations in the biopharma industry. She emphasizes the importance of collaboration and strategic insights in developing therapies for underrecognized patient communities. Her experiences highlight the supportive culture at BioMarin and her commitment to making a significant impact on patients with genetically defined conditions.
Read more →BMRNBioMarin Contacts Inozyme Contacts Traci McCarty, Investors Stefan Riley, Investors BioMarin Pharmaceutical Inc. Inozyme Pharma, Inc. (415) 455-7558 (617) 461-2442 Marni Kottle, Media Todd Cooper, Media BioMarin Pharmace
BioMarin Pharmaceutical Inc. has announced its acquisition of Inozyme Pharma for $270 million in cash. This strategic move is aimed at enhancing BioMarin's enzyme therapy portfolio by adding INZ-701, a late-stage enzyme replacement therapy for ENPP1 Deficiency. The acquisition is expected to close in Q3 2025, pending regulatory approval and completion of customary conditions. BioMarin anticipates first pivotal data for INZ-701 in children in early 2026, with potential market launch in 2027.
Read more →BMRNBioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Inozyme Pharma, Inc. (Nasdaq: INZY) announced today that BioMarin has entered into a definitive...
BioMarin Pharmaceutical Inc. has announced its acquisition of Inozyme Pharma for approximately $270 million, enhancing its enzyme therapy portfolio with the addition of INZ-701. This drug, currently in Phase 3 trials, is designed to treat ENPP1 Deficiency, a rare genetic condition with no approved therapies. The acquisition is expected to close in the third quarter of 2025, following regulatory approval and other customary conditions. BioMarin aims to leverage this acquisition to continue its commitment to developing innovative treatments for patients with serious genetic disorders.
Read more →BMRNBioMarin Scientists Helping Reclassify Genetic ‘Variants of Uncertain Significance’ to Improve Diagnosis of Hypochondroplasia
BioMarin is working to improve the diagnosis of hypochondroplasia by reclassifying genetic variants of uncertain significance associated with the FGFR3 gene. Their research, presented at a major genetics conference, aims to provide definitive diagnoses and better access to care for patients. This initiative highlights the company's commitment to enhancing genetic understanding and patient outcomes.
Read more →BMRNBioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from studies of VOXZOGO® (vosoritide), demonstrating meaningful impact on tibial ...
BioMarin Pharmaceutical Inc. has presented new data on VOXZOGO (vosoritide) demonstrating its positive effects on tibial bowing in children with achondroplasia, as discussed at international endocrinology meetings. The data indicate significant reductions in tibial bowing and potential height increases, particularly when treatment is started early. Additionally, the research highlights the prevalence of comorbidities associated with hypochondroplasia, calling attention to the necessity of early diagnosis. BioMarin remains committed to advancing VOXZOGO's development for various skeletal conditions.
Read more →BMRNBioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the first quarter ended March 31, 2025....
BioMarin Pharmaceutical Inc. reported its financial results for the first quarter of 2025, showcasing total revenues of $745 million, which represents a 15% increase year-over-year. The company also achieved a remarkable 107% rise in GAAP diluted earnings per share, reaching $0.95. BioMarin emphasized the ongoing strong demand for its products and provided positive updates on its clinical programs, including favorable results from the Phase 3 PALYNZIQ study and advancements in its VOXZOGO pipeline. Additionally, the company reaffirmed its full-year guidance, projecting revenues between $3.1 to $3.2 billion for 2025.
Read more →BMRNInvestors Media Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance Firs
BioMarin Pharmaceutical Inc. reported strong financial results for the first quarter of 2025, with total revenues reaching $745 million, representing a 15% increase year-over-year. The company also saw significant growth in GAAP diluted earnings per share, which rose by 107% compared to the prior year. Notably, demand for VOXZOGO increased by 40%, and positive advancements were made in their clinical pipeline, including results from PALYNZIQ studies. BioMarin reaffirmed its full-year guidance, anticipating continued momentum in expanding its therapies and market presence.
Read more →BMRNBioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a...
BioMarin Pharmaceutical Inc. will host a conference call and webcast on May 1, 2025, at 4:30 p.m. ET to discuss their first quarter financial results and provide a business update. Alexander Hardy, President and CEO, will lead the call. Interested parties can access the live audio through the investor section of the company's website, where a replay will also be available for a week. BioMarin is noted for its commitment to advancing treatments for rare genetic conditions.
Read more →BMRNSergio Covarrubias Turns Passion for Genomic Medicine into Impact
Sergio Covarrubias, a leader in gene editing at BioMarin, shares his journey in genomic medicine. He highlights the importance of connection and collaboration in science, driven by a desire to positively impact patients. Covarrubias reflects on his experiences and aspirations, emphasizing the role of mentorship and support in his career.
Read more →BMRNBioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary...
BioMarin Pharmaceutical Inc. has announced positive results from the Phase 3 PEGASUS trial for PALYNZIQ, which showed a statistically significant reduction in blood Phe levels among adolescents aged 12-17 with phenylketonuria (PKU). The company plans to submit these findings to global health authorities later this year to seek approval for extending the drug's indication to younger patients. PALYNZIQ is currently the only approved enzyme therapy for adults with PKU, and the trial results could enhance treatment options for adolescents transitioning to adult care.
Read more →BMRNBioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive new data from studies of VOXZOGO® (vosoritide) in children with achondroplasia...
BioMarin presented positive new data at the 2025 ACMG Annual Clinical Genetics Meeting regarding VOXZOGO (vosoritide) for children under 3 with achondroplasia. A study showed strong adherence and a favorable safety profile in 63 children, with no treatment-related adverse events. Additionally, data on PALYNZIQ (pegvaliase-pqpz) emphasized its efficacy in lowering blood Phe levels and improving quality of life for adults with phenylketonuria. These findings reinforce the therapeutic benefits of BioMarin's treatments in managing these conditions.
Read more →BMRNDriving Progress for Children with Achondroplasia
Dr. Ravi Savarirayan, a leader in skeletal dysplasia research, discusses his journey and the advancements in achondroplasia care over the past two decades. He emphasizes the importance of new treatment guidelines and the need for families to have access to accurate information. Dr. Savarirayan highlights the ongoing challenges and the commitment to improving the overall health of children with achondroplasia.
Read more →BMRNJohanna Lucas on Building the Right Teams to Make a Profound Impact
Johanna Lucas, Executive Director of Talent Acquisition at BioMarin, reflects on her decade-long journey with the company, emphasizing the importance of building strong connections during recruitment. She shares her motivations, including a personal connection to oncology, and the collaborative spirit that drives her team to hire exceptional talent. Lucas also appreciates the supportive culture at BioMarin, especially during challenging personal times.
Read more →BMRNBioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the TD Cowen 45th Annual Healthcare Conference on...
BioMarin Pharmaceutical Inc. will present at the TD Cowen 45th Annual Healthcare Conference on March 4, 2025, at 6:50 AM PT in Boston, MA. An audio webcast of the event will be accessible live and archived for a limited time. The conference highlights BioMarin's commitment to innovation and its extensive pipeline in developing therapies for rare genetic conditions.
Read more →BMRNBioMarin Announces Appointment of Timothy P. Walbert to Board of Directors BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president and chief...
BioMarin Pharmaceutical Inc. has appointed Timothy P. Walbert to its Board of Directors, effective Feb. 24, 2025. Walbert, previously the CEO of Horizon Therapeutics, brings over 30 years of experience in the biopharmaceutical industry. His appointment aligns with BioMarin's strategy to focus on innovation and growth in addressing the needs of patients with rare genetic conditions. This addition to the board is expected to enhance BioMarin's direction and expertise in advancing new medicines.
Read more →BMRNBioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the fourth quarter and full year ended December 31, 2024....
BioMarin Pharmaceutical Inc. reported strong financial results for the fourth quarter and full year ended December 31, 2024, with total revenues reaching $2.85 billion, an 18% year-over-year increase. The company’s President and CEO highlighted an operational transformation that positions BioMarin for growth in 2025, anticipating double-digit revenue and profitability growth. Key products contributing to revenue include VOXZOGO, VIMIZIM, and PALYNZIQ, with promising developments in their pipeline candidates, particularly for Duchenne Muscular Dystrophy and skeletal conditions. The company expects to submit applications to expand treatment eligibility based on upcoming clinical results in 2025.
Read more →BMRNBioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a...
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced a conference call and webcast scheduled for February 19, 2025, to discuss its fourth quarter and full-year 2024 financial results. CEO Alexander Hardy will lead the presentation, providing updates on the company's performance and business outlook. The event showcases BioMarin's dedication to transparency and engagement with investors. The call will also be accessible through a live audio webcast and will be archived for a week afterward.
Read more →BMRNLiving the BioMarin 8: Operating Principles That Guide Our Work
BioMarin has introduced the 'BioMarin 8', a set of operating principles designed to guide the company's teams in fulfilling their mission of transforming genetic discoveries into impactful medicines. CEO Alexander Hardy highlights that these principles are a reflection of the company's successful legacy and a roadmap for future achievements. Employees share insights on how these principles are implemented in their daily work.
Read more →BMRNKristen DeAndrade Turns Her Lived Experience into Her Life’s Work
Kristen DeAndrade, an advocate for individuals with skeletal dysplasia, founded The Little Legs Big Heart Foundation to promote inclusivity and support. After hosting a successful conference for the community, she continues to raise awareness about healthcare challenges faced by those with achondroplasia. Kristen emphasizes the importance of education and representation in addressing misconceptions about dwarfism.
Read more →BMRNBioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has initiated a legal action against Ascendis Pharma A/S for...
BioMarin Pharmaceutical Inc. has filed a legal action against Ascendis Pharma A/S in the European Unified Patent Court, asserting infringement of its European patent covering long-acting variants of C-Type Natriuretic Peptide (CNP). This strategic move aims to protect the company’s intellectual property rights, which are crucial for the biotechnology sector focused on rare genetic conditions. The litigation underscores BioMarin's dedication to innovation and the advancement of treatments that address significant medical needs.
Read more →BMRNJames Sabry on BioMarin’s Unique Proposition
James Sabry, EVP and Chief Business Officer at BioMarin, highlights the company's unique position in the biopharma industry, focusing on genetically defined conditions. He emphasizes the strength of BioMarin's R&D, manufacturing, and commercial capabilities, which make it an attractive partner for smaller biotech firms. Sabry also discusses the current challenges in capital markets and the pressure on larger companies to target broader patient populations.
Read more →BMRNBioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at...
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that its CEO, Alexander Hardy, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2024, in San Francisco. The presentation is expected to offer insights into the company's innovative therapies and strategic direction. An audio webcast will be available for those unable to attend in person, ensuring accessibility to the presentation.
Read more →BMRNBioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive and consistent results from multiple real-world evidence studies of VOXZOGO®...
BioMarin Pharmaceutical Inc. presented new real-world evidence supporting the safety and efficacy of VOXZOGO (vosoritide) for children with achondroplasia at the ESPE Meeting 2024. Data indicates that children treated with VOXZOGO exhibited significant increases in height, consistent with previous clinical trial results. The ongoing collection of more than 6,000 patient-years of safety data reinforces the drug's profile as a beneficial treatment option. BioMarin is also pursuing the drug's use in other related conditions, reflecting its commitment to address the unmet needs in pediatric patients with genetic skeletal disorders.
Read more →BMRNBioMarin to Participate in Three Upcoming Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at three upcoming investor conferences....
BioMarin Pharmaceutical Inc. has announced its participation in three upcoming investor conferences, where management will present key information. The events will feature live audio webcasts, with archived versions accessible for a limited time post-conference. BioMarin, a biotechnology company based in San Rafael, California, has been recognized for its innovative approach to developing therapies for rare genetic conditions.
Read more →BMRNBioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook Third Quarter 2024 Total Revenues of $746 million (+28% Y/Y and +32% at Constant Currency Y/Y); Year-to-date 2024 Total Revenues of $2.11 billion...
BioMarin Pharmaceutical Inc. reported a total revenue of $746 million for the third quarter of 2024, reflecting a 28% year-over-year increase. VOXZOGO contributed significantly to this growth, with a 54% increase in revenue for the product. Additionally, GAAP diluted earnings per share surged by 162% to $0.55. BioMarin also revised its full-year revenue guidance upward, reflecting a strong performance across its enzyme therapies portfolio and ongoing advancements in its clinical programs.
Read more →BMRNGreg Friberg Discusses Career Journey, What Brought Him to BioMarin
Greg Friberg has joined BioMarin as Executive Vice President and Chief R&D Officer, bringing nearly two decades of clinical development experience. He expressed enthusiasm for BioMarin's innovative genetic science and its commitment to addressing rare genetic conditions. Friberg aims to enhance the company's R&D efforts and significantly increase the number of patients reached by their medicines by 2034.
Read more →BMRNSocial Media Influencer Strives to Make Carnival Inclusive for All
Rebeca Costa, a lawyer and influencer with achondroplasia, is advocating for greater accessibility at Rio de Janeiro's Carnival. Recognizing the limitations faced by individuals with disabilities, she has collaborated with Carnival organizers to implement changes such as lower bar counters and accessible restrooms. Through her efforts, she aims to ensure that everyone can fully enjoy the celebration, fostering a culture of respect and inclusion.
Read more →BMRNBioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a...
BioMarin Pharmaceutical Inc. has announced that its CEO, Alexander Hardy, will host a conference call and webcast on October 29, 2024, to discuss the company's third-quarter financial results and provide a business update. The event highlights the company's transparency and commitment to engaging with investors. Interested parties can access the live audio webcast on BioMarin's investor website, and a replay will be available for one week after the call.
Read more →BMRNPKU Advocate, Parent Shares Personal Experience with Early Diagnosis
Denise Queally shares her experience with her daughter Caroline's early diagnosis of phenylketonuria (PKU), emphasizing the importance of newborn screening. The diagnosis allowed for effective management of Caroline's condition, leading Denise to become an advocate for PKU awareness and support. She discusses the role of the New England Connection for PKU and Allied Disorders (NECPAD) in providing resources and community for families affected by PKU.
Read more →BMRNRARE Scholars Program Supports College Students Living with Genetic Conditions
BioMarin's RARE Scholars program continues to support college students with rare genetic conditions, providing financial assistance and fostering leadership. This year's recipients include students studying pharmacy, public health, and animal science, all of whom are committed to advocacy and community engagement. The program has awarded over $125,000 since its inception in 2018.
Read more →BMRNPerseverance and Positivity: Chris’s Journey with MPS IVA
Chris, diagnosed with MPS IVA, has faced significant challenges since infancy. Despite the diagnosis being a source of fear for his parents, Chris has remained active and positive, engaging in various activities. His outlook inspires his family, who have developed a supportive care plan to help him manage his condition.
Read more →BMRNBioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting Results from Ongoing CANOPY Clinical Program for VOXZOGO Showcase Impact of C-Type Natriuretic Peptide (CNP) as Master Regulator of Growth-Related...
BioMarin Pharmaceutical Inc. announced that positive results from the CANOPY clinical program for VOXZOGO® (vosoritide) will be presented at the 2024 International Skeletal Dysplasia Society meeting. The findings highlight meaningful health-related quality of life improvements and significant increases in bone length while maintaining strength in children with achondroplasia. Additionally, ongoing studies suggest VOXZOGO may also benefit children with conditions such as hypochondroplasia and Noonan syndrome. The treatment is gaining recognition as a new standard of care for achondroplasia.
Read more →BMRNHope for a Brighter Future: Kainen’s Story
Cathy's son, Kainen, was diagnosed with Duchenne muscular dystrophy after showing physical challenges. The family sought support from CureDuchenne, a nonprofit organization, which helped them connect with others and learn about managing the condition. They remain optimistic about future advancements in treatment that could enhance Kainen's mobility and quality of life.
Read more →BMRNBioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host its Investor Day today in New York. The event begins at 10:30 a.m. Eastern Time and can be...
BioMarin Pharmaceutical Inc. is hosting its Investor Day today at 10:30 a.m. Eastern Time in New York, which can be accessed virtually. The event will include presentations from the leadership team, focusing on the company's strategic priorities aimed at delivering significant value creation. A question-and-answer session is also planned following the presentations. BioMarin is recognized for its commitment to innovative therapies addressing rare genetic disorders.
Read more →BMRNBioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) hosted an Investor Day earlier today, where President and Chief Executive Officer Alexander Hardy and...
BioMarin Pharmaceutical Inc. hosted an Investor Day where CEO Alexander Hardy introduced a new corporate strategy focused on creating sustained value for stakeholders. The updated strategy involves a restructured company model and a $500 million cost transformation program aimed at improving financial performance. BioMarin provided long-term financial guidance, projecting total revenues to reach $4 billion by 2027. The company also highlighted its innovation pipeline, indicating plans for significant product launches in the coming years.
Read more →BMRN‘Her Future is in Her Own Hands’: KK’s Journey with Achondroplasia
The article highlights the inspiring journey of KK, a 10-year-old girl with achondroplasia, who actively participates in various activities like soccer and swimming. Her family fosters a supportive environment, encouraging her to pursue her interests and voice her healthcare needs. KK's positive attitude and determination serve as a testament to her resilience and hope for the future.
Read more →BMRNBioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller, Executive Vice President, Chief Financial Officer of BioMarin will...
BioMarin Pharmaceutical Inc. has announced that its CFO, Brian Mueller, will present at the 22nd Annual Morgan Stanley Global Healthcare Conference on September 5, 2024. The presentation will be available via a live audio webcast, with an archived version accessible later. BioMarin, known for its focus on genetic therapies, continues to lead in developing treatments for rare genetic disorders.
Read more →BMRNBioMarin Announces New R&D and Business Development Leadership BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the appointments of Greg Friberg, M.D., as Executive Vice President, Chief Research &...
BioMarin Pharmaceutical Inc. has announced significant leadership transitions, with Greg Friberg appointed as Executive Vice President and Chief Research & Development Officer, and James Sabry taking on the role of Executive Vice President and Chief Business Officer. These appointments follow the retirement of long-serving Hank Fuchs, who has played a pivotal role in the company's R&D efforts. BioMarin also noted the resignation of Brinda Balakrishnan from her position, effective October 1. The company expressed confidence in Friberg and Sabry's capabilities to lead its R&D and business development efforts moving forward.
Read more →BMRNBioMarin to Host 2024 Investor Day on September 4th in New York BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host an Investor Day with financial analysts and institutional investors on Wednesday, September 4,...
BioMarin Pharmaceutical Inc. will host an Investor Day on September 4, 2024, in New York City aimed at financial analysts and institutional investors. The event will feature presentations from the executive management team, covering the company's pipeline, strategic plans, and growth opportunities. A live webcast will accompany the event, making the presentations widely accessible to interested stakeholders. This Investor Day emphasizes BioMarin's commitment to transparency and engagement with the financial community.
Read more →BMRNBioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced it will make changes to its ROCTAVIAN® business to focus commercial operations on three...
BioMarin Pharmaceutical Inc. announced a strategic shift for its ROCTAVIAN product, concentrating on the U.S., Germany, and Italy. By reducing operational expenses to about $60 million annually by 2025, the company aims to make ROCTAVIAN profitable by the end of that year. The company will continue supporting patients treated with ROCTAVIAN while ensuring resources are allocated to therapies that have the most significant impact. Notably, the treatment has shown impressive results, with 82% of participants remaining off prophylaxis four years post-treatment.
Read more →BMRNBioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance Second Quarter 2024 Total Revenues of $712 million (+20% Y/Y and +25% at Constant Currency Y/Y); First Half 2024 Total Revenues of $1.36 billion...
BioMarin Pharmaceutical Inc. reported a robust 20% year-over-year revenue growth for the second quarter of 2024, totaling $712 million. Alongside strong performance in its VOXZOGO treatment, the company revealed an increase in assessments and interest from families for its therapeutic products. With a focus on operational efficiency, BioMarin's non-GAAP diluted earnings per share rose by 78% year-over-year. The company has updated its full-year guidance to reflect continued strong demand and revenue projections.
Read more →BMRNU.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental...
BioMarin Pharmaceutical Inc. announced that the U.S. FDA has approved an expanded indication for BRINEURA (cerliponase alfa) to include children under 3 years with CLN2 disease, aiming to begin treatment before the onset of symptoms. This approval is based on a Phase 2 clinical trial demonstrating that early administration can delay disease progression and preserve motor function. The therapy is critical for improving quality of life in affected children, as CLN2 disease is known to be rapidly debilitating and life-limiting. The approval represents a significant milestone for families facing this severe genetic condition.
Read more →BMRNBioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a...
BioMarin Pharmaceutical Inc. has scheduled a conference call and webcast for August 5, 2024, at 4:30 PM ET to discuss its financial results for the second quarter of 2024. Alexander Hardy, the President and CEO, will lead the discussion, which aims to provide a general business update. Interested parties can access the live audio through the investor section of BioMarin's website, with a replay available for one week following the event.
Read more →BMRNLiving with PKU: Jonathan’s Story
Jonathan Springborn shares his personal journey living with phenylketonuria (PKU), a rare genetic condition. He reflects on the challenges he faced during childhood, including dietary restrictions and feelings of isolation. However, with advancements in care and community support, he has learned to manage his condition effectively and hopes to inspire others in the PKU community.
Read more →BMRNChoosing CNP: The Science Behind Human Growth
BioMarin has made significant advancements in understanding the role of C-type natriuretic peptide (CNP) in regulating growth, particularly in skeletal conditions like achondroplasia. The company has conducted extensive research and clinical trials, demonstrating the potential of CNP analogs to improve treatment outcomes. With ongoing studies, BioMarin aims to address various genetic short stature conditions, enhancing therapeutic options for affected families.
Read more →BMRNBioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the presentation of new data from an investigator-led analysis of the Phase 2 111-205...
BioMarin Pharmaceutical Inc. announced the presentation of new data on VOXZOGO (vosoritide) at the upcoming International Conference on Children's Bone Health. The Phase 2 111-205 study showed that children with achondroplasia saw significant increases in bone length while maintaining strength over five years. Additional findings indicated VOXZOGO's positive impact on health-related quality of life, particularly regarding physical functioning. The company is also addressing unmet medical needs in hypochondroplasia, as highlighted in their secondary study results.
Read more →BMRNBioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 Congress BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that new data supporting the long-term safety and efficacy of ROCTAVIAN® (valoctocogene...
BioMarin Pharmaceutical Inc. presented new Phase 3 data for ROCTAVIAN (valoctocogene roxaparvovec-rvox) at the ISTH 2024 Congress, highlighting its long-term safety and efficacy. The four-year follow-up results from the largest gene therapy study in hemophilia A showed that a significant percentage of patients achieved zero treated bleeds and maintained stable Factor VIII levels. Additionally, patients reported enhanced health-related quality of life, with improvements evident even for those with low FVIII levels. The data underscores ROCTAVIAN's potential to reduce the burden of ongoing treatments for individuals with severe hemophilia A.
Read more →BMRNFamily Camp Helps Create Community, Support Networks for People with PKU
The flok Family Camp has become a vital resource for families affected by phenylketonuria (PKU), offering community support and educational opportunities. Established in 2003, the camp brings together individuals with PKU to share experiences and learn about managing the condition. With activities and resources tailored to their needs, attendees find a sense of belonging and hope.
Read more →BMRNBioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President, and Chief Executive Officer of BioMarin will present at...
BioMarin Pharmaceutical Inc. has announced that its CEO, Alexander Hardy, will be presenting at the BofA Securities 2024 Healthcare Conference on May 15, 2024. The presentation will be accessible via live audio webcast, with an archived version available later on the company's website. BioMarin is known for its focus on genetic discovery and has developed eight commercial therapies targeting rare genetic disorders.
Read more →BMRNNew Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive new data supporting the safety and efficacy of VOXZOGO® (vosoritide) in children...
BioMarin Pharmaceutical Inc. has announced positive new data regarding its drug VOXZOGO (vosoritide) for treating children with various growth-related conditions, including achondroplasia, Noonan syndrome, and idiopathic short stature. The data, presented at the Pediatric Endocrine Society Annual Meeting, demonstrated significant increases in annualized growth velocity across the studied conditions. Safety results were in line with the established profile of VOXZOGO. This new evidence supports the drug's potential to positively impact growth in a wider range of genetic conditions affecting stature.
Read more →BMRNBioMarin Reports Record Financial Results for the First Quarter 2024 First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of $0.46 (+70%...
BioMarin Pharmaceutical Inc. reported robust financial results for the first quarter of 2024, with total revenues of $649 million, a 9% increase year-over-year. The company also noted a significant rise in GAAP diluted earnings per share, which grew 70% to $0.46. Growth was driven by strong demand for VOXZOGO, with net product revenues up by 74% compared to the same period last year. The company reaffirmed its full-year revenue guidance and raised expectations for non-GAAP operating margins and earnings per share.
Read more →BMRNEFiled: Mar 27 2024 12:01PM EDT Transaction ID 72616079 Case No. Multi-Case IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE ELAINE WANG, derivatively on : behalf of BIOMARIN : PHARMACEUTICAL INC., : : C.A. No. 2023-005
BioMarin Pharmaceuticals Inc. is involved in legal proceedings concerning allegations of fiduciary breaches by its executives, specifically related to purported false statements about its Valrox gene therapy application to the FDA. Two derivative actions initiated by shareholders Elaine Wang and Bill Tsantes claim that executives engaged in misconduct, including selling stock at inflated prices. After extended negotiations, a Stipulation of Compromise and Settlement was proposed, which remains subject to court approval. The defendants deny any wrongdoing, asserting compliance with legal duties. The outcome of these legal actions could significantly impact the company's governance and shareholder trust.
Read more →BMRNBioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a...
BioMarin Pharmaceutical Inc. is set to host its first quarter 2024 financial results conference call and webcast on April 24, 2024, at 4:30 p.m. ET. Alexander Hardy, the company’s CEO, will lead the discussion, focusing on financial results and business updates. The event signifies the company's continued commitment to transparency and investor communication. Interested parties can attend via the company’s investor website, with a replay available afterward.
Read more →BMRNWhere Are They Now? Catching Up with Alumni of Our RARE Scholars Program
The article highlights the achievements of alumni from BioMarin's RARE Scholars program, which supports U.S. college students with rare genetic conditions. Each alumnus shares how the program has positively influenced their educational and career paths, leading to roles in fields such as medical device design, neurology, and life sciences consulting. The program has awarded over $100,000 in scholarships since its inception in 2018.
Read more →BMRNA 100-Mile Road to Diagnosis: A Mother Shares Her Son’s Journey with Hypochondroplasia
Lora Vance shares her son Benjamin's journey with hypochondroplasia, a genetic condition affecting bone growth. After a challenging diagnosis process, Lora reflects on societal acceptance and the difficulties Benjamin faces growing up. Despite these challenges, she remains hopeful and committed to advocating for awareness and acceptance of his condition.
Read more →BMRNFrom Height to Health: Changing the Conversation in Achondroplasia
The article discusses the complexities of achondroplasia, emphasizing that height is not the only concern for affected individuals. It highlights the ongoing research by BioMarin to understand the condition better and improve health outcomes. Advocates call for a holistic approach to support the achondroplasia community, addressing both physical and psychological challenges.
Read more →BMRNNew Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive early results from an investigator-sponsored Phase 2 study of VOXZOGO®...
BioMarin Pharmaceutical Inc. announced promising results for its drug VOXZOGO (vosoritide) in treating children with hypochondroplasia and achondroplasia at the 2024 ACMG Annual Clinical Genetics Meeting. In a Phase 2 study, VOXZOGO showed an increase in annualized growth velocity, indicating potential for improved growth outcomes. The drug has also demonstrated long-term benefits for children with achondroplasia, including significant height gains and enhancements in quality of life. Presentations at the conference will further detail these findings, marking a progressive step for treatment options for growth-related conditions.
Read more →BMRNBioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer....
BioMarin Pharmaceutical Inc. has appointed Cristin Hubbard as its new Chief Commercial Officer, effective May 20, 2024. Ms. Hubbard, who has over 20 years of experience in biopharmaceuticals, previously held a senior role at Roche Pharma where she managed global product strategy. She will succeed Jeff Ajer, who has led the commercial organization for 11 years. BioMarin's CEO expressed confidence in Hubbard's ability to drive growth and innovation as the company continues to advance its portfolio of rare genetic therapies.
Read more →BMRNBioMarin Scheduled to Participate in March Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management is scheduled to participate in four upcoming investor conferences in March....
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is set to attend four investor conferences in March, which includes events hosted by Cowen, Leerink Partners, Jefferies, and Barclays. These conferences provide BioMarin an opportunity to showcase its advancements in genetic therapies and connect with potential investors. A live webcast of the company's presentations will be available on its website, along with a replay post-conference. This involvement indicates BioMarin's ongoing commitment to engage with the investment community.
Read more →BMRNBioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024 Total FY'23 Revenues of $2.42 Billion (+15% Y/Y and +20% Y/Y at Constant Currency); GAAP Diluted Earnings per Share of $0.87 (+16% Y/Y) and Non-GAAP...
BioMarin Pharmaceutical Inc. reported record financial results for the fourth quarter and full year of 2023, with total revenues reaching $2.42 billion, a 15% increase from the previous year. The company's performance was significantly bolstered by its product VOXZOGO, which saw an impressive 178% revenue growth year-over-year. For 2024, BioMarin has provided positive guidance, expecting continued growth through strategic priorities including maximizing the VOXZOGO opportunity and enhancing operational efficiency. The firm is hosting a conference call to discuss these results and future plans.
Read more →BMRNBioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a...
BioMarin Pharmaceutical Inc. has announced that CEO Alexander Hardy will host a conference call on February 22, 2024, at 4:30 p.m. ET. The call will focus on the company’s fourth quarter and full-year financial results for 2023 and will also include a general business update. Interested parties can access the call via a live audio webcast on the BioMarin website, with an option for replay available for one week after the event.
Read more →BMRNBioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
BioMarin Pharmaceutical Inc. announced plans to present new data on ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) at the 2024 EAHAD Congress. The results indicate that after seven years, the gene therapy continued to show durable benefits for adults with severe hemophilia A, with a significant reduction in bleeding rates and sustained factor VIII activity. The study demonstrated that most patients did not need to return to regular prophylaxis. The presentation is set for February 7, 2024, with additional studies planned for February 9.
Read more →BMRNBioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at...
BioMarin Pharmaceutical Inc. announced that CEO Alexander Hardy will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, in San Francisco. The conference is a significant platform for companies in the healthcare sector to discuss their strategies and innovations. An audio webcast of the presentation will be available live and archived thereafter for public access. BioMarin continues to pursue advancements in genetic therapies, emphasizing its commitment to patients with rare genetic disorders.
Read more →BMRNInvestors Media Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 218-7111 BioMarin Announces Governance Enhancements and Value Creation Initiatives Board
BioMarin Pharmaceutical Inc. has announced significant governance enhancements aimed at boosting long-term shareholder value. The board appointed three new independent directors and established a Strategic and Operating Review Committee to assess business strategy and operations. Additionally, the company entered into a cooperation agreement with Elliott Investment Management to facilitate dialogue and collaboration on value creation. These changes highlight BioMarin's proactive approach to strengthening its governance structure and operational performance.
Read more →BMRNBioMarin Announces Governance Enhancements and Value Creation Initiatives BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
BioMarin Pharmaceutical Inc. announced significant governance enhancements aimed at long-term shareholder value creation, including the appointment of three new independent directors and the formation of a Strategic and Operating Review Committee. This committee will focus on maximizing the company's operational performance, profitability, and long-term planning. Additionally, BioMarin will collaborate with Elliott Investment Management to facilitate constructive engagement. An investor day is planned for 2024 to further engage with stakeholders.
Read more →BMRNBioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
BioMarin Pharmaceutical Inc. has reached an agreement with the German National Association of Statutory Health Insurance Funds on the reimbursement for ROCTAVIAN (valoctocogene roxaparvovec-rvox), the first gene therapy for severe hemophilia A to receive a federal price approval in Germany. The therapy is priced at approximately €28,933.53 per vial, equating to about $900,000 per patient. This agreement involves an outcome-based reimbursement model and ensures access for approximately 2,000 adults with hemophilia A in Germany. Additionally, BioMarin is progressing with final price negotiations in Italy and continues to work to enhance access in the U.S.
Read more →BMRNBioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, announced...
BioMarin Pharmaceutical Inc. has announced the retirement of CEO Jean-Jacques Bienaimé, who has led the company for 18 years, and appointed Alexander Hardy as the new president and CEO effective December 1, 2023. Hardy, with more than 30 years of experience including his previous role as CEO of Genentech, will also hold a director position on BioMarin's board. Richard A. Meier will take over as the chair of the board of directors. Bienaimé's leadership has significantly contributed to the company's growth and profitability, positioning it strongly for future developments.
Read more →BMRNBioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year • Full-year 2023 Total Revenues and Earnings Per Share Financial Guidance Narrowed; VOXZOGO® and ROCTAVIAN® Net Product Revenue Guidance Adjusted for ...
BioMarin Pharmaceutical Inc. reported a strong financial performance for the third quarter of 2023, showing a 15% increase in total revenues compared to the previous year. The company announced the FDA approval of VOXZOGO for all ages with open growth plates, expanding access to new patient demographics. Additionally, BioMarin is advancing its reimbursement network for ROCTAVIAN, with positive negotiations expected to conclude by year-end in Germany and Italy. Overall, the company projects revenues to approach $3 billion in 2024.
Read more →BMRNCaring for Children with Achondroplasia: An Interview with Dr. Ciara McDonnell
Dr. Ciara McDonnell discusses the advancements in care for children with achondroplasia, highlighting the evolution of treatment and the importance of multidisciplinary approaches. She emphasizes the medical challenges faced in infancy and the psychosocial issues that arise as children grow older. Dr. McDonnell expresses optimism for the future, driven by the resilience of affected children and the community's efforts to improve understanding and support.
Read more →BMRNU.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
BioMarin Pharmaceutical Inc. announced that the U.S. FDA has approved its drug VOXZOGO (vosoritide) for children under 5 years with achondroplasia, expanding its previous indication which only included older children. This approval, granted under accelerated conditions, is based on evidence of improved growth velocity in clinical trials. The company aims to address the treatment needs of around 800 pediatric patients under 5 with this condition. VOXZOGO is already approved in several other countries, including Japan and Brazil, and has shown promising long-term growth benefits in younger patients.
Read more →BMRNBioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
BioMarin Pharmaceutical Inc. announced a conference call and webcast scheduled for November 1, 2023, where CEO Jean-Jacques Bienaimé will discuss the company's third-quarter financial results and provide a business update. The call aims to engage interested parties, with details available on the BioMarin website. The company emphasizes its dedication to transformational therapies in genetic conditions and its robust research pipeline.
Read more →BMRNRARE Scholars Program Provides Support to College Students Living with Genetic Conditions
BioMarin's RARE Scholars program provides financial support to U.S. college students with rare genetic conditions, including MPS and PKU. Since its launch in 2017, the program has awarded over $100,000 to 22 students, helping them pursue their academic and career goals. Recipients share their inspiring stories and the positive impact of the program on their lives.
Read more →BMRNBioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
BioMarin Pharmaceutical Inc. announced that new data on VOXZOGO (vosoritide) will be presented at the ESPE Meeting, showcasing long-term growth benefits in children with achondroplasia. The Phase 2 extension study revealed significant height increases in children treated with VOXZOGO, particularly when initiated before age 5. Insights from an early access program in France highlighted its safety and effectiveness, confirming findings from clinical trials. The EMA has positively recommended expanding VOXZOGO's approval for younger children, while the FDA is set to review an application to include those under 5 years of age in the U.S.
Read more →BMRNBioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
BioMarin Pharmaceutical Inc. received a favorable opinion from the European CHMP to extend the use of VOXZOGO (vosoritide) for children aged 4 months and older with achondroplasia. This decision is based on positive results from Phase 2 clinical trials that indicated significant growth improvements. The FDA has also set a target action date of October 21, 2023, for a supplemental New Drug Application to include younger children in the U.S. market. The company has experienced high global demand for VOXZOGO since its introduction, indicating a promising future for the treatment of this condition.
Read more →BMRNBioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will update...
BioMarin Pharmaceutical Inc. will present its research and development pipeline on September 12th in New York, focusing on early-stage product candidates and new indications for therapies like VOXZOGO and ROCTAVIAN. The event will feature discussions with external clinicians from leading global institutions, providing valuable insights into the company's innovative approaches. The pipeline includes several next-generation product candidates targeting various conditions, showcasing BioMarin's commitment to addressing significant unmet medical needs in genetic disorders.
Read more →BMRNBioMarin Teams Use Genetic Expertise and Computational Tools to Target More Common Conditions
BioMarin is leveraging its genetic expertise to expand treatment options beyond rare conditions to more common genetic disorders. The company employs various drug delivery methods and innovative tools like the polygenic score to identify patients who may benefit from new therapies. This strategic shift aims to address complex genetic issues involving multiple genes and mutations.
Read more →BMRNBioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will host an...
BioMarin Pharmaceutical Inc. will conduct an R&D Day on September 12, 2023, where company leadership and external medical experts will review seven product candidates in clinical development. Key topics will include ROCTAVIAN for severe hemophilia A and VOXZOGO for achondroplasia, including discussions around new indications for these therapies. The event will be webcast live at 8:00 a.m. ET, providing insights into BioMarin's ongoing commitment to transforming lives through genetic discovery.
Read more →BMRNBioMarin to Participate in Three Upcoming Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that company management will present at three upcoming investor conferences in September....
BioMarin Pharmaceutical Inc. has announced its participation in three upcoming investor conferences in September 2023. Company management will provide insights during these presentations, which will be accessible through live audio webcasts. Following the events, archived versions of the presentations will also be available on the company's website. This engagement reflects BioMarin's ongoing commitment to informing stakeholders about its advancements in biotechnology.
Read more →BMRNBioMarin Announces First Person Treated Commercially with ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Europe BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
BioMarin Pharmaceuticals has achieved a significant milestone by commercially treating an individual with severe hemophilia A in Germany using ROCTAVIAN. Ongoing discussions for reimbursement are in progress in France and Italy, indicating a potential expansion of therapy access across Europe. Following FDA approval, ROCTAVIAN is also now available in the U.S., with treatment centers actively screening candidates. This one-time gene therapy aims to transform treatment options for patients suffering from this chronic condition.
Read more →BMRNBioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date VOXZOGO® Growth Continued in the Second Quarter Driven by Global Demand Resulting in Increased Full Year 2023 Guidance Pivotal Program with VOXZOGO...
BioMarin Pharmaceutical Inc. announced impressive financial results for the second quarter and first half of 2023. Total revenues were reported at $595.3 million for the quarter, showing a 12% increase year-over-year. Notably, VOXZOGO revenues soared by 229%, contributing to increased guidance for the full year. The company also received U.S. approval for ROCTAVIAN, a significant addition to its product portfolio. However, some enzyme product revenues saw a slight decline in the quarter.
Read more →BMRNRaising a Child with Hemophilia: BioMarin Employee Jess Klass Shares Her Story
Jess Klass, a BioMarin employee, shares her journey raising her son Matthias, who was diagnosed with severe hemophilia A shortly after birth. Despite the challenges and anxieties associated with his condition, Jess emphasizes the importance of empowering Matthias and remaining hopeful for future treatment advancements. Her role at BioMarin allows her to advocate for patients and contribute to innovative solutions in hemophilia care.
Read more →BMRNBioMarin to Host Second-Quarter 2023 Financial Results Conference Call and Webcast on Monday, July 31, at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
BioMarin Pharmaceutical Inc. is set to host a conference call and webcast on July 31, 2023, at 4:30 p.m. ET, led by CEO Jean-Jacques Bienaimé. The event will focus on the discussion of the company's second-quarter 2023 financial results alongside a general business update. Interested stakeholders can access the live audio via BioMarin's investor website, and a replay will be available for one week post-event.
Read more →BMRNU.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
The FDA has approved BioMarin's ROCTAVIAN (valoctocogene roxaparvovec-rvox), marking it as the first gene therapy for adults with severe hemophilia A. This one-time treatment has demonstrated substantial long-term efficacy, with patients experiencing a mean reduction of 52% in annualized bleeding rates over three years. BioMarin plans to ensure access for eligible patients through collaborations with treatment centers and insurers. The approval is based on comprehensive data from the GENEr8-1 Phase 3 study, which included 134 participants.
Read more →BMRNBioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
BioMarin Pharmaceutical Inc. announced it will present new data on its gene therapy ROCTAVIAN (valoctocogene roxaparvovec) at the ISTH 2023 Congress. This includes results from the Phase 3 GENEr8-1 study, which is the largest trial for hemophilia gene therapy. The data will focus on the therapy's long-term effects on treatment efficacy and quality of life for adults with severe hemophilia A. The company is also preparing for a target action date from the FDA for its biologics license application for ROCTAVIAN.
Read more →BMRNBioMarin to Participate in Bank of America 2023 Health Care Conference BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller, Executive Vice President, Chief Financial Officer of BioMarin will...
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced its participation in the Bank of America 2023 Health Care Conference. Brian Mueller, the company's Chief Financial Officer, will present on May 10, 2023, at 3:40 PM PT in Las Vegas, NV. An audio webcast of his presentation will be available live, with an archived version accessible on the company's website afterward. This event highlights BioMarin's commitment to transparency and investor relations.
Read more →BMRNBioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues Growth of VOXZOGO® Accelerated with Rapid Uptake in Japan and Brazil Resulting in Increased Full-year 2023 Guidance Full-year 2023 Top-line and...
BioMarin Pharmaceutical Inc. announced its financial results for the first quarter of 2023, highlighting a record 15% year-over-year growth in total revenues, amounting to $596.4 million. This impressive growth was driven mainly by a substantial increase in the revenues from VOXZOGO, which surged by 346%. However, the company reported a decrease in GAAP net income compared to the previous year, raising concerns over certain declining product revenues. BioMarin updated its full-year 2023 financial guidance, maintaining optimism amidst mixed product performance.
Read more →BMRNBioMarin to Host First Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, April 26, at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
BioMarin Pharmaceutical Inc. will host a conference call and webcast on April 26, 2023, at 4:30 p.m. ET to discuss its first-quarter financial results and provide a general business update. The call will be led by CEO Jean-Jacques Bienaimé and is accessible through the company's investor website. BioMarin aims to provide a comprehensive overview of its current financial standing and discuss its ongoing commitment to developing therapies for rare genetic disorders.
Read more →BMRNBioMarin to Share Updated Data at 2023 American College of Medical Genetics and Genomics (ACMG) Meeting Demonstrating Commitment to Understanding Long-Term Benefit of VOXZOGO® in Children with Achondroplasia BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will present...
BioMarin Pharmaceutical Inc. will present updated findings on VOXZOGO at the 2023 ACMG meeting, emphasizing its long-term benefits in treating children with achondroplasia. Seven-year data indicates sustained improvement in growth velocity compared to untreated peers. VOXZOGO shows continued safety and well-tolerance in patients. This significant presentation aims to enhance understanding of the treatment’s effects as more data becomes available.
Read more →BMRNFDA Accepts BioMarin's Supplemental New Drug Application to Expand Use of VOXZOGO® (vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 5 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, announced...
BioMarin has announced that the FDA has accepted its supplemental New Drug Application (sNDA) for VOXZOGO (vosoritide) to treat children with achondroplasia under the age of five. This decision is based on encouraging results from a Phase 2 clinical trial and addresses a significant gap in available treatments for this young population. The FDA has set a target action date of October 21, 2023. Additionally, the sNDA is supported by similar safety and efficacy profiles in children under five compared to older children.
Read more →BMRN▼ -6.8%on this newsshared move
BioMarin Provides Update on FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
BioMarin Pharmaceutical Inc. has announced an extension by the FDA of the review period for its gene therapy, ROCTAVIAN, for severe hemophilia A, with a new action target date set for June 30, 2023. This extension is due to the submission of a substantial three-year data analysis from the Phase 3 GENEr8-1 study. The ongoing studies and designations such as RMAT suggest a commitment to addressing this unmet medical need, enhancing expectations for the therapy's future in treatment protocols.
Read more →BMRNBioMarin to Participate in Three Investor Conferences in March BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in three upcoming investor conferences in March....
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will participate in three investor conferences in March, including the Cowen Healthcare Conference and the Barclays Global Healthcare Conference. These events will feature live webcasts accessible on BioMarin's website. The company's updates during these conferences will provide insights into its ongoing efforts in developing targeted therapies for genetic disorders. BioMarin is noted for its history of innovation in the biotechnology space.
Read more →BMRNBioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business VOXZOGO $169 Million Contribution Drives Record Full Year 2022 Total Revenues of $2.1 Billion In 2023, More than 15% Growth in Total Revenues and...
BioMarin Pharmaceutical Inc. reported record financial results for Q4 and full year 2022, achieving total revenues of $2.1 billion, driven largely by the successful launch of VOXZOGO. The company experienced a significant increase in net product revenues from VOXZOGO, which contributed $169 million, marking a dramatic rise from previous years. Additionally, BioMarin has an optimistic outlook for 2023, anticipating a revenue increase of over 15%. However, they faced challenges with decreasing revenues from KUVAN products due to increased competition in the market.
Read more →BMRNBioMarin to Participate Virtually at SVB Securities Global Biopharma Conference on February 16, 2023 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer and Brian Mueller,...
BioMarin Pharmaceutical Inc. has announced its participation in the upcoming SVB Securities Global Biopharma Conference on February 16, 2023. The company's Chairman and CEO, Jean-Jacques Bienaimé, along with CFO Brian Mueller, will represent BioMarin virtually. This event underscores BioMarin's ongoing engagement with the broader biopharmaceutical industry and its dedication to advancing therapies for genetic conditions.
Read more →BMRNBioMarin to Host Fourth Quarter and Full-Year 2022 Financial Results Conference Call and Webcast on Monday, February 27, at 4:30 p.m. ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
BioMarin Pharmaceutical Inc. has announced a conference call and webcast scheduled for February 27, 2023, at 4:30 p.m. ET. The call will cover the fourth quarter and full-year 2022 financial results, along with a general business update led by CEO Jean-Jacques Bienaimé. Interested parties can access the live webcast and will be able to view a replay on the company's website for one week after the event. BioMarin, a biotechnology company founded in 1997, specializes in therapies for genetic conditions.
Read more →BMRNst Annual J.P. Morgan ai0MARIN Healthcare Conference
BioMarin Pharmaceutical Inc. presented at the J.P. Morgan Healthcare Conference, highlighting its positive financial outlook for 2023 with anticipated double-digit revenue growth and a commercial launch for ROCTAVIAN. The company plans to expand the market for VOXZOGO through new age indication approvals. However, they caution that various risks and uncertainties may affect their forecasted outcomes, including regulatory and clinical trial challenges. The company also notes significant revenue potential driven by both VOXZOGO and ROCTAVIAN as part of their growth strategy.
Read more →BMRNBioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™ in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at 3-Year Analysis BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
BioMarin Pharmaceutical Inc. announced positive results from its Phase 3 GENEr8-1 study of ROCTAVIAN, a gene therapy for severe hemophilia A, showing an 80% reduction in annualized bleed rates over three years. The study, the largest of its kind with 134 participants, also reported that 92% of patients were off prophylaxis. The company aims to leverage outcomes-based agreements in Germany to facilitate patient access, with ongoing discussions for additional agreements. The FDA's review of the Biologics License Application is ongoing, with a target PDUFA date of March 31, 2023.
Read more →BMRN▲ +6.3%on this newsshared move
BioMarin to Present at 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, at 10:30 am PT /1:30 pm ET, in San Francisco, CA BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the...
BioMarin Pharmaceutical Inc. will be presenting at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023. CEO Jean-Jacques Bienaimé will lead the presentation, which emphasizes the company's dedication to transforming lives through genetic discovery. BioMarin has established itself with eight successful therapies for rare genetic conditions and continues to pursue opportunities for first-to-market products in this area.
Read more →BMRNEuropean Medicines Agency Validates Application for Extension of Indication for VOXZOGO® (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, announced...
BioMarin Pharmaceutical Inc. announced that the European Medicines Agency validated its application to extend the indication for VOXZOGO (vosoritide) to treat children with achondroplasia under the age of 2. This is alongside a supplemental New Drug Application to the FDA for treating children under 5. The validation indicates that the submission is complete and the review process will begin, with potential action from health authorities expected in the second half of 2023. Results from a global Phase 2 study demonstrated an increase in growth velocity in all age cohorts involved in the trial.
Read more →BMRN▲ +7.2%on this news
BioMarin Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced advancements in the U.S. Food and Drug Administration (FDA) review of the Biologics License...
FDA No Longer Plans to Hold an Advisory Committee Meeting, as Previously Planned, to Discuss the Biologics License Application (BLA) BioMarin Remains on Track to Host Scheduled Manufacturing Inspections by FDA in the Coming Weeks SAN RAFAEL, Calif. , Nov. 23, 2022 /PRNewswire/
Read more →BMRNBioMarin Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today a progress update on its Biologics License Application (BLA) for valoctocogene...
FDA Pre-Licensure Inspection of Gene Therapy Manufacturing Facility Scheduled FDA Requests Submission of Upcoming 3-Year Data Analysis from Phase 3 GENEr8-1 Study Current PDUFA Target Action Date of March 31, 2023 , Could Be Extended by 3 Months, If 3-Year Data Submission Deeme
Read more →BMRNBioMarin to Participate in Two Upcoming Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at two upcoming investor conferences. To access the live...
SAN RAFAEL, Calif. , Nov. 3, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. ( NASDAQ : BMRN ) today announced that management will present at two upcoming investor conferences. To access the live webcasts , please visit: https://investors.biomarin.com/ . An archived version of
Read more →BMRNBioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®) VOXZOGO® $48 Million Contribution in the Quarter Results in BioMarin Raising Full-year 2022 VOXZOGO Net Product Revenue Guidance to Between $140...
SAN RAFAEL, Calif. , Oct. 26 , 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (BioMarin or the Company) today announced financial results for the third quarter ended September 30, 2022. "As anticipated, BioMarin is on-track to deliver double-digit revenue grow
Read more →BMRNFDA Accepts BioMarin's Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S. Food and Drug Administration (FDA) accepted the Company's resubmission of...
If Approved, Would Be 1st Gene Therapy in U.S. for Treatment of Severe Hemophilia A PDUFA Target Action Date is March 31, 2023 SAN RAFAEL, Calif. , Oct. 12, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the U.S. Food and Drug Administrat
Read more →BMRNBioMarin Simplifies Organizational Structure to Increase Efficiency BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced its decision to redesign the organization to better focus investments that advance its R&D ...
For over two decades, BioMarin has established industry leadership in genetics and molecular biology resulting in the rapid discovery, development, and commercialization of eight approved therapies, mostly in ultra-rare diseases. Having successfully evolved the pipeline to treat
Read more →BMRNBioMarin to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, October 26, at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , Oct. 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 26 th , at 4:30 p.m. ET to di
Read more →BMRNBioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the Company resubmitted a Biologics License Application (BLA) to the U.S. Food and...
BLA Includes Substantial Body of Data from Pivotal Phase 3 and Ongoing Phase 1/2 Studies If Approved, Would Be 1st Gene Therapy in U.S. for Treatment of Severe Hemophilia A SAN RAFAEL, Calif. , Sept. 29, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announce
Read more →BMRNBioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN™ (valoctocogene roxaparvovec), Assessed to Provide Substantial Cost Savings Per Patient in a Preliminary Independent Report BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Institute for Clinical and Economic Review (ICER) released a Draft Evidence...
Institute for Clinical and Economic Review (ICER) Base-Case Model Report Results in $4 Million Savings Versus Emicizumab Prophylaxis Per Patient Over a Lifetime Biologics License Application (BLA) Resubmission to FDA on Track for End of September 2022 SAN RAFAEL, Calif. , Sept.
Read more →BMRNFirst Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the European Commission (EC) has granted conditional marketing authorization (CMA)...
Maintains Orphan Drug Designation (ODD) in the EU Providing 10-years of Market Exclusivity Significant Benefit Over Existing Therapies for Patients with Severe Hemophilia A in EU Based on EMA Determination of ODD Conference Call and Webcast to be Held Wed., Aug. 24th at 8:00 pm
Read more →BMRNBioMarin Announces Record Revenues in Second Quarter 2022; Increases Full-year 2022 Top and Bottom-line Guidance VOXZOGO™ $34 Million Contribution Drives Total Revenues of $534 Million in the Quarter; Total Revenues Grew 13% Year-Over-Year, Excluding Kuvan...
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) SAN RAFAEL, Calif. , Aug. 3, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (BioMarin or the Company) today announced financial results for the second quarter ended June 30, 2
Read more →BMRNBioMarin to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, August 3, at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , July 20, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, August 3 rd , at 4:30 p.m. ET to dis
Read more →BMRNBioMarin Presents Findings from Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the International Society on Thrombosis and Haemostasis (ISTH) 2022 Congress July 9-12, Including 4 Oral and 2 Poster Presentations BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that it presented four oral presentations and two poster presentations on valoctocogene...
Commitment to Advancing Care for People with Hemophilia A Demonstrated with Largest and Longest, Ongoing Clinical Development Program for any Gene Therapy in Hemophilia A European Commission Approval for Valoctocogene Roxaparvovec Expected Q3 2022 SAN RAFAEL, Calif. , July 11,
Read more →BMRNBioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive...
European Commission Approval Expected Q3 2022 1st Gene Therapy for Treatment of Hemophilia A Recommended for Approval in Europe More than 20,000 Adults with Severe Hemophilia A in BioMarin Territories Across Europe, the Middle East and Africa Conference Call Scheduled for Frid
Read more →BMRNBioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO® (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan granted approval of the...
No Lower Age Restriction for Treatment Japan Accounts for Approximately Half of the 1,500 Patient Opportunity in APAC Region SAN RAFAEL, Calif. , June 21, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that the Ministry of Health, Labor and We
Read more →BMRNBioMarin Announces Favorable Results from Global Phase 2 Study of VOXZOGO™ (vosoritide) for Injection in Infants and Young Children with Achondroplasia at The Endocrine Society Annual Meeting, ENDO 2022 (June 11-14), in Atlanta BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) presented data at The Endocrine Society Annual Meeting, ENDO 2022, demonstrating the Company's ongoing...
Improvement in Height Z-Score and Annualized Growth Velocity Observed, Consistent with Children Over 5 Interactions with Health Authorities Planned for H2 2022 to Discuss Expanding Access to Younger Children SAN RAFAEL, Calif. , June 13, 2022 /PRNewswire/ -- BioMarin Pharmaceut
Read more →BMRN▼ -7.2%on this news
BioMarin Announces Durable Hemostatic Efficacy Maintained Over 6 years in Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A 95% Reduction in Mean Annualized Bleed Rate (ABR) and 96% Reduction in Mean Annualized Factor VIII Usage from Baseline Through Year 6 in 6e13 vg/kg...
SAN RAFAEL, Calif. , May 31, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today updated results from its ongoing open-label Phase 1/2 study, which represents the longest duration of clinical observation for valoctocogene roxaparvovec, an investigati
Read more →BMRNBioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company's Growth Plans BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Company hired two pharmaceutical industry leaders in their respective areas of...
Humaira Serajuddin Named to Newly Created Role of Senior Vice President, Chief Marketing Officer Erin Burkhart , Named Group Vice President, Chief Accounting Officer SAN RAFAEL, Calif. , May 5, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced th
Read more →BMRNBioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced five platform presentations and one poster presentation on valoctocogene roxaparvovec, an...
Ongoing Clinical Development Program Represents Largest and Longest Development Program for any Gene Therapy in Hemophilia A, Demonstrates Commitment to Advancing Care for People with Hemophilia A SAN RAFAEL, Calif. , May 5, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NAS
Read more →BMRNBioMarin to Participate in the BofA Securities 2022 Healthcare Conference, Thursday, May 12 at 8:40amPT/11:40amET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the...
SAN RAFAEL, Calif. , May 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the BofA Securities Healthcare Conference on May 12 at 8:40am PT / 11:40am ET in Las Ve
Read more →BMRNInvestors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Record Revenues in First Quarter 2022 BioMarin Reports R
Contact Investors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Record Revenues in First Quarter 2022 BioMarin Reports Record First Quarter Total Revenues of $519 Million D
Read more →BMRNBioMarin Announces Record Revenues in First Quarter 2022 BioMarin Reports Record First Quarter Total Revenues of $519 Million Driven by a $20 Million VOXZOGO Contribution; Total Revenues Grew 11%...
SAN RAFAEL, Calif. , April 27, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (BioMarin or the Company) today announced financial results for the first quarter ended March 31, 2022. "We begin 2022 from a position of financial strength including significant con
Read more →BMRNBioMarin to Host First Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, April 27, at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , April 13, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 27 th , at 4:30 p.m. ET to di
Read more →BMRNBioMarin Announces Publication in New England Journal of Medicine of One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced publication of results from the Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an...
New England Journal of Medicine Publishes Editorial: Prepare the Way for Hemophilia A Gene Therapy Significantly Reduced Bleeding and Factor VIII Utilization Compared to Baseline Factor VIII Prophylactic Therapy Mean Annualized Bleeding Rate (ABR) Reduced by 84% (p-value <0.001
Read more →BMRNInvestors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Fourth Quarter and Full Year 2021 Financial Results and
Contact Investors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates Full-year 2021 Total Revenues of $
Read more →BMRNBioMarin Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, ...
SAN RAFAEL, Calif. , Feb. 23, 2022 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) BioMarin Announces Fourth Quarter and Full-year 2021 Results December 31, 2021 December 31, 2020 Cash, cash equivalents and investments Bi
Read more →BMRNBioMarin Provides Updates on Progress in Gene Therapy Programs BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced updates on its investigational gene therapy programs in clinical development. In February 2022, ...
SAN RAFAEL, Calif. , Feb. 17, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced updates on its investigational gene therapy programs in clinical development. In February 2022 , the Company received additional requests from the Food and Drug Administratio
Read more →BMRNBioMarin to Participate in Two Upcoming Virtual Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences. An audio webcast of ...
SAN RAFAEL, Calif. , Feb. 16, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that management will participate in two upcoming virtual conferences. An audio webcast of the presentations will be available live. You can access the webcast at: https
Read more →BMRNBioMarin to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Wednesday, February 23 at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , Feb. 10, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 23rd , at 4:30 p.m. ET to d
Read more →BMRNBioMarin Sells Priority Review Voucher for $110 Million
BioMarin Sells Priority Review Voucher for $110 Million SAN RAFAEL, Calif., Feb. 9, 2022-SAN RAFAEL, Calif.,-BioMarin Pharmaceutical Inc. (Nasdaq BMRN) today announced that it has entered into a definitive agreement with an undisclosed purchaser to sell the Rare Pediatric Diseas
Read more →BMRNBioMarin Announces Oral Presentation of 2-Year Analysis of Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A at 15th Annual Congress of European Association for Haemophilia and Allied Disorders (EAHAD) 2-4 February BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Company presented positive results from a two-year analysis of the Phase 3...
SAN RAFAEL, Calif. , Feb. 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that the Company presented positive results from a two-year analysis of the Phase 3 GENEr8-1 study and an overall safety update of valoctocogene roxaparvovec, an investi
Read more →BMRNBioMarin Demonstrates Enduring Commitment to Advancing the Standard of Care in Hemophilia A at 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) February 2-4 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Company will be presenting data in several presentations on valoctocogene...
SAN RAFAEL, Calif. , Feb. 2, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that the Company will be presenting data in several presentations on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe
Read more →BMRNBioMarin Announces Stable and Durable Annualized Bleed Control in the Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at Two Year Analysis BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene...
SAN RAFAEL, Calif. , Jan. 9, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced positive results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe he
Read more →BMRNBioMarin to Participate in Two Virtual Investor Conferences in January BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at two...
SAN RAFAEL, Calif. , Jan. 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at two virtual conferences in January. To access the live webcasts, please visit: https://
Read more →BMRNBIOMARIN ALERT: Bragar Eagel & Squire, P.C. is Investigating BioMarin Pharmaceuticals on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioMarin Pharmaceuticals (NASDAQ: BMRN) on behalf of long-term stockholders following a class action complaint t
Read more →BMRNBioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Skyline Therapeutics (formerly Geneception), a gene and cell therapy company focused on developing...
SAN RAFAEL, Calif. and SHANGHAI , Dec. 16, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) and Skyline Therapeutics (formerly Geneception), a gene and cell therapy company focused on developing novel treatments for unmet medical needs, today announced a multi-ye
Read more →BMRNBIOMARIN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceuticals and Encourages Investors to Contact the Firm
NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against BioMarin Pharmaceuticals (“BioMarin” or the “Company”) (NASDAQ: BMRN) in the United S
Read more →BMRNBioMarin Appoints Former CEO of Celgene Corporation, Mark Alles, to Board of Directors BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of...
SAN RAFAEL, Calif. , Dec. 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former CEO of Celgene Corporation, Mark Alles , to its Board of Directors effectiv
Read more →BMRNBioMarin to Hold Virtual R&D Day at 11:00am ET Today BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host a virtual R&D Day beginning at 8:00am PT/11:00am ET today, Tuesday, November 30, 2021. BioMarin ...
SAN RAFAEL, Calif. , Nov. 30, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) will host a virtual R&D Day beginning at 8:00am PT/ 11:00am ET today, Tuesday, November 30, 2021 . BioMarin management and external experts will provide an update to the investment com
Read more →BMRNBioMarin to Participate in Two Upcoming Virtual Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual investor conferences. An audio...
SAN RAFAEL, Calif. , Nov. 29, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that management will participate in two upcoming virtual investor conferences. An audio webcast of the presentations will be available live. You can access the webcasts
Read more →BMRN▲ +10.3%on this newsshared move
BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to...
SAN RAFAEL, Calif. , Nov. 19, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VOXZOGO™ (vosoritide) for Injection, indicated to increase linear growth in pediatr
Read more →BMRNBIOMARIN PHARMACEUTICAL INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against BioMarin Pharmaceutical Inc.
NEW YORK, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) in the United States District Court for
Read more →BMRNBioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, ...
SAN RAFAEL, Calif. , Oct. 27, 2021 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (BioMarin or the Company) today announced financial results for the third quarter ended September
Read more →BMRNInvestors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updat
Contact Investors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates Strong Commercial Launch of VOXZOGO for the Treat
Read more →BMRNBioMarin to Participate in Four Upcoming Virtual Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in four upcoming virtual investor conferences. An audio...
SAN RAFAEL, Calif. , Oct. 25, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that management will participate in four upcoming virtual investor conferences. An audio webcast of the presentations will be available live. You can access the webcast
Read more →BMRNBioMarin to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, October 27 at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , Oct. 12, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 27 , at 4:30 p.m. ET to disc
Read more →BMRNBioMarin Hires Industry Veterans to Fill Key Roles in R&D and Technical Operations BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Company hired two industry veterans Harold S. Bernstein, M.D., Ph.D. as Senior...
SAN RAFAEL, Calif. , Oct. 4, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that the Company hired two industry veterans Harold S. Bernstein , M.D., Ph.D. as Senior Vice President, Chief Medical Officer and Head of Clinical Development and Ganes
Read more →BMRN▼ -8.4%on this news
U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S Food and Drug Administration (FDA) placed a clinical hold on the BMN 307...
SAN RAFAEL, Calif. , Sept. 6, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the U.S Food and Drug Administration (FDA) placed a clinical hold on the BMN 307 Phearless Phase 1/2 study. The Phearless study is evaluating BMN 307, an investiga
Read more →BMRN▲ +6%on this news
European Commission Approves BioMarin's VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Commission (EC) has granted marketing authorization for VOXZOGO®...
SAN RAFAEL, Calif. , Aug. 27, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the European Commission (EC) has granted marketing authorization for VOXZOGO® (vosoritide), a once daily injection to treat achondroplasia in children from the age
Read more →BMRNBioMarin to Participate in Three Upcoming Virtual Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in three upcoming virtual investor conferences. An audio ...
SAN RAFAEL, Calif. , Aug. 25, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that management will participate in three upcoming virtual investor conferences. An audio webcast of the presentations will be available live. You can access the webcas
Read more →BMRNInvestors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Second Quarter 2021 Financial Results and Corporate Upda
Contact Investors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates Total Revenues Grew 17% in the Second Quarter 20
Read more →BMRNBioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2021 2020...
SAN RAFAEL, Calif. , July 28, 2021 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (BioMarin or the Company) today announced financial results for the second quarter ended June 30,
Read more →BMRNBioMarin Announces Oral Presentation at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress with 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec in Adults with Severe Hemophilia A, Demonstrating Continued, Durable Clinical Benefit BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today new data for valoctocogene roxaparvovec, an investigational gene therapy treatment for...
SAN RAFAEL, Calif. , July 21, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today new data for valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A, from its open-label Phase 1/2 study during an or
Read more →BMRNBioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced new data for valoctocogene roxaparvovec, an investigational gene therapy for the...
SAN RAFAEL, Calif. , July 19, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced new data for valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, in its positive pivotal study, GENEr8-1,
Read more →BMRNEuropean Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) validated the Company's Marketing Authorization...
SAN RAFAEL, Calif. , July 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the European Medicines Agency (EMA) validated the Company's Marketing Authorization Application (MAA) for its investigational gene therapy, valoctocogene roxaparvo
Read more →BMRNBioMarin to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, July 28 at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , July 14, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, July 28 , at 4:30 p.m. ET to discuss
Read more →BMRNBioMarin Announces 12 Presentations at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced three oral presentations and nine poster presentations related to valoctocogene...
SAN RAFAEL, Calif. , July 2, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced three oral presentations and nine poster presentations related to valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hem
Read more →BMRNBioMarin Resubmits Marketing Authorization Application (MAA) to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company resubmitted a Marketing Authorization Application (MAA) to the European...
SAN RAFAEL, Calif. , June 28, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the company resubmitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational gene therapy, valoctocogene roxa
Read more →BMRNBioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive...
It is estimated that over 11,000 children across Europe , Middle East , and Africa are affected by achondroplasia and eligible for treatment with vosoritide, if approved by a health authority. Approximately a third of this population are in countries authorized to sell under the
Read more →BMRNBioMarin to Participate in the Virtual BofA Securities 2021 Napa Biopharma Conference BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in the BofA Securities 2021 Napa Biopharma Conference on ...
SAN RAFAEL, Calif. , June 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that management will participate in the BofA Securities 2021 Napa Biopharma Conference on June 16, 2021 at 3:30pm ET . An audio webcast of the presentation will be avai
Read more →BMRNEuropean Medicines Agency Grants BioMarin's Request for Accelerated Assessment of Valoctocogene Roxaparvovec for Treatment of Severe Hemophilia A BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) has granted its request for accelerated...
SAN RAFAEL, Calif. , May 24, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the European Medicines Agency (EMA) has granted its request for accelerated assessment of valoctocogene roxaparvovec, for adults with severe hemophilia A. Accelerat
Read more →BMRNBioMarin Provides Highlights of 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec with the Longest Duration of Clinical Experience for a Gene Therapy in Hemophilia A BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results from an open-label Phase 1/2 study of...
SAN RAFAEL, Calif. , May 19, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today an update to its previously reported results from an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with
Read more →BMRNBioMarin Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced three oral and three poster presentations on valoctocogene roxaparvovec, an...
SAN RAFAEL, Calif. , May 12, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced three oral and three poster presentations on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A at the Amer
Read more →BMRNInvestors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces First Quarter 2021 Financial Results and Corporate Updat
Contact Investors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates Full-year 2021 Financial Guidance Reaffirmed Tot
Read more →BMRNBioMarin Announces First Quarter 2021 Financial Results and Corporate Updates Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2021 2020 % Change Total Revenues $ ...
SAN RAFAEL, Calif. , April 29, 2021 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (BioMarin or the Company) today announced financial results for the first quarter ended March 31
Read more →BMRNAllen Institute and BioMarin Team Up To Develop Gene Therapies For Rare Brain Diseases The Allen Institute and BioMarin Pharmaceutical Inc. announced a collaboration today that will use technologies developed at the Allen Institute to...
SEATTLE and SAN RAFAEL, Calif. , April 28, 2021 /PRNewswire/ -- The Allen Institute and BioMarin Pharmaceutical Inc. announced a collaboration today that will use technologies developed at the Allen Institute to create new gene therapies aimed at rare genetic diseases of the cent
Read more →BMRNBioMarin Announces New and Updated Data at 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and Potential Treatment Choice BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) presented new and updated data at the 2021 American College of Medical Genetics and Genomics (ACMG)...
SAN RAFAEL, Calif. , April 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) presented new and updated data at the 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting that demonstrates the Company's ongoing commitment
Read more →BMRNBioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , April 13, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 29 , at 4:30 p.m. ET to discus
Read more →BMRNBioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society's Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose...
SAN RAFAEL, Calif. , March 20, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of vosoritide was presented at an oral presentation at ENDO21, the Endocrine So
Read more →BMRNBioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced...
SAN RAFAEL, Calif. , March 8, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to valoctocogene roxaparvovec, an investigational gen
Read more →BMRNBioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized,...
SAN RAFAEL, Calif. , March 3, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an investigational, once daily injection analog o
Read more →BMRNInvestors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Fourth Quarter and Record Full-year 2020 Financial Resul
Contact Investors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Fourth Quarter and Record Full-year 2020 Financial Results and Corporate Updates Full-year 2020 Total Revenu
Read more →BMRNBioMarin Announces Fourth Quarter and Record Full-year 2020 Financial Results and Corporate Updates Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, ...
SAN RAFAEL, Calif. , Feb. 25, 2021 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (BioMarin or the Company) today announced financial results for the fourth quarter and full year
Read more →BMRNBioMarin to Participate in Four Upcoming Virtual Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in four upcoming virtual conferences. An audio webcast...
SAN RAFAEL, Calif. , Feb. 24, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that management will participate in four upcoming virtual conferences. An audio webcast of the presentations will be available live. You can access the webcast at: http
Read more →BMRNBioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of Directors BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of...
SAN RAFAEL, Calif. , Feb. 18, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former Goldman Sachs partner and executive in the life sciences industry, Maykin H
Read more →BMRNBioMarin Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality Index BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the Company received the top score of 100 on the Human Rights Campaign Foundation's 2021...
SAN RAFAEL, Calif. , Jan. 28, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced the Company received the top score of 100 on the Human Rights Campaign Foundation's 2021 Corporate Equality Index (CEI), the nation's foremost benchmarking survey and r
Read more →BMRNBioMarin to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , Jan. 26, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 25 , at 4:30 p.m. ET to disc
Read more →BMRNBioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene...
SAN RAFAEL, Calif. , Jan. 10, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with
Read more →BMRNBioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that children in the open-label long-term extension of the Phase 3 study of vosoritide,...
SAN RAFAEL, Calif. , Dec. 21, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that children in the open-label long-term extension of the Phase 3 study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (C
Read more →BMRNBioMarin Pharmaceutical, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit: Portnoy Law Firm
Investors with losses are encouraged to contact the firm before November 24, 2020; click here to submit trade information LOS ANGELES, Nov. 20, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of BioMarin Pharm
Read more →BMRNBioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that...
SAN RAFAEL, Calif. and TORONTO , Nov. 17, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics' artificial intelligence drug discovery platf
Read more →BMRNBioMarin to Participate in Three Upcoming Virtual Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in three upcoming virtual conferences. An audio webcast...
SAN RAFAEL, Calif. , Nov. 12, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that management will participate in three upcoming virtual conferences. An audio webcast of the presentations will be available live. You can access the webcast at: htt
Read more →BMRNBioMarin Expands Vosoritide Clinical Program BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the Company is expanding its clinical program for vosoritide, an investigational...
SAN RAFAEL, Calif. , Nov. 9, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the Company is expanding its clinical program for vosoritide, an investigational analog of C-type Natriuretic Peptide (CNP), with two new Phase 2 studies. The first
Read more →BMRNBioMarin Announces Third Quarter 2020 Total Revenues of $477 Million Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, ...
SAN RAFAEL, Calif. , Nov. 5, 2020 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (BioMarin or the Company) today announced financial results for the third quarter ended September
Read more →BMRNInvestors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Third Quarter 2020 Total Revenues of $477 Million Top-li
Contact Investors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Third Quarter 2020 Total Revenues of $477 Million Top-line Results from 52-week Phase 3 Study with Valoctoco
Read more →BMRNBioMarin to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on November 10 at 12:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, and Brian Mueller,...
SAN RAFAEL, Calif. , Nov. 4, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, and Brian Mueller , Executive Vice President, Chief Financial Officer, will participate in the Credit S
Read more →BMRNFood and Drug Administration Accepts BioMarin's New Drug Application for Vosoritide to Treat Children with Achondroplasia BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application...
SAN RAFAEL, Calif. , Nov. 2, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for vosoritide, an investigational, once daily injection analog of C-type Na
Read more →BMRNBioMarin to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Thursday, November 5 at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , Oct. 22, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, November 5 , at 4:30 p.m. ET to discu
Read more →BMRNBioMarin, Pioneer in Rare Disease Treatments for Phenylketonuria (PKU), Receives FDA Approval of Label Expansion to Allow Maximum Dose of 60 mg for Palynziq® (pegvaliase-pqpz) Injection for Treatment of Adults with PKU BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics...
SAN RAFAEL, Calif. , Oct. 7, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) to increase the maximum allowable dose of 60 mg with
Read more →BMRNScientific Luminary and MacArthur Fellowship Winner, Kevin Eggan, Ph.D., Joins BioMarin as Head of Research and Early Development BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the Company hired scientific luminary and MacArthur Fellowship winner, Kevin Eggan, Ph.D., ...
SAN RAFAEL, Calif. , Oct. 5, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced the Company hired scientific luminary and MacArthur Fellowship winner, Kevin Eggan , Ph.D., as Group Vice President, Head of Research and Early Development, effective to
Read more →BMRNBioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Receives FDA Fast Track Designation for PKU Investigational Gene Therapy, BMN 307 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a pioneer in developing treatments for phenylketonuria (PKU) and gene therapies, announced today that...
SAN RAFAEL, Calif. , Oct. 2, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), a pioneer in developing treatments for phenylketonuria (PKU) and gene therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to
Read more →BMRNBioMarin to Participate in Upcoming Virtual Investor Conference BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller, Executive Vice President, Chief Financial Officer, will participate...
SAN RAFAEL, Calif. , Sept. 29, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Brian Mueller , Executive Vice President, Chief Financial Officer, will participate in Morningstar's Management Behind the Moat Conference on September 30, 2020 a
Read more →BMRNBIOMARIN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors t
Read more →BMRNBioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Doses First Participant in Global PHEARLESS Phase 1/2 Study of BMN 307 Gene Therapy BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has dosed the first participant in the global PHEARLESS Phase 1/2 study with BMN...
SAN RAFAEL, Calif. , Sept. 24, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that it has dosed the first participant in the global PHEARLESS Phase 1/2 study with BMN 307, an investigational gene therapy for the treatment of individuals with PKU
Read more →BMRNBioMarin Announces Presentation of Vosoritide Phase 3 Data in Children with Achondroplasia at the American Society for Bone and Mineral Research 2020 Annual Meeting BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Lynda Polgreen, MD, MS, Lundquist Institute for Biomedical Innovation at Harbor-UCLA ...
SAN RAFAEL, Calif. , Sept. 11, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Lynda Polgreen , MD, MS, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA , USA will present data from the randomized, do
Read more →BMRNBioMarin Announces The Lancet Publishes Detailed Vosoritide Phase 3 Data Demonstrating Statistically Significant Increase in Annualized Growth Velocity (AGV) Over 52 Weeks in Children with Achondroplasia BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that The Lancet has published online results from a randomized, double-blind, phase 3,...
SAN RAFAEL, Calif. , Sept. 8, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that The Lancet has published online results from a randomized, double-blind, phase 3, placebo-controlled, multicenter trial for vosoritide, an investigational analog o
Read more →BMRNBioMarin Submits New Drug Application to U.S. Food and Drug Administration for Vosoritide to Treat Children with Achondroplasia BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug...
SAN RAFAEL, Calif. , Aug. 20, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vosoritide, an investigational, once daily injection analog of C-t
Read more →BMRNBioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL)...
SAN RAFAEL, Calif. , Aug. 19, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to the Company's Biologics License Application (BLA) for valoctocogene roxaparv
Read more →BMRNEuropean Medicines Agency Validates BioMarin's Marketing Authorization Application for Vosoritide to Treat Children with Achondroplasia BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) validated the Company's Marketing Authorization...
SAN RAFAEL, Calif. , Aug. 13, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the European Medicines Agency (EMA) validated the Company's Marketing Authorization Application (MAA) for vosoritide, an investigational, once daily injection anal
Read more →BMRNBioMarin to Participate in Two Upcoming Virtual Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jeff Ajer, Executive Vice President and Chief Commercial Officer, and Brian Mueller, ...
SAN RAFAEL, Calif. , Aug. 10, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jeff Ajer , Executive Vice President and Chief Commercial Officer, and Brian Mueller , Executive Vice President, Chief Financial Officer will participate in the 20
Read more →BMRNInvestors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Second Quarter 2020 Total Revenue Growth of 11% to $430
Contact Investors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Second Quarter 2020 Total Revenue Growth of 11% to $430 million U.S. Marketing Application for Valoctocogene
Read more →BMRNBioMarin Announces Second Quarter 2020 Total Revenue Growth of 11% to $430 million Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2020 2019...
SAN RAFAEL, Calif. , Aug. 4, 2020 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (BioMarin or the Company) today announced financial results for the second quarter ended June 30,
Read more →BMRNBioMarin Submits Marketing Authorization Application to European Medicines Agency for Vosoritide to Treat Children with Achondroplasia BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company submitted a Marketing Authorization Application (MAA) to the European...
SAN RAFAEL, Calif. , July 23, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vosoritide, an investigational, once daily injection a
Read more →BMRNBioMarin to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, August 4 at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , July 21, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, August 4 , at 4:30 p.m. ET to discuss
Read more →BMRNBioMarin Promotes Company Veteran, Brian R. Mueller, to Executive Vice President, CFO BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the promotions of Brian R. Mueller to Executive Vice President, Chief Financial Officer...
SAN RAFAEL, Calif. , June 29, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced the promotions of Brian R. Mueller to Executive Vice President, Chief Financial Officer and of Andrea L. Acosta to Group Vice President, Chief Accounting Officer. Mr. M
Read more →BMRNBioMarin to Participate in the Virtual BofA Securities 2020 Napa Biopharma Conference BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Henry Fuchs, M.D., President, Worldwide Research & Development and Brian Mueller,...
SAN RAFAEL, Calif. , June 23, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Henry Fuchs , M.D., President, Worldwide Research & Development and Brian Mueller , Acting Chief Financial Officer, will participate in the BofA Securities 2020 Na
Read more →BMRNBioMarin Provides Additional Data from Recent 4 Year Update of Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in Late-Breaking Oral Presentation at World Federation of Hemophilia Virtual Summit BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today additional data from its previously reported four-year update of an open-label Phase 1/2...
SAN RAFAEL, Calif. , June 17, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today additional data from its previously reported four-year update of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment
Read more →BMRNBioMarin to Participate in Two Upcoming Virtual Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer; Henry Fuchs, M.D.,...
SAN RAFAEL, Calif. , June 3, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer; Henry Fuchs , M.D., President, Worldwide Research & Development; and Brian Mueller , Acting Chief Finan
Read more →BMRNBioMarin Provides Highlights of 4 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of...
SAN RAFAEL, Calif. , May 31, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with se
Read more →BMRNInvestors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 For Immediate Release : BioMarin Announces Closing of Exercise by Initial
Investors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 For Immediate Release: BioMarin Announces Closing of Exercise by Initial Purchasers of Option to Purchase an Additional $50 milli
Read more →BMRNBioMarin Announces Closing of Exercise by Initial Purchasers of Option to Purchase an Additional $50 million of 1.25% Senior Subordinated Convertible Notes due 2027 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the initial purchasers of the previously announced offering of its 1.25% Senior...
SAN RAFAEL, Calif. , May 19, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that the initial purchasers of the previously announced offering of its 1.25% Senior Subordinated Convertible Notes due 2027 in a private placement to qualified institut
Read more →BMRNBioMarin Announces Proposed Private Offering of $500 Million of Senior Subordinated Convertible Notes BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it intends to offer, subject to market conditions and other factors, $500.0 million...
SAN RAFAEL, Calif. , May 11, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of senior subordinated convertible notes due 2027 in
Read more →BMRNBioMarin Announces Pricing of Upsized $550 Million Senior Subordinated Convertible Notes Offering BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the pricing of $550.0 million aggregate principal amount of 1.25% senior subordinated...
SAN RAFAEL, Calif. , May 11, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced the pricing of $550.0 million aggregate principal amount of 1.25% senior subordinated convertible notes due 2027 in a private placement to qualified institutional buyers
Read more →BMRNInvestors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 For Immediate Release : BioMarin Announces Proposed Private Offering of $
Contacts: Investors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 For Immediate Release: BioMarin Announces Proposed Private Offering of $500 Million of Senior Subordinate
Read more →BMRNBioMarin to Participate in Two Upcoming Virtual Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in the Bank of America Global Research Health Care...
SAN RAFAEL, Calif. , May 6, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that management will participate in the Bank of America Global Research Health Care Conference on May 14, 2020 at 2:20pm ET and the RBC Capital Markets Global Healthcare
Read more →BMRNBioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has entered into a preclinical collaboration and license agreement with...
SAN RAFAEL, Calif. , May 3, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that the company has entered into a preclinical collaboration and license agreement with DiNAQOR AG (DiNAQOR), a gene therapy platform company, to develop novel gene ther
Read more →BMRNInvestors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces First Quarter 2020 Total Revenue Growth of 25% to $502 m
Contact Investors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces First Quarter 2020 Total Revenue Growth of 25% to $502 million U.S. Marketing Application for Valoctocogene
Read more →BMRNBioMarin Announces First Quarter 2020 Total Revenue Growth of 25% to $502 million Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2020 2019 % Change Total Revenues $ ...
SAN RAFAEL, Calif. , April 29, 2020 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (BioMarin or the Company) today announced financial results for the first quarter ended March 31
Read more →BMRNBioMarin Updates Timing of First Quarter 2020 Financial Results Conference Call and Webcast to Wednesday, April 29 at 4:15pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , April 22, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 29 , at 4:15 p.m. ET to discu
Read more →BMRNBioMarin Appoints Global Pharmaceutical Veteran C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive Vice President of Global Manufacturing and Technical Operations, Effective May 4 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the appointment of C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive Vice...
SAN RAFAEL, Calif. , April 21, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced the appointment of C. Greg Guyer , Ph.D., to Chief Technical Officer, Executive Vice President of Global Manufacturing and Technical Operations. Effective May 4 , Dr.
Read more →BMRNBioMarin to Host First Quarter 2020 Financial Results Conference Call and Webcast on Thursday, April 30 at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , April 14, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 30 , at 4:30 p.m. ET to discus
Read more →BMRNBioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that based on recent meetings with health authorities in the US and Europe, the Company...
SAN RAFAEL, Calif. , April 6, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that based on recent meetings with health authorities in the US and Europe , the Company plans to submit marketing applications to the US Food and Drug Administration (
Read more →BMRNBioMarin's Brinda Balakrishnan, M.D., Ph.D., Honored with 2020 40 Under 40 Award from the San Francisco Business Times BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Brinda Balakrishnan, M.D., Ph.D., has been named to the San Francisco Business Times...
SAN RAFAEL, Calif. , March 9, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Brinda Balakrishnan , M.D., Ph.D., has been named to the San Francisco Business Times 2020 "40 Under 40" list. Now in its ninth year, the San Francisco Business Ti
Read more →BMRNBioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, ...
SAN RAFAEL, Calif. , Feb. 26, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (BioMarin or the Company) today announced financial results for the fourth quarter and full year 2019. Total Net Product Revenues for the fourth quarter of 2019 increased to $436.6 m
Read more →BMRNInvestors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Resul
Contact Investors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results Full-year 2019 Total Revenues Increased 14% to $1
Read more →BMRNBioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the...
SAN RAFAEL, Calif. , Feb. 20, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) to the FDA for its investigational AAV5 gene t
Read more →BMRNBioMarin to Participate in Two Upcoming Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in the 9th Annual Leerink Partners Global Healthcare...
SAN RAFAEL, Calif. , Feb. 12, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that management will participate in the 9th Annual Leerink Partners Global Healthcare Conference on February 26, 2020 at 10:00am ET in New York City and the Cowen and C
Read more →BMRNBioMarin Announces CFO Succession BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced the transition of Executive Vice President and Chief Financial Officer Dan Spiegelman....
SAN RAFAEL, Calif. , Feb. 3, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced the transition of Executive Vice President and Chief Financial Officer Dan Spiegelman . Mr. Spiegelman will remain as an employee and senior advisor until September 1,
Read more →BMRNBioMarin to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Wednesday, February 26 at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , Jan. 29, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 26 , at 4:30 p.m. ET to dis
Read more →BMRNBioMarin, Pioneer in Phenylketonuria, to Begin Clinical Trial with BMN 307 Gene Therapy BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a pioneer in treatments for the rare disease Phenylketonuria (PKU) and in gene therapy clinical...
SAN RAFAEL, Calif. , Jan. 13, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), a pioneer in treatments for the rare disease Phenylketonuria (PKU) and in gene therapy clinical research, announced today that both the U.S. Food and Drug Administration (FDA) and the
Read more →BMRNBioMarin to Participate in Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top on January 9, 2020 in New York BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at Goldman ...
SAN RAFAEL, Calif. , Jan. 8, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top on January 9,
Read more →BMRNBioMarin to Present at 38th Annual J.P. Morgan Healthcare Conference in San Francisco BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the ...
SAN RAFAEL, Calif. , Jan. 6, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the 38 th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 7
Read more →BMRNBioMarin Announces New England Journal of Medicine Publishes 3 Years of Follow-up Data in Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A ioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the New England Journal of Medicine (NEJM) published an independently peer-reviewed...
SAN RAFAEL, Calif. , Jan. 2, 2020 /PRNewswire/ --BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the New England Journal of Medicine (NEJM) published an independently peer-reviewed article on up to three years of data from an ongoing Phase 1/2 study to evaluate
Read more →BMRNBioMarin Submits Biologics License Application to U.S. Food and Drug Administration for Valoctocogene Roxaparvovec to Treat Hemophilia A BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company submitted a Biologics License Application (BLA) to the U.S. Food and...
SAN RAFAEL, Calif. , Dec. 23, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its investigational AAV gene therapy, valoctocogene
Read more →BMRNBioMarin Announces Positive Final Results from Placebo-Controlled Phase 3 Data in Children with Achondroplasia Treated with Vosoritide BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today reported positive final results from its randomized, double-blind, placebo-controlled Phase 3 study ...
SAN RAFAEL, Calif. , Dec. 16, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today reported positive final results from its randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of vosoritide. The placebo-adjusted change
Read more →BMRNBioMarin Submits Marketing Authorization Application to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company submitted a Marketing Authorization Application (MAA) to the European...
SAN RAFAEL, Calif. , Nov. 21, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational gene therapy, valoctocogene roxapa
Read more →BMRNPoised for Significant Growth and Profitability, BioMarin Shares Company Highlights During R&D Day on November 14th in New York BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) updated the investment community on the Company's research and development portfolio, which is focused on ...
SAN RAFAEL, Calif. , Nov. 14, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) updated the investment community on the Company's research and development portfolio, which is focused on innovative therapies to treat rare diseases. "BioMarin is at an inflection po
Read more →BMRNBioMarin Announces Cumulative Additional Height Gain of 9.0 cm over 54 months versus Natural History in Children with Achondroplasia Treated with Vosoritide in Phase 2 Study BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) provided an update on its clinical program for vosoritide, an analog of C-type Natriuretic Peptide (CNP), ...
SAN RAFAEL, Calif. , Nov. 14, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) provided an update on its clinical program for vosoritide, an analog of C-type Natriuretic Peptide (CNP), in children with achondroplasia, the most common form of disproportionate shor
Read more →BMRNBioMarin to Participate in Jefferies London Healthcare Conference on November 21, 2019 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the...
SAN RAFAEL, Calif. , Nov. 12, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Jefferies London Healthcare Conference on November 21, 2019 at 1:20pm GMT / 8:20am
Read more →BMRNBioMarin to Highlight Innovative Development Pipeline at R&D Day on November 14th BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host an R&D Day at 8:00am ET on Thursday, November 14, 2019. BioMarin management and external...
SAN RAFAEL, Calif. , Nov. 6, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) will host an R&D Day at 8:00am ET on Thursday, November 14, 2019 . BioMarin management and external experts will provide an update to the investment community on the Company's developme
Read more →BMRNBioMarin Announces Third Quarter 2019 Financial Results Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, ...
SAN RAFAEL, Calif. , Oct. 23, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (BioMarin or the Company) today announced financial results for the third quarter ended September 30, 2019. Total Net Product Revenues for the third of quarter 2019 increased to $450
Read more →BMRNInvestors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Third Quarter 2019 Financial Results - The Company Ac
Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Third Quarter 2019 Financial Results - The Company Achieved Record Total Revenues of $461.1 million; Incr
Read more →BMRNBioMarin to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, October 23 at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , Oct. 9, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 23 , at 4:30 p.m. ET to discu
Read more →BMRNBioMarin Promotes Lon Cardon, Ph.D. to Chief Scientific Strategy Officer BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the promotion of Lon Cardon, Ph.D. to Chief Scientific Strategy Officer, a newly created...
SAN RAFAEL, Calif. , Oct. 7, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced the promotion of Lon Cardon , Ph.D. to Chief Scientific Strategy Officer, a newly created role to enrich BioMarin's pipeline, which drives the future growth of the compa
Read more →BMRNBioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Robert Baffi, Ph.D., President of Global Manufacturing and Technical Operations,...
SAN RAFAEL, Calif. , Oct. 1, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Robert Baffi , Ph.D., President of Global Manufacturing and Technical Operations, will participate in a fireside discussion at the Jefferies Gene Therapy/Editing Su
Read more →BMRNBioMarin, Pioneer in Phenylketonuria (PKU) Therapies, Submits Clinical Trial Application (CTA) in U.K. for Investigational Gene Therapy for PKU BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a pioneer in treatments for rare disease Phenylketonuria (PKU) and in gene therapies, today announced...
SAN RAFAEL, Calif. , Sept. 26, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ), a pioneer in treatments for rare disease Phenylketonuria (PKU) and in gene therapies, today announced that it has submitted a Clinical Trial Application (CTA) with the Medicines and
Read more →BMRNBioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer and Henry...
SAN RAFAEL, Calif. , Sept. 9, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that Dan Spiegelman , Executive Vice President and Chief Financial Officer and Henry Fuchs , M.D., President, Worldwide Research & Development, will present at the Mor
Read more →BMRNBioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer, will present...
SAN RAFAEL, Calif. , Aug. 28, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Dan Spiegelman , Executive Vice President and Chief Financial Officer, will present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 10,
Read more →BMRNBioMarin Announces Second Quarter 2019 Financial Results Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2019 2018...
SAN RAFAEL, Calif. , Aug. 1, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (BioMarin or the Company) today announced financial results for the second quarter ended June 30, 2019. Total Net Product Revenues for the second of quarter 2019 increased to $379.1 m
Read more →BMRNInvestors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Second Quarter 2019 Financial Results - Total Revenue
Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Second Quarter 2019 Financial Results - Total Revenues of $387.8 million in the Quarter - Full-year 2019
Read more →BMRNBioMarin to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1 at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , July 16, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, August 1 , at 4:30 p.m. ET to discuss
Read more →BMRNBioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of...
SAN RAFAEL, Calif. , July 9, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ), a global leader in providing therapies for rare genetic diseases, today announced the appointment of pharmaceutical veteran and former Johnson & Johnson executive, Liz McKee Anderson ,
Read more →BMRNBioMarin Plans Regulatory Submissions for Marketing Authorization of Valoctocogene Roxaparvovec to Treat Severe Hemophilia A in 4Q 2019 in both U.S. and Europe BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that based on recent meetings with health authorities in the U.S. and Europe, the company ...
SAN RAFAEL, Calif. , July 8, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that based on recent meetings with health authorities in the U.S. and Europe , the company plans to submit marketing applications to both the U.S. Food and Drug Administ
Read more →BMRNBioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia from July 6-10, 2019 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that Professor John Pasi, M.B., Ch.B., Ph.D., from Barts and the London School of...
SAN RAFAEL, Calif. , June 26, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that Professor John Pasi , M.B., Ch.B., Ph.D., from Barts and the London School of Medicine and Dentistry and principal investigator for the valoctocogene roxaparvovec
Read more →BMRNBioMarin Earns Milestone Payments from Pfizer for TALZENNA® (talazoparib) for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Company earned a $15 million milestone payment from Pfizer, Inc. This milestone...
SAN RAFAEL, Calif. , June 21, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that the Company earned a $15 million milestone payment from Pfizer, Inc. This milestone payment was triggered by the European Commission (EC) approval of TALZENNA ® (t
Read more →BMRNBioMarin Announces New England Journal of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up to 42 Months in Children with Achondroplasia BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that the New England Journal of Medicine (NEJM) published online today results from a Phase 2...
SAN RAFAEL, Calif. , June 18, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced that the New England Journal of Medicine (NEJM) published online today results from a Phase 2 dose-finding and extension study for vosoritide, an investigational analog of C-
Read more →BMRNBioMarin to Participate in Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11 in Rancho Palos Verdes, CA BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Henry Fuchs, M.D., President, Worldwide Research & Development, will present at the...
SAN RAFAEL, Calif. , June 5, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Henry Fuchs , M.D., President, Worldwide Research & Development, will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11 at 8
Read more →BMRNBioMarin Announces Approval of Vimizim® (elosulfase alfa) in China for Treatment of Morquio A Syndrome BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that Vimizim® (elosulfase alfa) has been approved by the National Medical Products...
SAN RAFAEL, Calif. , June 4, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that Vimizim® (elosulfase alfa) has been approved by the National Medical Products Administration (NMPA) for the treatment of patients with mucopolysaccharidosis type IV
Read more →BMRNBioMarin Provides 3 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of...
SAN RAFAEL, Calif. , May 28, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with se
Read more →BMRNBioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe ...
SAN RAFAEL, Calif. , May 28, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A achieved pre-specified clinical criteria for regulatory review in
Read more →BMRNBioMarin to Host Conference Call Tuesday, May 28, 2019 to Provide a Valoctocogene Roxaparvovec Phase 2 and Phase 3 Update BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will host a conference call and webcast on Tuesday, May 28 at 8:00am ET...
SAN RAFAEL, Calif. , May 27, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that management will host a conference call and webcast on Tuesday, May 28 at 8:00am ET to discuss program updates. Conference Call and Webcast Information Interested
Read more →BMRNBioMarin to Participate in 2019 RBC Capital Markets Global Healthcare Conference on May 21 in New York City BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Robert Baffi, Ph.D., Executive Vice President, Technical Operations, will...
SAN RAFAEL, Calif. , May 16, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that Robert Baffi , Ph.D., Executive Vice President, Technical Operations, will participate in a gene therapy manufacturing focused fireside chat at the RBC Capital Mar
Read more →BMRNBioMarin to Participate in Bank of America Merrill Lynch Health Care Conference on May 15 in Las Vegas BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the...
SAN RAFAEL, Calif. , May 8, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Bank of America Merrill Lynch Health Care Conference on May 15 at 11:20am PT / 2:20
Read more →BMRNEuropean Commission Approves Palynziq® (pegvaliase injection) for Treatment of Phenylketonuria (PKU) in Patients Aged 16 Years or Older BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the European Commission (EC) has granted marketing authorization for Palynziq®...
SAN RAFAEL, Calif. , May 6, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that the European Commission (EC) has granted marketing authorization for Palynziq® (pegvaliase injection) at doses of up to 60 mg once daily, to reduce blood phenylalani
Read more →BMRNBioMarin Announces First Quarter 2019 Financial Results Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2019 2018 % Change Total Revenues $ ...
SAN RAFAEL, Calif. , April 25, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (BioMarin or the Company) today announced financial results for the first quarter ended March 31, 2019 . Total Net Product Revenues for the first quarter 2019 increased to $394.5 mi
Read more →BMRNInvestors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces First Quarter 2019 Financial Results - Total Revenues
Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces First Quarter 2019 Financial Results - Total Revenues Top $400 million in the Quarter - Full-year 2019 T
Read more →BMRNForbes Names BioMarin 4th Best Midsize Employer in America BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has been ranked fourth on Forbes magazine's 2019 list of America's Best Midsize...
SAN RAFAEL, Calif. , April 17, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that it has been ranked fourth on Forbes magazine's 2019 list of "America's Best Midsize Employers," increasing from 51 st on last year's 2018 list. BioMarin was ranke
Read more →BMRNBioMarin to Host First Quarter 2019 Financial Results Conference Call and Webcast on Thursday, April 25 at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , April 2, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 25 , at 4:30 p.m. ET to discuss
Read more →BMRNBioMarin to Participate in Cowen and Company 39th Annual Health Care Conference on March 12 in Boston BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the...
SAN RAFAEL, Calif. , March 6, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Cowen and Company Health Care Conference on March 12 at 10:40am ET in Boston. To
Read more →BMRNBioMarin Receives Positive CHMP Opinion in Europe for Palynziq® (pegvaliase Injection) for Treatment of Patients with Phenylketonuria (PKU) Aged 16 and Older BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee...
SAN RAFAEL, Calif. , March 1, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion for the
Read more →BMRNBioMarin Announces Full Year and Fourth Quarter 2018 Results Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, ...
SAN RAFAEL, Calif. , Feb. 21, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (BioMarin or the Company) today announced financial results for the full year and fourth quarter of 2018. Net Loss for 2018 decreased $39.8 million or 34%, to $77.2 million , compared
Read more →BMRNInvestors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Full Year and Fourth Quarter 2018 Results - Total Re
Contacts: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Full Year and Fourth Quarter 2018 Results - Total Revenues for 2018 Grow 14% Year-over-Year to $1.5 Bil
Read more →BMRNBioMarin Announces Ongoing Study Demonstrates Durable Treatment Benefit from Brineura® (cerliponase alfa) for 3 Years BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that an ongoing open-label extension study treating patients with Brineura® (cerliponase...
SAN RAFAEL, Calif. , Feb. 7, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that an ongoing open-label extension study treating patients with Brineura ® (cerliponase alfa) continued to show a reduced rate of decline compared to a natural history
Read more →BMRNBioMarin Announces 14 Presentations at 15th Annual WORLDSymposium™ 2019 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in four platform and 10 poster presentations at the...
SAN RAFAEL, Calif. , Feb. 4, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the company will present data in four platform and 10 poster presentations at the 15 th Annual WORLD Symposium TM being held February 4-8, 2019 in Orlando, Florida
Read more →BMRNBioMarin to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast on Thursday, February 21 at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , Jan. 23, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 21 , at 4:30 p.m. ET to disc
Read more →BMRNth 37 Annual J.P. Morgan Healthcare Conference Jean-Jacques Bienaim Chairman and Chief Executive Officer BioMarin Pharmaceutical Inc. 2019 Safe Harbor Statement This non-confidential presentation contains forward-looking
Jean-Jacques Bienaim Chairman and Chief Executive Officer BioMarin Pharmaceutical Inc. 2019 Exhibit 99.1 th 37 Annual J.P. Morgan Healthcare Conference Jean-Jacques Bienaim Chairman and Chief Executive Officer BioMarin Pharmaceutical Safe Harbor Statement This non-confidential p
Read more →BMRNBioMarin Highlights Key Milestones for 2019 at 37th Annual J.P. Morgan Healthcare Conference in San Francisco BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a company focused on innovative therapies to treat rare diseases, provided highlights to the investment...
SAN RAFAEL, Calif. , Jan. 7, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), a company focused on innovative therapies to treat rare diseases, provided highlights to the investment community on its key milestones for 2019 at the 37 th Annual J.P. Morgan Healthc
Read more →BMRNBioMarin to Present at 37th Annual J.P. Morgan Healthcare Conference in San Francisco BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the ...
SAN RAFAEL, Calif. , Dec. 18, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé , Chairman and Chief Executive Officer, will participate in the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 8
Read more →BMRNBioMarin Promotes Amy Wireman to Group Vice President, Human Resources BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the promotion of Amy Wireman to Group Vice President, Human Resources. Ms. Wireman's...
SAN RAFAEL, Calif. , Dec. 3, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced the promotion of Amy Wireman to Group Vice President, Human Resources. Ms. Wireman's promotion to lead the Human Resources function globally is effective on January 1 ,
Read more →BMRNBioMarin to Participate in Citi's 13th Annual Biotech Conference on December 5 in New York City BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in Citi's 13th Annual Biotech Conference on December 5...
SAN RAFAEL, Calif. , Dec. 3, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that management will participate in Citi's 13th Annual Biotech Conference on December 5 in New York City. To access the live webcast, please visit the investor section
Read more →BMRNBioMarin and Believe Limited Announce the Debut of 'Hemophilia: The Musical' BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the debut of the Broadway-style 'Hemophilia: The Musical,' a first-of-its-kind theatrical ...
SAN RAFAEL, Calif. , Nov. 12, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced the debut of the Broadway-style 'Hemophilia: The Musical,' a first-of-its-kind theatrical production featuring 25 students affected by a bleeding disorder. A recording
Read more →BMRNBioMarin to Participate in Two Investor Conferences in November BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in two investor conferences this November. To access...
SAN RAFAEL, Calif. , Nov. 8, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that management will participate in two investor conferences this November. To access the events that are accessible by live webcasts, please visit the investor section
Read more →BMRNBioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on November 7th in New York BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) updated the investment community on the Company's research and development portfolio, which is focused on ...
SAN RAFAEL, Calif. , Nov. 7, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) updated the investment community on the Company's research and development portfolio, which is focused on innovative therapies to treat rare and ultra-rare diseases. "BioMarin is poise
Read more →BMRNBioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on November 7th in New York BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host an R&D Day from 8:30am (ET) to 11:30am (ET) on Wednesday, November 7, 2018 in New York City....
SAN RAFAEL, Calif. , Nov. 1, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) will host an R&D Day from 8:30am (ET) to 11:30am (ET) on Wednesday , November 7, 2018 in New York City . BioMarin management and external experts will provide an update to the investmen
Read more →BMRNInvestors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Third Quarter 2018 Results - First Nine Months of 201
Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Third Quarter 2018 Results - First Nine Months of 2018 Total Revenues Grow 19% Year-over-year to $1.14 Bi
Read more →BMRNBioMarin Announces Third Quarter 2018 Results Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, ...
SAN RAFAEL, Calif. , Oct. 25, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (BioMarin or the Company) today announced financial results for the third quarter ended September 30, 2018 . The financial results that follow represent a comparison of the third quar
Read more →BMRNBioMarin Receives Milestone Payments from Pfizer for Talzenna® (Talazoparib) for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Company earned $15 million in milestone payments from Pfizer Inc. These milestone ...
SAN RAFAEL, Calif. , Oct. 16, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that the Company earned $15 million in milestone payments from Pfizer Inc. These milestone payments were triggered by the U.S. Food and Drug Administration (FDA) approv
Read more →BMRNBioMarin and Believe Limited Announce Selection of 25 High School Students to Perform in First-of-its-Kind 'Hemophilia: The Musical' BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the twenty-five high school students from across the U.S. who will participate in...
SAN RAFAEL, Calif. , Oct. 11, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced the twenty-five high school students from across the U.S. who will participate in 'Hemophilia: The Musical,' a first-of-its-kind theatrical production written and infor
Read more →BMRNForbes Names BioMarin Among World's Best Employers BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that Forbes' named the company to its list, Global 2000: World's Best Employers. It is...
SAN RAFAEL, Calif. , Oct. 11, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that Forbes' named the company to its list, Global 2000: World's Best Employers. It is ranked within the top 300 out of a total of 2000 companies and fifth among the ni
Read more →BMRNBioMarin to Host Third Quarter 2018 Financial Results Conference Call and Webcast on Thursday, October 25 at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , Oct. 4, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 25 , at 4:30 p.m. ET to discus
Read more →BMRNBioMarin to Participate in Two Investor Conferences in October BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in two investor conferences this October. To access the ...
SAN RAFAEL, Calif. , Sept. 19, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that management will participate in two investor conferences this October. To access the events that are accessible by live webcasts, please visit the investor sectio
Read more →BMRNBioMarin Announces 20 Poster Presentations at Society for the Study of Inborn Errors of Metabolism (SSIEM) Symposium 2018 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present 20 poster presentations at the Society for the Study of...
SAN RAFAEL, Calif. , Sept. 5, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the company will present 20 poster presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Symposium 2018, which will be held on Septembe
Read more →BMRNBioMarin to Participate in Three Investor Conferences in September BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in three investor conferences this September. To access ...
SAN RAFAEL, Calif. , Aug. 22, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that management will participate in three investor conferences this September. To access the events that are accessible by live webcasts, please visit the investor sec
Read more →BMRNInvestors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 FOR IMMEDIATE RELEASE BioMarin Announces Second Quarter 2018 Results - T
Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Second Quarter 2018 Results - Total Revenues of $372.8 million in the Quarter - Received Approval of its
Read more →BMRNBioMarin Announces Second Quarter 2018 Results Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2018 2017...
SAN RAFAEL, Calif. , Aug. 2, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (BioMarin or the Company) today announced financial results for the second quarter ended June 30, 2018 . The financial results that follow represent a comparison of the second quarter
Read more →BMRNBioMarin to Host Second Quarter 2018 Financial Results Conference Call and Webcast on Thursday, August 2 at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , July 11, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, August 2 , at 4:30 p.m. ET to discuss
Read more →BMRNBioMarin Partners with Believe Limited for 'Breaking Through!' Musical Theater Intensive BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced an exclusive partnership with Believe Limited to produce the 'Breaking Through!' musical...
SAN RAFAEL, Calif. , July 9, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced an exclusive partnership with Believe Limited to produce the 'Breaking Through!' musical theater intensive. The first-of-its-kind program is a three-day music workshop f
Read more →BMRNBioMarin Announces First Recipients of RARE Scholars Scholarship Program BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that it has awarded the first five recipients of the RARE Scholars program, an annual...
SAN RAFAEL, Calif. , June 28, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that it has awarded the first five recipients of the RARE Scholars program, an annual scholarship for students living with rare disease. The RARE Scholars program provi
Read more →BMRNBioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company dosed the first participant in a global Phase 2 study for vosoritide, an...
SAN RAFAEL, Calif. , June 14, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the company dosed the first participant in a global Phase 2 study for vosoritide, an analog of C-type Natriuretic Peptide (CNP), in infants and young children with
Read more →BMRNBioMarin Receives Milestone Payments from Pfizer for Talazoparib BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Company received $20 million in milestone payments from Pfizer Inc. These...
SAN RAFAEL, Calif. , June 7, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that the Company received $20 million in milestone payments from Pfizer Inc. These milestone payments were triggered by the U.S. Food and Drug Administration (FDA) accep
Read more →BMRNBioMarin Receives Standard Approval for Palynziq™ (pegvaliase-pqpz) Injection for Treatment of Adults with Phenylketonuria (PKU), a Rare Genetic Disease BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that BioMarin received standard approval from the U.S. Food and Drug Administration (FDA)...
SAN RAFAEL, Calif. , May 24, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that BioMarin received standard approval from the U.S. Food and Drug Administration (FDA) for Palynziq™ (pegvaliase-pqpz) Injection to reduce blood phenylalanine (Phe) c
Read more →BMRNBioMarin Provides 2 Years of Clinical Data in 6e13 vg/kg Dose from Ongoing Phase 1/2 Study in Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at World Federation of Hemophilia 2018 World Congress BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of...
SAN RAFAEL, Calif. , May 22, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy treatment
Read more →BMRNBioMarin Announces 1 Platform and 3 Poster Presentations at World Federation of Hemophilia 2018 World Congress BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the company will present data in one platform presentation and three poster...
SAN RAFAEL, Calif. , May 17, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that the company will present data in one platform presentation and three poster presentations at the World Federation of Hemophilia (WFH) 2018 World Congress from May 2
Read more →BMRNBioMarin Announces First Patient Dosed in Phase 1/2 Study Evaluating Valoctocogene Roxaparvovec Gene Therapy in Severe Hemophilia A Patients with Pre-existing AAV5 Antibodies BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has dosed the first patient in a Phase 1/2 study (BMN 270-203) evaluating its...
SAN RAFAEL, Calif. , May 15, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that it has dosed the first patient in a Phase 1/2 study (BMN 270-203) evaluating its investigational gene therapy, valoctocogene roxaparvovec, in severe hemophilia A pa
Read more →BMRNBioMarin to Attend Upcoming Investor Conference BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in...
SAN RAFAEL, Calif. , May 2, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that Jean-Jacques Bienaimé , Chairman and Chief Executive Officer, will participate in the Bank of America Merrill Lynch Health Care Conference on May 15, 2018 at 10:40a
Read more →BMRNBioMarin Named To Forbes List Of America's Best Mid-size Employers BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has been ranked 51st overall among 500 companies on Forbes magazine's 2018 list...
SAN RAFAEL, Calif. , May 1, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that it has been ranked 51st overall among 500 companies on Forbes magazine's 2018 list of "America's Best Mid-size Employers," and third among companies in the biotechno
Read more →BMRNBioMarin Announces First Quarter 2018 Financial Results Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2018 2017 % Change Total...
SAN RAFAEL, Calif. , April 25, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced financial results for the first quarter ended March 31, 2018 . For the quarter ended March 31 , 2018 GAAP Net Loss was $44.1 million , or $0.25 loss per basic and $0.
Read more →BMRNInvestors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 FOR IMMEDIATE RELEASE BioMarin Announces First Quarter 2018 Financial Re
Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces First Quarter 2018 Financial Results - Total Revenues Top $373 million in the Quarter; GAAP Net Loss of $
Read more →BMRNNew England Journal of Medicine Published Open-label Study Showing Brineura® (cerliponase alfa) Reduced the Rate of Clinical Decline of Children with CLN2 Disease, a Form of Batten Disease BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the New England Journal of Medicine (NEJM) published updated results from a...
SAN RAFAEL, Calif. , April 24, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that the New England Journal of Medicine (NEJM) published updated results from a multi-center, open-label, dose-escalation and ongoing extension study evaluating the e
Read more →BMRNBioMarin to Host First Quarter 2018 Financial Results Conference Call and Webcast on Wednesday, April 25 at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , April 18, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 25 , at 4:30 p.m. ET to discu
Read more →BMRNEuropean Medicines Agency (EMA) Accepts BioMarin's Marketing Application for Pegvaliase MAA for Treatment of Phenylketonuria (PKU) BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the European Medicines Agency (EMA) has accepted BioMarin's submission of a Marketing ...
SAN RAFAEL, Calif. , March 28, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that the European Medicines Agency (EMA) has accepted BioMarin's submission of a Marketing Authorization Application (MAA) for pegvaliase, a PEGylated recombinant phen
Read more →BMRNBioMarin's Gene Therapy Manufacturing Facility Recognized with Industry Award BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the International Society for Pharmaceutical Engineering (ISPE) selected the...
SAN RAFAEL, Calif. , March 21, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the International Society for Pharmaceutical Engineering (ISPE) selected the company's gene therapy manufacturing facility as the 2018 Facility of the Year Catego
Read more →BMRNRare Disease Day 2018: BioMarin Launches RARE Scholars Scholarship Program BioMarin today announced the launch of RARE Scholars, an annual scholarship for students living with rare disease. RARE Scholars aims to empower...
SAN RAFAEL, Calif. , Feb. 28, 2018 /PRNewswire/ -- BioMarin today announced the launch of RARE Scholars, an annual scholarship for students living with rare disease. RARE Scholars aims to empower patients with continued education by recognizing students living with rare diseases
Read more →BMRNInvestors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 FOR IMMEDIATE RELEASE BioMarin Announces Fourth Quarter and Full Year 20
Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Fourth Quarter and Full Year 2017 Financial Results - Record Total Revenues of $1.3 Billion for Full Year
Read more →BMRNBioMarin Announces Fourth Quarter and Full Year 2017 Financial Results Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, ...
SAN RAFAEL, Calif. , Feb. 22, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced financial results for the fourth quarter and year ended December 31, 2017 . For the quarter ended December 31, 2017 GAAP Net Loss was $51.4 million , or $0.29 and $0.3
Read more →BMRNBioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at WORLDSymposium™ 2018 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it presented interim data from a Phase 1/2 trial for BMN 250, an investigational...
SAN RAFAEL, Calif. , Feb. 7, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that it presented interim data from a Phase 1/2 trial for BMN 250, an investigational enzyme replacement therapy using a novel fusion of recombinant human alpha-N-acetyl
Read more →BMRNWORLDSymposium Recognizes BioMarin's Brineura® (cerliponase alfa) with 2018 New Treatment Award BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that The WORLDSymposium 2018 awarded Brineura® (cerliponase alfa) the New Treatment...
SAN RAFAEL, Calif. , Feb. 6, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that The WORLD Symposium 2018 awarded Brineura ® (cerliponase alfa) the New Treatment Award, which recognizes important achievements in therapeutic advancements for lyso
Read more →BMRNBioMarin Announces 20 Presentations at 14th Annual WORLDSymposium™ 2018 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in five oral and 15 poster presentations at the 14th...
SAN RAFAEL, Calif. , Feb. 5, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the company will present data in five oral and 15 poster presentations at the 14 th Annual WORLD Symposium TM being held February 5-9, 2018 in San Diego, California
Read more →BMRNBioMarin Receives Anticipated Notification of PDUFA Extension for Pegvaliase Biologics License Application (BLA) to May 28, 2018 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete ...
SAN RAFAEL, Calif. , Dec. 22, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the Biologics License Application (BLA) for its investigational
Read more →BMRNBioMarin Doses First Patient in Global GENEr8-1 Phase 3 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has dosed the first patient in the global GENEr8-1 Phase 3 study with the 6e13...
SAN RAFAEL, Calif. , Dec. 19, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that it has dosed the first patient in the global GENEr8-1 Phase 3 study with the 6e13 vg/kg dose for valoctocogene roxaparvovec (formerly BMN 270), an investigational
Read more →BMRNBioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 American Society of Hemophilia (ASH) Meeting BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced updates on valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy...
SAN RAFAEL, Calif. , Dec. 11, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced updates on valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy treatment for severe hemophilia at ASH. Efficacy Data with Valoctocogene Roxaparvov
Read more →BMRNBioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting Concurrent with NEJM Publication BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of...
SAN RAFAEL, Calif. , Dec. 9, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy treatment
Read more →BMRNBioMarin Announces Presentations at 59th American Society of Hematology Annual Meeting & Exposition BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in a late breaking abstract session at the 59th...
SAN RAFAEL, Calif. , Dec. 6, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the company will present data in a late breaking abstract session at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition being held December 9
Read more →BMRNBioMarin Sells Second Priority Review Voucher for $125 Million BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into a definitive agreement to sell the Rare Pediatric Disease...
SAN RAFAEL, Calif. , Nov. 27, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that it has entered into a definitive agreement to sell the Rare Pediatric Disease Priority Review Voucher (PRV) it obtained in April of this year for a lump sum paymen
Read more →BMRNInvestors : Media : Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 For Immediate Release BioMarin Sells Second Priority Review Voucher fo
Contact: Investors : Media : Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Sells Second Priority Review Voucher for $125 Million SAN RAFAEL, Calif., Nov. 27, 2017 - BioMarin Pharmaceutical
Read more →BMRNBioMarin to Attend Three Upcoming Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in Credit Suisse's 26th Annual Healthcare Conference on...
SAN RAFAEL, Calif. , Oct. 31, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that management will participate in Credit Suisse's 26 th Annual Healthcare Conference on November 7, 2017 at 9:10am MT / 11:10am ET , in Scottsdale, Arizona , the Stif
Read more →BMRNBioMarin Announces Third Quarter 2017 Financial Results Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, ...
SAN RAFAEL, Calif. , Oct. 26, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced financial results for the third quarter ended September 30, 2017 . For the quarter ended September 30, 2017 , GAAP Net Loss was $(12.5) million , or $(0.07) per basic
Read more →BMRNFDA Grants Breakthrough Therapy Designation for BioMarin's Valoctocogene Roxaparvovec (formerly BMN 270), an Investigational Gene Therapy for Hemophilia A BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S. Food and Drug Administration (FDA) granted valoctocogene roxaparvovec...
SAN RAFAEL, Calif. , Oct. 26, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the U.S. Food and Drug Administration (FDA) granted valoctocogene roxaparvovec (formerly BMN 270) Breakthrough Therapy Designation. The FDA's Breakthrough Therapy
Read more →BMRNInvestors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 FOR IMMEDIATE RELEASE BioMarin Announces Third Quarter 2017 Financial Re
Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Third Quarter 2017 Financial Results - Company Announces Total Revenues of $334.1 million in the Third Qu
Read more →BMRNBioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) updated the investment community on the Company's development portfolio, which is focused on innovative...
SAN RAFAEL, Calif. , Oct. 18, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) updated the investment community on the Company's development portfolio, which is focused on innovative therapies to treat rare and ultra-rare diseases. BioMarin Selects BMN 290 for F
Read more →BMRNPopular Science Names BioMarin's Brineura® (cerliponase alfa) One of the Top Health Innovations of 2017 with Best of What's New Award BioMarin announced today that Brineura® (cerliponase alfa) has been awarded the 2017 Popular Science Best of What's New award in the health...
SAN RAFAEL, Calif. , Oct. 18, 2017 /PRNewswire/ -- BioMarin announced today that Brineura ® (cerliponase alfa) has been awarded the 2017 Popular Science "Best of What's New" award in the health category. Each year, Popular Science reviews thousands of new products and innovations
Read more →BMRNBioMarin Pharmaceutical, Inc. (Nasdaq: BMRN) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, Oct. 16, 2017 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical, Inc. (Nasdaq:BMRN), a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes, will visit the Nasdaq MarketSite in Times Square in celebration of
Read more →BMRNBioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York Key program updates will include the following: BMN 270 gene therapy for hemophilia A: 4e13 dose and Phase 3 Study Design Vosoritide for...
SAN RAFAEL, Calif. , Oct. 11, 2017 /PRNewswire/ -- Key program updates will include the following: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) will host an R&D Day from 8am (ET) to 1pm (ET) on Wednesday, October 18, 2017 in New York City . BioMarin management and external expe
Read more →BMRNBioMarin to Host Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday, October 26 at 4:30 p.m. ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , Oct. 10, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 26 , at 4:30 p.m. ET to discu
Read more →BMRNBioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of...
SAN RAFAEL, Calif. , Oct. 3, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former Baxalta Chief Financial Officer and Chief Operations Officer, Robert J. Homb
Read more →BMRNFDA Not Currently Planning to Hold Advisory Committee Meeting for BioMarin's Pegvaliase Biologics License Application (BLA) BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has provided the company with the...
SAN RAFAEL, Calif. , Sept. 14, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that the U.S. Food and Drug Administration (FDA) has provided the company with the "Day-74" filing communication for its Biologics License Application (BLA) for pegval
Read more →BMRNBioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at 13th International Congress of Inborn Errors of Metabolism (ICIEM) 2017 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it presented interim data from the dose escalation arm of a Phase 1/2 trial for BMN...
SAN RAFAEL, Calif. , Sept. 6, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that it presented interim data from the dose escalation arm of a Phase 1/2 trial for BMN 250, an investigational enzyme replacement therapy using a novel fusion of reco
Read more →BMRNBioMarin Announces 3 Platform and 15 Poster Presentations at 13th International Congress of Inborn Errors of Metabolism 2017 BioMarin (Nasdaq:BMRN) announced that the company will present data in three platform presentations and fifteen poster presentations at the 13th...
SAN RAFAEL, Calif. , Sept. 5, 2017 /PRNewswire/ -- BioMarin (Nasdaq: BMRN ) announced that the company will present data in three platform presentations and fifteen poster presentations at the 13th International Congress of Inborn Errors of Metabolism (ICIEM) being held September
Read more →BMRNFDA Accepts BioMarin's Pegvaliase Biologics License Application (BLA) and Grants Priority Review Designation BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the...
SAN RAFAEL, Calif. , Aug. 29, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for pegvaliase, a PEGylated recombinant phenyl
Read more →BMRNBioMarin Announces Exercise in Full of Underwriters' Option to Purchase Additional 0.599% Senior Subordinated Convertible Notes Due 2024 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the underwriters of its recently announced public offering of 0.599% senior...
SAN RAFAEL, Calif. , Aug. 23, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the underwriters of its recently announced public offering of 0.599% senior subordinated convertible notes due 2024 (the Notes) have exercised in full their option
Read more →BMRNForbes Ranks BioMarin 12th Most Innovative Company in the World BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has been ranked 12th on Forbes magazine's 2017 list of the World's Most...
SAN RAFAEL, Calif. , Aug. 21, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that it has been ranked 12 th on Forbes magazine's 2017 list of the "World's Most Innovative Companies." BioMarin, a pharmaceutical company focused on rapidly developin
Read more →BMRNBioMarin to Attend Upcoming Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in Citi's Annual Biotech Conference on September 6,...
SAN RAFAEL, Calif. , Aug. 15, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that management will participate in Citi's Annual Biotech Conference on September 6, 2017 in Boston , Baird's 2017 Global Healthcare Conference on September 7, 2017 in
Read more →BMRNBioMarin Announces Offering of $450 Million of 0.599% Senior Subordinated Convertible Notes Due 2024 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), announced today an underwritten offering of $450 million aggregate principal amount of 0.599% senior...
SAN RAFAEL, Calif. , Aug. 7, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), announced today an underwritten offering of $450 million aggregate principal amount of 0.599% senior subordinated convertible notes due 2024 (the Notes). BioMarin has also granted the
Read more →BMRNBioMarin Announces Offering of $450 Million of Senior Subordinated Convertible Notes Due 2024
BioMarin Announces Offering of $450 Million of Senior Subordinated Convertible Notes Due 2024 SAN RAFAEL, Calif., Aug. 7, 2017 /PRNewswire/ BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), announced today an underwritten offering of $450 million aggregate principal amount of senior
Read more →BMRNBioMarin Announces Second Quarter 2017 Financial Results Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2017 2016...
SAN RAFAEL, Calif. , Aug. 2, 2017 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced financial results for the second quarter ended June 30, 2017 . For the quarter end
Read more →BMRNInvestors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 FOR IMMEDIATE RELEASE BioMarin Announces Second Quarter 2017 Financial R
Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Second Quarter 2017 Financial Results - Company Announces Record Total BioMarin Revenues of $317.4 millio
Read more →BMRNBioMarin Announces Plans to Progress Both the 6e13vg/kg and 4e13 vg/kg Doses of BMN 270, its Investigational Gene Therapy for Hemophilia A, into Phase 3 Studies BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it will expand its development plan for BMN 270, its investigational gene therapy...
SAN RAFAEL, Calif. , Aug. 2, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that it will expand its development plan for BMN 270, its investigational gene therapy for hemophilia A, to include an additional Phase 3 study of the 4e13 vg/kg dose ba
Read more →BMRNBioMarin to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2 at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , July 31, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, August 2 , at 4:30 p.m. ET to discus
Read more →BMRNBioMarin's Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg Dose Maintains Average Factor VIII Levels within Normal Range for over One Year BioMarin Provides BMN 270 Data at International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress Initiation of Phase 3 Registrational Study ...
SAN RAFAEL, Calif. , July 11, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today an update to its previously reported interim results of an open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for severe hemophilia A. Th
Read more →BMRNBioMarin Submits Pegvaliase Biologics License Application (BLA) to the U.S. FDA for Treatment of Phenylketonuria (PKU) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that the company submitted a Biologics License Application (BLA) on Friday, June 30, 2017 to...
"We believe that pegvaliase offers the promise of an important new treatment option for those adult patients with PKU unable to manage their condition with existing treatments. Pegvaliase has been shown to lower blood Phe levels, which was the primary endpoint for registration of
Read more →BMRNBioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis 2017 Congress BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in a late breaking abstract session at the...
SAN RAFAEL, Calif. , June 16, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the company will present data in a late breaking abstract session at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress being held July 8
Read more →BMRNEuropean Commission Approves Brineura™ (cerliponase alfa), the First Treatment for CLN2 Disease, a Form of Batten Disease and Ultra-Rare Brain Disorder in Children BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the European Commission (EC) has granted marketing authorization for Brineura™...
SAN RAFAEL, Calif. , June 1, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced the European Commission (EC) has granted marketing authorization for Brineura™ (cerliponase alfa), the first treatment approved in the European Union for the treatment o
Read more →BMRNBioMarin to Attend Upcoming Investor Conference BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer, will...
SAN RAFAEL, Calif. , May 31, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that Dan Spiegelman , Executive Vice President and Chief Financial Officer, will participate in the Goldman Sachs 38th Annual Global Healthcare Conference on June 13, 2
Read more →BMRNInvestors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 FOR IMMEDIATE RELEASE BioMarin Announces First Quarter 2017 Financial Re
Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces First Quarter 2017 Financial Results - First Quarter 2017 Total BioMarin Revenues Increase 28% Year over
Read more →BMRNBioMarin Announces First Quarter 2017 Financial Results Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2017 2016 % Change Total BioMarin...
SAN RAFAEL, Calif. , May 4, 2017 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced financial results for the first quarter ended March 31, 2017 . For the quarter ende
Read more →BMRNBioMarin to Attend Two Upcoming Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in...
SAN RAFAEL, Calif. , May 2, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that Jean-Jacques Bienaimé , Chairman and Chief Executive Officer, will participate in Deutsche Bank's 42 nd Annual Health Care Conference on May 3, 2017 at 9:20am ET ,
Read more →BMRNFDA Approves Brineura™ (cerliponase alfa) for the Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare Pediatric Brain Disorder in Children BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) approved Brineura™ (cerliponase alfa) to...
SAN RAFAEL, Calif. , April 27, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that the U.S. Food and Drug Administration (FDA) approved Brineura™ (cerliponase alfa) to slow the loss of ambulation in symptomatic pediatric patients 3 years of age
Read more →BMRNBioMarin Receives Positive CHMP Opinion in Europe for Brineura™ (cerliponase alfa) for First Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare and Fatal Brain Disorder in Children BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee...
SAN RAFAEL, Calif. , April 21, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion for the
Read more →BMRNBioMarin to Host First Quarter 2017 Financial Results Conference Call and Webcast on Thursday, May 4 at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , April 20, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 4 , at 4:30 p.m. ET to discuss f
Read more →BMRNBioMarin Announces Kuvan® (sapropterin dihydrochloride) Patent Challenge Settlement BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that it has entered into a settlement agreement with Par Pharmaceutical that resolves...
SAN RAFAEL, Calif. , April 13, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that it has entered into a settlement agreement with Par Pharmaceutical that resolves patent litigation in the United States (U.S.) related to BioMarin's Kuvan® (sapr
Read more →BMRNInvestors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 For Immediate Release : BioMarin Announces Kuvan (sapropterin dihydrochlo
Contacts: Investors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 For Immediate Release: BioMarin Announces Kuvan (sapropterin dihydrochloride) Patent Challenge Settlement Retains
Read more →BMRNBioMarin Announces Fourth Quarter and Full Year 2016 Financial Results Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, ...
SAN RAFAEL, Calif. , Feb. 23, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced financial results for the fourth quarter and year ended December 31, 2016 . For the quarter ended December 31, 2016 , GAAP net loss was $91 million , or ($0.53) per ba
Read more →BMRNBioMarin Announces 11 Presentations at 13th Annual WORLDSymposium™ 2017 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in four oral and seven poster presentations at the...
SAN RAFAEL, Calif. , Feb. 15, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the company will present data in four oral and seven poster presentations at the 13 th Annual WORLD Symposium ™ being held February 13-17, 2017 in San Diego, Calif
Read more →BMRNBioMarin to Attend Three Investor Conferences in 1Q17 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in...
SAN RAFAEL, Calif. , Feb. 8, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that Jean-Jacques Bienaimé , Chairman and Chief Executive Officer, will participate in the Leerink Partners 6 th Annual Global Healthcare Conference on February 16, 201
Read more →BMRNBioMarin to Host Fourth Quarter and Full Year 2016 Financial Results Conference Call and Webcast on Thursday, February 23 at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
SAN RAFAEL, Calif. , Feb. 7, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 23 , at 4:30 p.m. ET to discu
Read more →BMRNBioMarin Receives Access to Priority Medicines (PRIME) Regulatory Support from EMA for BMN 270 Gene Therapy in Hemophilia A BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the European Medicines Agency (EMA) has granted access to its Priority Medicines...
SAN RAFAEL, Calif. , Feb. 1, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today that the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) regulatory initiative for the company's investigational gene therapy treatm
Read more →BMRNBioMarin to Provide Update to Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A at 35th Annual J.P. Morgan Healthcare Conference BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today an update to its positive interim results of an open-label Phase 1/2 study of BMN 270, an...
SAN RAFAEL, Calif. , Jan. 8, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) announced today an update to its positive interim results of an open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for severe hemophilia A, which will be p
Read more →BMRNBioMarin to Present at 35th Annual J.P. Morgan Healthcare Conference in San Francisco BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in...
SAN RAFAEL, Calif. , Jan. 3, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that Jean-Jacques Bienaimé , Chairman and Chief Executive Officer, will participate in the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 8
Read more →BMRNBioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
BioMarin Pharmaceutical has commenced a global Phase 3 trial for vosoritide, targeting children aged 5-14 with achondroplasia. The study will assess growth velocity changes over one year compared to a placebo. Following this, a separate Phase 2 study will evaluate vosoritide's effects in infants and toddlers. The company has received orphan drug designation for vosoritide in the US and Europe.
Read more →BMRNBioMarin to Attend Three Upcoming Investor Conferences
- Credit Suisse 25th Annual Healthcare Conference on November 7 in Scottsdale, Arizona - Jefferies 2016 London Healthcare Conference on November 16 in London - Citi 2016 Global Healthcare Conference on December 8 in New York City SAN RAFAEL, Calif., Nov. 03, 2016 (GLOBE NEWSWI
Read more →BMRNBioMarin Announces Third Quarter 2016 Financial Results
BioMarin Pharmaceutical Inc. reported a 34% increase in total revenues for Q3 2016, amounting to $280 million. Key products Vimizim and Kuvan saw significant revenue growth, with Vimizim's revenues at $81 million and Kuvan's at $91 million. Despite a GAAP net loss of $43 million, the company has a strong cash position of $1.4 billion. Upcoming regulatory decisions for Brineura and positive data from gene therapy programs were highlighted.
Read more →BMRNBioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting
BioMarin Pharmaceutical Inc. presented promising data on vosoritide, an investigational treatment for achondroplasia, at the ASHG 2016 Meeting. The highest dose of 30 µg/kg/day demonstrated a 46% increase in growth velocity, comparable to the 15 µg/kg/day dose. The treatment was well tolerated, with no serious adverse events reported. A Phase 3 study is set to begin by the end of 2016.
Read more →BMRNUK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A
BioMarin Pharmaceutical Inc. announced that the UK's MHRA has approved the continuation of enrollment in the Phase 1/2 study of BMN 270, a gene therapy for severe hemophilia A. The study was previously suspended due to safety concerns regarding elevated ALT levels. With the removal of the corticosteroid requirement, BioMarin aims to optimize the study design for a future Phase 2b trial.
Read more →BMRNBioMarin to Host Third Quarter 2016 Financial Results Conference Call and Webcast on Thursday, October 27 at 4:30pm ET
SAN RAFAEL, Calif., Oct. 11, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 27, at 4:30 p.m. ET to discu
Read more →BMRNBioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics
BioMarin Pharmaceutical Inc. announced plans to seek a review of a Patent Trial and Appeal Board ruling regarding its composition of matter patent related to exon 51 skipping antisense oligonucleotides. The company previously won a ruling in its favor concerning the method of use patent for treating Duchenne muscular dystrophy. BioMarin holds an enforceable patent in Europe for its method, but the outcome of ongoing patent disputes is still uncertain.
Read more →BMRNBioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease
BioMarin Pharmaceutical has announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application for Brineura (cerliponase alfa) aimed at treating CLN2 disease, a severe form of Batten disease. The EMA's validation initiates a formal review process, with a potential decision expected by Q3 2017. The drug has received Orphan Drug Designation and is undergoing accelerated assessment due to its significant public health implications.
Read more →BMRNBioMarin Announces Two Oral and 16 Poster Presentations at Society for the Study of Inborn Errors of Metabolism 2016 Annual Meeting
BioMarin Pharmaceutical Inc. announced its participation in the SSIEM 2016 Annual Meeting, where it will present two oral and 16 poster presentations. The presentations will cover various aspects of rare genetic diseases, including updates on Brineura for CLN2 disease and pegvaliase for phenylketonuria (PKU). Both therapies are in advanced stages of regulatory review.
Read more →BMRNBioMarin Announces Update to Brineura™ (Cerliponase Alfa) Program for Treatment of CLN2 Disease, a Form of Batten Disease
BioMarin announced an update on cerliponase alfa for CLN2 disease, showing sustained efficacy after 81 weeks of treatment. The FDA has extended the PDUFA action date to April 27, 2017, following a request for updated efficacy data. The treatment continues to demonstrate a significant reduction in disease progression, with no new safety concerns reported.
Read more →BMRNBioMarin to Attend Upcoming Investor Conferences
Citi’s 11th Annual Biotech Conference September 7 in Boston Robert W. Baird & Co. 2016 Global Healthcare Conference September 8 in New York Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology September 28 in New York SAN RAFAEL, Calif., Aug. 31, 2016 (GLOBE NEWS
Read more →BMRNBioMarin Announces Pricing of Public Offering of Common Stock
SAN RAFAEL, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a price to the public of $96.00 per share. The gross proceeds to BioMarin fro
Read more →BMRNBioMarin Announces Public Offering of Common Stock
SAN RAFAEL, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of 7,500,000 shares of its common stock in an underwritten public offering. BioMarin has also granted the underwri
Read more →BMRNBioMarin Announces Second Quarter 2016 Financial Results
- Second Quarter 2016 Total BioMarin Revenue Increases 20.0% Y/Y to $300.1 million - Vimizim Net Product Revenue Increases 98.1% Y/Y and Contributes $106.8 million in the Second Quarter 2016; Vimizim Full-year Revenue Guidance Increased to $340 to $360 million - Kuvan Net Produ
Read more →BMRNBioMarin Provides Positive Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A in Late Breaking Oral Presentation at the World Federation of Hemophilia (WFH) 2016 World Congress
6 of 7 High Dose Patients Show Factor VIII levels above 50%, 7th patient above 10% No Clinically Relevant Sustained Rises in ALT Phase 2b Study to Begin Mid-2017 for Potential Accelerated Approval Filing Conference Call and Web-cast with Slides to be Held Wednesday, July 27th
Read more →BMRNBioMarin to Provide Updated Data for BMN 270 in Hemophilia A in Late Breaking Oral Presentation at the World Federation of Hemophilia (WFH) 2016 World Congress July 27th
SAN RAFAEL, Calif., July 21, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that interim results of an open-label, Phase 1/2 study of BMN 270, an AAV5-FVIII Gene transfer in severe Hemophilia will be presented at the XXXII International Congre
Read more →BMRNBioMarin Appoints Two BioPharmaceutical Veterans to Board of Directors, Willard Dere, M.D. and Kathryn E. Falberg
SAN RAFAEL, Calif., July 18, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of two biopharmaceutical veterans to its Board of Directors: Willard Dere, M.D., Pro
Read more →BMRNBioMarin to Host Second Quarter 2016 Financial Results Conference Call and Webcast on Thursday, August 4 at 4:30pm ET
SAN RAFAEL, Calif., July 14, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, August 4, at 4:30 p.m. ET to discuss
Read more →BMRNBioMarin Announces Acceptance of Late Breaking Abstract for BMN 270 at the World Federation of Hemophilia (WFH) 2016 World Congress July 27 in Orlando, FL
SAN RAFAEL, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the upcoming oral presentation summarizing a late breaking abstract accepted for the XXXII International Congress of the World Federation of Hemophilia. The presentati
Read more →BMRNBioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa™ (drisapersen) in Europe
SAN RAFAEL, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has withdrawn its Kyndrisa™ (drisapersen) Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) following discussions at the May 20
Read more →BMRNBioMarin Announces EMA Grants Accelerated Assessment for Cerliponase Alfa, Experimental Treatment for a Form of Batten Disease
EU and U.S. Marketing Application Submissions Planned for Mid-Year 2016 Company Seeking Priority Review in the U.S. SAN RAFAEL, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the European Medicines Agency (EMA) has grant
Read more →BMRNBioMarin Announces First Quarter 2016 Financial Results
-First Quarter 2016 Total BioMarin Revenue Increases 16.7% Y/Y to $236.7 million -Vimizim Net Product Revenue Increases 43.5% Y/Y and Contributes $72.6 million in the First Quarter 2016; Vimizim Full-year Revenue Guidance Increased to $315 to $340 million - Kuvan Net Product Re
Read more →BMRNBioMarin Enrolls First Patient in Phase 1/2 Trial of NAGLU Fusion Protein BMN 250 for Treatment of MPS IIIB (Sanfilippo B Syndrome)
SAN RAFAEL, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has enrolled the first patient in a Phase 1/2 trial for BMN 250, an investigational enzyme replacement therapy using a novel fusion of recombinant human alpha
Read more →BMRNBioMarin Provides Program Update on Vosoritide in Achondroplasia
New Data Shows Durable and Consistent Effects on Mean Annualized Growth Velocity for up to 12 months with Increases of 46%-65% from Baseline Phase 3 Randomized Controlled Study Planned to Start at End of 2016 SAN RAFAEL, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- BioMarin Phar
Read more →BMRNBioMarin Provides Encouraging Preliminary Data on First 8 Patients in Hemophilia A Gene Therapy Program
Two High Dose Patients Show Increasing Levels of Factor VIII Above 50% Five of Six High Dose Patients Show Factor VIII Levels Above 5% SAN RAFAEL, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today preliminary data from an ongo
Read more →BMRNBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, April 18, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases, will visit the Nasda
Read more →BMRNBioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on April 20th in New York
SAN RAFAEL, Calif., April 18, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will host an R&D Day from 8am (ET) to 12pm (ET) on Wednesday, April 20, 2016 in New York City. BioMarin management and external experts will provide an update to the investment commu
Read more →BMRNBioMarin to Host First Quarter 2016 Financial Results Conference Call and Webcast on Thursday, April 28 at 4:30pm ET
SAN RAFAEL, Calif., April 12, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 28, at 4:30 p.m. ET to discus
Read more →BMRNBioMarin Receives European Orphan Drug Designation for BMN 270, First Investigational AAV-Factor VIII Gene Therapy for Patients with Hemophilia A
SAN RAFAEL, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BMN 270, an investigational gene therapy for the treatment of hemophilia A, has been granted orphan drug designation by the European Commission. In the European
Read more →BMRNBioMarin Phase 3 Study of Pegvaliase for Phenylketonuria (PKU) Meets Primary Endpoint of Blood Phenylalanine (Phe) Reduction (p<0.0001)
In 8-week Placebo-Controlled Portion No Benefit in Inattention or Mood Scores Were Observed Approximately, 60% of Patients Maintained Phe Levels At or Below Medical Guidelines over Long-Term Extension Study Conference Call and Webcast with Slides to Be Held Today at 8:30 AM ET
Read more →BMRNBioMarin to Attend Three Upcoming Investor Conferences in March
- Cowen and Company 36th Annual Health Care Conference on March 8 in Boston - Raymond James 37th Annual Institutional Investors Conference on March 9 in Orlando - Barclays Global Healthcare Conference on March 16 in Miami SAN RAFAEL, Calif., March 03, 2016 (GLOBE NEWSWIRE) --
Read more →BMRNBioMarin Announces Positive Data From Cerliponase Alfa Program for Treatment of CLN2 Disease, a Form of Batten Disease, at 12th Annual WORLDSymposium(TM) 2016
80% Reduction in Clinical Disease Progression in One Year Compared to Natural History (p <0.0001) Company Plans to Submit Marketing Applications Starting Mid-Year 2016 SAN RAFAEL, Calif., March 02, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announ
Read more →BMRNBioMarin Receives Orphan Drug Designation From FDA for First AAV-Factor VIII Gene Therapy, BMN 270, for Patients With Hemophilia A
SAN RAFAEL, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BMN 270, an investigational gene therapy for the treatment of patients with hemophilia A, has been granted orphan drug designation by the U.S. Food and Drug Admi
Read more →BMRNBioMarin Announces BioMarin RareConnections(TM) Rebranding and Consolidating BioMarin’s Comprehensive Support and Services for Eligible Rare Disease Patients
SAN RAFAEL, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the launch of BioMarin RareConnectionsTM, rebranding its patient-focused offering formally known as the BioMarin Patient and Physician Support (BPPS). For over 10 year
Read more →BMRNBioMarin Announces 21 Presentations at 12th Annual WORLDSymposium™ 2016 February 29-March 4 in San Diego, California: 6 Oral and 15 Poster
SAN RAFAEL, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company will present data in six oral and 15 poster presentations at the 12th Annual WORLDSymposiumTM being held February 29-March 4, 2016 in San Diego, Calif
Read more →BMRNBioMarin Announces Fourth Quarter and Full Year 2015 Financial Results
- Full-year 2015 Total BioMarin Revenue Increases 18.8% to $889.9 million Year-over-Year - Vimizim Net Product Revenue Contributes Over $228 million to 2015 Top-line - Full-year 2016 Total BioMarin Revenue Guidance of Between $1.05 billion to $1.10 billion - Company Anticipate
Read more →BMRNBioMarin to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ET
SAN RAFAEL, Calif., Jan. 28, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 25, at 4:30 p.m. ET to disc
Read more →BMRNBioMarin Announces Interim Analysis of INSPIRE Clinical Trial in Pompe Disease at 34th Annual J.P. Morgan Annual Healthcare Conference
SAN RAFAEL, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced interim results from INSPIRE, a Phase 2 trial for reveglucosidase alfa, a fusion protein of insulin-like growth factor 2 and acid alpha-glucosidase (IGF2-GAA) being st
Read more →BMRNBioMarin to Present at 34th Annual J.P. Morgan Healthcare Conference in San Francisco
SAN RAFAEL, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2016 at
Read more →BMRNBioMarin Announces Addition of David Pyott, Former Allergan Chairman and CEO, to Company’s Board of Directors
SAN RAFAEL, Calif., Jan. 04, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that David Pyott has been elected to the company’s board of directors. Mr. Pyott is the former Chairman and Chief Executive Officer of Allergan and will join the BioMa
Read more →BMRNBioMarin Announces That FDA Has Advised it Will Not Take Action on the Kyndrisa™ (drisapersen) New Drug Application by the PDUFA Date
SAN RAFAEL, Calif., Dec. 18, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that they had not yet completed their review process and would be unable to take an action by
Read more →BMRNBioMarin Posts Presentation From FDA Advisory Committee Meeting for Kyndrisa(TM) (drisapersen) for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
SAN RAFAEL, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Company’s presentation from the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA)’s meeting for Ky
Read more →BMRNBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Announced Today the Stock is Halted
SAN RAFAEL, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that NASDAQ has halted trading of the company’s stock. The Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) of the U.S. Food and Drug Administrati
Read more →BMRNBioMarin Announces Data Analysis Demonstrating Consistent Efficacy of Kyndrisa™ (drisapersen) in Comparable Patients Across Three Randomized Studies
SAN RAFAEL, Calif., Nov. 20, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced data analysis for Kyndrisa demonstrating consistent evidence of efficacy in comparable patients across three randomized, placebo-controlled studies that were conducted
Read more →BMRNBioMarin Announces Third Quarter 2015 Financial Results and Company Update
- Vimizim Net Product Revenue $65 million in the Quarter; Vimizim Full-year Revenue Guidance Increased to $220 to $235 million - Full-year Total BioMarin Revenue Guidance Increased to $880 million to $900 million - FDA Advisory Committee to Review Kyndrisa™ (drisapersen) Novemb
Read more →BMRNBioMarin to Attend Upcoming Investor Conference in November
SAN RAFAEL, Calif., Oct. 27, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the Credit Suisse Healthcare Conference on November 11, 2015 at 9:30 am MT, or 1
Read more →BMRNBioMarin Announces FDA Advisory Committee to Review Drisapersen for Treatment of Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
SAN RAFAEL, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review the New Drug Application (NDA) for d
Read more →BMRNBioMarin to Host Third Quarter 2015 Financial Results Conference Call and Webcast on Thursday, October 29 at 4:30pm ET
SAN RAFAEL, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 29, at 4:30 p.m. ET to discu
Read more →BMRNBioMarin’s Initial 6-Month Data From Phase 2 Study of Vosoritide (BMN 111) in Children With Achondroplasia Presented at the American Society for Bone and Mineral Research Annual 2015 Meeting
SAN RAFAEL, Calif., Oct. 12, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dr. Melita Irving, Clinical Geneticist, Guy's and St Thomas’ NHS Foundation Trust, Evelina Children’s Hospital London, UK, presented the initial six-month data fr
Read more →BMRNBioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise From Merck Serono
Strengthens and Expands BioMarin's Leadership Position Serving PKU Patients with Rights to Both Kuvan (sapropterin dihydrochloride) and Pegvaliase Beyond North America 2016 Full-year Guidance for Kuvan Expected to be Between $320M-$350M including $70M-$80M in New Revenue from RO
Read more →BMRNBioMarin to Present Research Results on Duchenne Muscular Dystrophy and Pompe Disease Programs at the 20th International Congress of the World Muscle Society
SAN RAFAEL, Calif., Sept. 30, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company will present research results at the 20th International Congress of the World Muscle Society, including one oral presentation in Pompe disease and tw
Read more →BMRNBioMarin Receives Favorable Ruling in the Use of Exon 51 Antisense Oligonucleotides Patent Interference
SAN RAFAEL, Calif., Sept. 29, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Patent Trial and Appeal Board (PTAB) issued a decision in favor of BioMarin's claims to the use of exon 51 antisense oligonucleotides to treat Duchenne muscu
Read more →BMRNBioMarin Enrolls First Patient in Phase 1/2 Trial of Gene Therapy Drug Candidate BMN 270 for the Treatment of Hemophilia A
SAN RAFAEL, Calif., Sept. 28, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has enrolled the first patient in a Phase 1/2 trial for BMN 270, an investigational gene therapy for the treatment of patients with hemophilia A. BMN 270 is a
Read more →BMRNBioMarin Announces Kuvan(R) (sapropterin dihydrochloride) Patent Challenge Settlement
SAN RAFAEL, Calif., Sept. 18, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that it has entered into a settlement agreement with Dr. Reddy's Laboratories, Inc. (Dr. Reddy's) that resolves patent litigation in the United States (U.S.) related
Read more →BMRNBioMarin to Attend Upcoming Investor Conferences in September
Morgan Stanley Global Healthcare Conference on September 16 in New York J.P. Morgan 6th Annual U.S. All Stars Conference on September 16 in London Bank of America Merrill Lynch Global Healthcare Conference on September 17 in London Leerink Partners 4th Annual Rare Disease Roun
Read more →BMRNBioMarin Launches kNOWyourDuchenne, Comprehensive Program for Patients With Duchenne Muscular Dystrophy to Understand Their Genetic Mutation
SAN RAFAEL, Calif., Sept. 1, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the introduction of kNOWyourDuchenne, a program to help families and physicians obtain and interpret genetic testing for patients with Duchenne muscular dystrophy. Thi
Read more →BMRNBioMarin Announces Two Oral and 19 Poster Presentations at the Society for the Study of Inborn Errors of Metabolism 2015 Annual Meeting
Oral Presentations Include Long-Term Safety and Efficacy with Pegvaliase for Control of Blood Phenylalanine in Adults with PKU and a Review of the Ongoing Development Program for Reveglucosidase Alfa for Late Onset Pompe Disease Poster Presentations Include 120-Week Safety and E
Read more →BMRNBioMarin Receives Rare Pediatric Disease Designation From FDA for Drisapersen for the Potential Treatment of Duchenne Muscular Dystrophy
SAN RAFAEL, Calif., Aug. 19, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for drisapersen, a potential treatment for patients with Duchenne Muscu
Read more →BMRNBioMarin Announces Second Quarter 2015 Financial Results and Company Update
- In First Six Months of 2015 Vimizim Sales Top $104 million and Total BioMarin Revenue Grows 32% Y/Y - First Patients Enrolled in 4th Cohort of Phase 2 Study of Vosoritide for the Treatment of Achondroplasia Financial Highlights ($ in millions, except per share data, unaudited
Read more →BMRNBioMarin Joins the NASDAQ-100 Index
SAN RAFAEL, Calif., July 27, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that it will become a component of the NASDAQ-100 Index (NASDAQ:NDX), the NASDAQ-100 Equal Weighted Index (NASDAQ:NDXE) and the NASDAQ-100 Ex-Technology Index (NASDAQ:
Read more →BMRNBioMarin Pharmaceutical Inc. to Join the NASDAQ-100 Index Beginning July 27, 2015
NEW YORK, July 22, 2015 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) today announced that BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), will become a component of the NASDAQ-100 Index® (Nasdaq:NDX), the NASDAQ-100 Equal Weighted Index (Nasdaq:NDXE) and the NASDAQ-100 Ex-Technology Inde
Read more →BMRNBioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
ABRAZO Phase 2 Study Meets Protocol-Specified Criteria to Expand Enrollment EMBRACA Phase 3 Study Enrollment Completion Targeted 1H 2016 SAN RAFAEL, Calif., July 20, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced an update on the ABRAZO Phas
Read more →BMRNBioMarin to Host Second Quarter 2015 Financial Results Conference Call and Webcast on Monday, August 3 at 4:30pm ET
SAN RAFAEL, Calif., July 15, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, August 3, at 4:30 p.m. ET to discuss second quarter
Read more →BMRNBioMarin Announces FDA Accepts Drisapersen NDA for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
FDA Grants Priority Review Status FDA PDUFA Date is December 27, 2015 SAN RAFAEL, Calif., June 29, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the submission of a New Dru
Read more →BMRNBioMarin Announces EMA Validates MAA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
SAN RAFAEL, Calif., June 25, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for drisapersen for the treatment of Duchenne Muscular Dystrophy amenab
Read more →BMRNBioMarin CEO Jean-Jacques Bienaime Awarded EY Entrepreneur Of The Year(R) 2015 Award in Northern California in Health and Life Sciences
SAN RAFAEL, Calif., June 15, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that EY awarded BioMarin CEO Jean-Jacques Bienaim the EY Entrepreneur Of The Year 2015 Award in the Health and Life Sciences category in Northern California. The award
Read more →BMRNBioMarin Submits Drisapersen MAA to EMA for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
SAN RAFAEL, Calif., June 8, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for drisapersen, an investigational antisense oligonucleotide drug
Read more →BMRNBioMarin Management to Present at the Deutsche Bank 40th Annual Health Care Conference on May 6th; Bank of America Merrill Lynch 2015 Health Care Conference on May 13th; and, the UBS Global Healthcare Conference on May 19th
SAN RAFAEL, Calif., May 1, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer at BioMarin, will present a company update at the Deutsche Bank 40th Annual Health Care Confere
Read more →BMRNBioMarin Announces First Quarter 2015 Financial Results and Company Update
- Vimizim Sales Top $50 million in First Quarter of 2015 and $127 million in First Four Quarters Since Launch - Full-year Vimizim Guidance Increased to $200 million to $220 million; Full-year Total Revenue Guidance increased to $850 million to $880 million - Rolling NDA Submiss
Read more →BMRNBioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
SAN RAFAEL, Calif., April 27, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced completion of the rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for drisapersen, an investigational exon-
Read more →BMRNBioMarin Presents Data on Duchenne Muscular Dystrophy at the 67th American Academy of Neurology Annual Meeting
Interim analysis of prospective natural history increases understanding of Duchenne muscular dystrophy BioMarin to present data from seven abstracts on Duchenne and Huntington's disease at AAN 2015 SAN RAFAEL, Calif., April 23, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical I
Read more →BMRNBioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SAN RAFAEL, Calif., April 21, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on April 15, 2015, the compensation committee of BioMarin's board of directors approved the grant to 58 newly hired employees of 48,320 restricted share units in
Read more →BMRNBioMarin to Host First Quarter 2015 Financial Results Conference Call and Webcast on Thursday, April 30 at 4:30pm ET
SAN RAFAEL, Calif., April 14, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 30, at 4:30 p.m. ET to discuss first quart
Read more →BMRNBioMarin Announces One Oral and 7 Poster Presentations at the 2015 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
SAN RAFAEL, Calif., March 30, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the results of a post-hoc sub-analysis of the PKU-016 or ASCEND study, the largest randomized controlled trial evaluating neurocognitive outcomes in patients with phe
Read more →BMRNBioMarin Announces Fourth Quarter and Full Year 2014 Financial Results
Total BioMarin Revenue Increased 37% to $751 million in 2014 Rolling Submission of NDA for Drisapersen Underway; Acquisition of Prosensa Complete Financial Highlights ($ in millions, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended Decembe
Read more →BMRNBioMarin Announces 2 Oral and 8 Poster Presentations at Lysosomal Disease Network's 11th Annual WORLD Symposium(TM)
SAN RAFAEL, Calif., Feb. 9, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the company would make two data presenations in addition to presenting eight posters at the Lysosomal Disease Network's 11th Annual WORLD Symposium from February 9
Read more →BMRNBioMarin to Host Fourth Quarter and Full Year 2014 Financial Results Conference Call and Webcast on Wednesday, February 25 at 4:30pm ET
SAN RAFAEL, Calif., Feb. 3, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 25, at 4:30pm ET to discuss fourth quart
Read more →BMRNBioMarin Announces Final Results of Tender Offer for Prosensa's Shares and Completion of Subsequent Offering Period
SAN RAFAEL, Calif., Jan. 30, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the final results of, and the completion of the subsequent offering period relating to, the previously announced tender offer by its subsidiaries, BioMarin Falcons B.V
Read more →BMRNBioMarin Announces Underwriters' Full Exercise of Option to Purchase Additional Shares
SAN RAFAEL, Calif., Jan. 23, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the underwriters for its recently announced public offering of 8,500,000 shares of its common stock (the "Firm Shares") exercised in full their option to purchase
Read more →BMRNBioMarin Announces Completion of Tender Offer for Prosensa's Shares and Commences Subsequent Offering Period
SAN RAFAEL, Calif., Jan. 15, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it completed the initial offering period for the previously announced tender offer for all of the outstanding ordinary shares of Prosensa Holding N.V. (Nasdaq:RNA
Read more →BMRNBioMarin Provides Preliminary Data From Ongoing Phase 1/2 Pivotal Study of BMN 190 for Treatment of CLN2 Disorder, a Form of Batten Disease
SAN RAFAEL, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced interim results from its Phase 1/2 pivotal study for BMN 190 or cerliponase alfa, a recombinant human tripeptidyl peptidase 1 (rhTPP1), to treat of patients with late
Read more →BMRNBioMarin Announces Planned Changes to Board of Directors Leadership Structure
- Jean-Jacques Bienaim to Assume the Role of Chairman - Richard Meier to Assume the Role of Lead Independent Director SAN RAFAEL, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that, after a tenure of more than a decade, Pier
Read more →BMRNBioMarin to Present at the J.P. Morgan Healthcare Conference
SAN RAFAEL, Calif., Jan. 6, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), today announced that Jean-Jacques Bienaim , Chief Executive Officer at BioMarin, will present a company update at the J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan
Read more →BMRNBioMarin Announces Approval of VIMIZIM(R) (elosulfase alfa) in Japan for Treatment of Morquio A Syndrome
SAN RAFAEL, Calif., Dec. 29, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the Ministry of Health, Labor and Welfare granted approval of the registration of VIMIZIM (elosulfase alfa) for the treatment of patients with mucopolysaccharidosis ty
Read more →BMRNBioMarin and Prosensa Announce Expiration of the Hart-Scott-Rodino Waiting Period for BioMarin's Proposed Acquisition of Prosensa
SAN RAFAEL, Calif., Dec. 24, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Prosensa Holding N.V. (Nasdaq:RNA) today announced the expiration of the mandatory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "
Read more →BMRNBioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Brazil for Treatment of Morquio A Syndrome
SAN RAFAEL, Calif., Dec. 10, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Ag ncia Nacional de Vigilancia Sanitaria (ANVISA), or the National Health Surveillance Agency Brazil, has approved VIMIZIM (elosulfase alfa) for the treatment
Read more →BMRNBioMarin to Highlight Breadth of Innovative Development Pipeline at Analyst and Investor Day on December 10th in New York
SAN RAFAEL, Calif., Dec. 9, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) will host an Analyst and Investor Day from 8am (ET) to 1pm (ET) on Wednesday, December 10, 2014 at The Plaza Hotel. BioMarin management and external experts will provide an update to t
Read more →BMRNBioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Australia for Treatment of Morquio A Syndrome
SAN RAFAEL, Calif., Dec. 7, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the Australian Therapeutic Goods Administration (TGA) granted approval of the registration of VIMIZIM (elosulfase alfa) for the treatment of patients with mucopolysacch
Read more →BMRNBioMarin to Host Analyst and Investor Day on December 10th in New York
SAN RAFAEL, Calif., Dec. 3, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) will host an Analyst & Investor Day for the investment community on Wednesday, December 10, 2014 from 8:00am to 1:00pm Eastern Time. Members of BioMarin's management team and industry
Read more →BMRNBioMarin and Prosensa Holding N.V. Reach Agreement on Intended Public Offer for 100% of Prosensa's Outstanding Stock; Will Add Duchenne Muscular Dystrophy Products to Rare-Disease Portfolio
Acquisition of Prosensa provides near-term opportunity to commercialize, if approved, its exon-skipping drug candidate,drisapersen, for Duchenne muscular dystrophy (DMD) Drisapersen is currently under a rolling review as part of a New Drug Application process and has Orphan, Fas
Read more →BMRNBioMarin Announces Third Quarter 2014 Financial Results
- VIMIZIM Sales Top $25 million in Second Full Quarter of Sales - Full Year Total BioMarin Revenue Guidance Increased Financial Highlights ($ in millions, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2014 2013 % Change 20
Read more →BMRNBioMarin to Host Third Quarter 2014 Financial Results Conference Call and Webcast on Thursday, October 23 at 4:30pm ET
SAN RAFAEL, Calif., Oct. 8, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 23, at 4:30 p.m. ET to discuss third quart
Read more →BMRNBioMarin Named by CenterWatch as One of the Fastest Developers of Medicines
SAN RAFAEL, Calif., Sept. 15, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that CenterWatch, a leading source for global clinical trial information, has named it one of the fastest drug developers in the industry. CenterWatch reviewed 307 th
Read more →BMRNBioMarin to Attend Upcoming Investor Conferences in London
- J.P. Morgan Annual U.S. All Stars Conference in London on September 16 - Bank of America Merrill Lynch Global Healthcare Conference in London on September 17 SAN RAFAEL, Calif., Sept. 10, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), today announced tha
Read more →BMRNBioMarin to Present at Upcoming Investor Conferences
- Baird 2014 Healthcare Conference on September 3 - Citi Annual Biotech Conference on September 4 - Morgan Stanley Global Healthcare Conference on September 9 SAN RAFAEL, Calif., Aug. 19, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), today announced that
Read more →BMRNBioMarin Announces Second Quarter 2014 Financial Results
- VIMIZIM Sales Top $14 million in First Full Quarter of Sales - Full Year Total BioMarin Revenue Guidance Increased Financial Highlights ($ in millions, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2014 2013 % Change 2014 2013 % Cha
Read more →BMRNBioMarin Sells Priority Review Voucher for $67.5 Million
SAN RAFAEL, Calif., July 30, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it has sold the Rare Pediatric Disease Priority Review Voucher (PRV) it obtained in February of this year. The Company received the voucher under an FDA program i
Read more →BMRNBioMarin to Host Second Quarter 2014 Financial Results Conference Call and Webcast on Wednesday, July 30 at 4:30pm ET
SAN RAFAEL, Calif., July 9, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today announced that Jean-Jacques Bienaim , Chief Executive Officer of BioMarin, will
Read more →BMRNBioMarin to Present at the Wells Fargo Healthcare Conference on June 17th
SAN RAFAEL, Calif., June 10, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today announced that management will present at the Wells Fargo Healthcare Conference
Read more →BMRNBioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease
SAN RAFAEL, Calif., May 27, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has dosed the first patient with BMN 701 (GILT-tagged Recombinant Human GAA) in the Phase 3 INSPIRE trial for Pompe disease. BMN 701 is a novel fusion protein o
Read more →BMRNBioMarin to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference on May 14th and the UBS Global Healthcare Conference on May 20th
SAN RAFAEL, Calif., May 6, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today announced that Dan Spiegelman, Executive Vice President and Chief Financial Offic
Read more →BMRNBioMarin Announces First Quarter 2014 Financial Results and VIMIZIM(TM) Launch Progress
- Total BioMarin Revenue Grew 18.5% in 1Q14 - 50 Patients Receiving Commercial VIMIZIM as of April 30 - VIMIZIM Approved in the U.S. and E.U.; Commercial Launch Underway in both Regions - PEG PAL Pivotal Study to be Optimized; Data Expected in 4Q15 Financial Highlights ($ in
Read more →BMRNBioMarin Announces European Commission Approval for VIMIZIM(R) (elosulfase alfa) for the Treatment of Morquio A Syndrome in Patients of All Ages
SAN RAFAEL, Calif., April 28, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the European Commission has granted marketing authorization for VIMIZIM (elosulfase alfa), the first specific treatment approved in the European Union for Mucopolysac
Read more →BMRNBioMarin to Host First Quarter 2014 Financial Results Conference Call and Webcast on Thursday, May 1 at 5:00 p.m. ET
SAN RAFAEL, Calif., April 16, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, at 5:00 p.m. ET to discuss first quarter
Read more →BMRNBioMarin Appoints Pioneer in Personalized Medicine, Dennis J. Slamon, M.D., Ph.D., to Board of Directors
SAN RAFAEL, Calif., March 21, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of Dennis J. Slamon, M.D., Ph.D., director of Clinical/Translational Research and d
Read more →BMRNBioMarin to Present at the Barclays Global Healthcare Conference in Miami
SAN RAFAEL, Calif., March 4, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today announced that Dan Oppenheimer, Group Vice President, Development and Portfolio
Read more →BMRNBioMarin Announces Fourth Quarter and Full Year 2013 Financial Results
Total Revenue Grows 9.5% in 2013 U.S. Commercial Launch of VIMIZIM Underway; Positive CHMP Opinion Received February 20 Financial Highlights ($ in millions, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2013 2012 % Change
Read more →BMRNBioMarin to Present at the Cowen Healthcare Conference in Boston
SAN RAFAEL, Calif., Feb. 25, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today announced that Dan Maher, Senior Vice President, Product Development will prese
Read more →BMRNBioMarin Receives Positive Opinion From the CHMP in the European Union for VIMIZIM(TM) (elosulfase alfa) for Morquio A Syndrome
SAN RAFAEL, Calif., Feb. 20, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the company's Marketing Author
Read more →BMRNBioMarin to Present at Two Upcoming Investor Conferences in New York
- 2014 Citi Global Healthcare Conference - 2014 RBC Capital Markets' Global Healthcare Conference SAN RAFAEL, Calif., Feb. 19, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the company will participate in two upcoming investor conferen
Read more →BMRNBioMarin to Discuss FDA Approval of VIMIZIM(TM) and Provide Preliminary 2013 Results
- Company to Host Conference Call and Webcast, Tuesday, February 18 at 8:00 a.m. ET - Review of Preliminary 2013 Results and 2014 Financial Guidance SAN RAFAEL, Calif., Feb. 17, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) will host a conference call and
Read more →BMRNBioMarin Announces FDA Approval for VIMIZIM(TM) (elosulfase alfa) for the Treatment of Patients With Morquio A Syndrome
SAN RAFAEL, Calif., Feb. 14, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved VIMIZIM (elosulfase alfa) for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).
Read more →BMRNBioMarin Presents 15 Abstracts From Basic Research to Clinical Trials at Lysosomal Disease Network's 10th Annual WORLDSymposium(TM)
12 Abstracts on MPS diseases and 3 on Pompe Disease 10-Year Naglazyme (galsulfase) Data Suggests Increased Survival of MPS VI Patients SAN RAFAEL, Calif., Feb. 13, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today 15 data presentations at the L
Read more →BMRNBioMarin Announces Selection of NAGLU Fusion Protein Drug Development Candidate BMN 250 for the Treatment of Sanfilippo B (MPS IIIB)
Potential to Add Fourth MPS Treatment to BioMarin Franchise Two presentations at Lysosomal Disease Network's 10th Annual WORLDSymposium SAN RAFAEL, Calif., Feb. 11, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has selected a new dr
Read more →BMRNBioMarin to Host Fourth Quarter and Full Year 2013 Financial Results Conference Call and Webcast on Monday, March 3 at 8:00 a.m. ET
SAN RAFAEL, Calif., Feb. 5, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, March 3, at 8:00 a.m. ET to discuss fourth quarter a
Read more →BMRNBioMarin Announces Agreement With Repligen for Pre-clinical Compounds
SAN RAFAEL, Calif., Jan. 21, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has entered into an agreement to purchase Repligen Corporation's histone deacetylase inhibitor (HDACi) library and related intellectual property. Potential app
Read more →BMRNBioMarin Doses First Patient in Phase 2 Trial With BMN 111 for the Treatment of Children With Achondroplasia
SAN RAFAEL, Calif., Jan. 14, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has dosed the first child in the Phase 2 trial with BMN 111, an analog of C-type Natriuretic Peptide (CNP), for the treatment of children with achondroplasia.
Read more →BMRNBioMarin Announces Selection of Factor VIII Gene Therapy Drug Development Candidate BMN 270 for the Treatment of Hemophilia A
SAN RAFAEL, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has selected an AAV-factor VIII vector, BMN 270, to develop for the treatment of hemophilia A and has initiated IND-enabling studies. BioMarin expects to initi
Read more →BMRNBioMarin Stock Trading Halted Today
SAN RAFAEL, Calif., Nov. 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that NASDAQ has halted trading of the company's stock. The U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) is m
Read more →BMRNBioMarin Announces French ATU Granted for Vimizim(TM) for the Treatment of Morquio A Syndrome
SAN RAFAEL, Calif., Nov. 15, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the French National Agency for Medicines and Health Products Safety (ANSM) has granted an Autorisation Temporaire d'Utilisation de cohorte (ATU cohort), or Tempor
Read more →BMRNBioMarin Initiates Phase 3 Trial for BMN 673 for the Treatment of Metastatic gBRCA Breast Cancer
SAN RAFAEL, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has dosed the first patient in its Phase 3 program to evaluate BMN 673, its poly ADP-ribose polymerase (PARP) inhibitor, in the treatment of metastatic germlin
Read more →BMRNBioMarin Announces Third Quarter 2013 Financial Results
Total Revenue Grows 6.9% in the Quarter and 8.9% for First Three Quarters of 2013 Advisory Committee Meeting for Vimizim Scheduled for November 19, 2013 Conference Call and Webcast to Be Held Today at 5:00 p.m. ET Financial Highlights ($ in millions, except per share data, una
Read more →BMRNBioMarin Announces Exercise by Underwriters of Full Over-Allotment Option
SAN RAFAEL, Calif., Oct. 10, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced that the underwriters for its recently announced public offering of $680 million of its senior subordinated convertible notes consisting of $340 million 0.75% Senior Subordi
Read more →BMRNBioMarin to Host Third Quarter 2013 Financial Results Conference Call and Webcast on Thursday, October 24 at 5:00 p.m. ET
SAN RAFAEL, Calif., Oct. 10, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 24, at 5:00 p.m. ET to discuss third quar
Read more →BMRNBioMarin Announces Pricing of $340 Million of Senior Subordinated Convertible Notes Due 2018 and $340 Million of Senior Subordinated Convertible Notes Due 2020
SAN RAFAEL, Calif., Oct. 9, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced the pricing on October 8, 2013 of a total offering of $680 million of its senior subordinated convertible notes consisting of $340 million 0.75% Senior Subordinated Convertib
Read more →BMRNBioMarin Announces Proposed Offering of $300 Million of Senior Subordinated Convertible Notes Due 2018 and $300 Million Senior Subordinated Convertible Notes Due 2020
SAN RAFAEL, Calif., Oct. 7, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of $600 million of its senior subordinated convertible notes consisting of $300 million Senior Subordinated Convert
Read more →BMRNBioMarin Provides Updated Phase 1/2 Data on BMN 673 in Breast Cancer at the European Cancer Congress 2013
- Confirmed RECIST Response Rate of 50% in gBRCA Breast Cancer Patients Treated With 1mg/day Phase 3 Dose - Overall Benefit Response Rate With 1mg/day Phase 3 Dose of 86% SAN RAFAEL, Calif., Sept. 29, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today ann
Read more →BMRNBioMarin Doses First Patient in Phase 1/2 Trial With BMN 190 for the Treatment of Neuronal Ceroid Lipofuscinosis Type 2, a Form of Batten Disease
SAN RAFAEL, Calif., Sept. 23, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has dosed the first patient in the Phase 1/2 trial for BMN 190, a recombinant human tripeptidyl peptidase 1 (rhTPP1) for the treatment of patients with neuron
Read more →BMRNBioMarin to Attend NewsMakers in the Biotech Industry Conference
SAN RAFAEL, Calif., Sept. 23, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dan Spiegelman, Chief Financial Officer at BioMarin, will present a company update at the NewsMakers in the Biotech Industry Conference in New York on Friday, Se
Read more →BMRNBioMarin Provides Highlights Ahead of Research and Development Day
Vimizim: Regulatory applications on track. FDA Advisory Committee Meeting expected to be scheduled for November 19, 2013. BMN 701: Maximal Inspiratory Pressure (MIP) accepted by FDA as primary endpoint for Phase 3 Study in Late Onset Pompe Disease. BMN 111: US and European Regu
Read more →BMRNBioMarin to Host a Research and Development Day on September 17th
SAN RAFAEL, Calif., Sept. 5, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) will host a Research and Development Day for the investment community on Tuesday, September 17, 2013 from 8:00 a.m. to 12:00 p.m. at The Plaza Hotel in New York City. Members of BioMa
Read more →BMRNBioMarin to Attend Upcoming Conferences: Citi Biotech Day, Morgan Stanley Global Healthcare Conference and Baird Healthcare Conference
SAN RAFAEL, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that BioMarin will attend the Citi Biotech Day in Boston on September 4th, the Morgan Stanley Global Healthcare Conference in New York City on September 9th and the Ba
Read more →BMRNBioMarin Appoints Richard Ranieri as Senior Vice President, Human Resources and Corporate Affairs
SAN RAFAEL, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the appointment of Richard Ranieri as Senior Vice President, Human Resources and Corporate Affairs. Mr. Ranieri will start on September 4, 2013. "We are very pleased
Read more →BMRNBioMarin Announces Oral Presentation of BMN 673 Most Recent Data on Breast and Ovarian Cancers at the European Cancer Congress 2013
SAN RAFAEL, Calif., Aug. 16, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that its abstract, PARP inhibition with BMN 673 in ovarian and breast cancer patients with deleterious mutations of BRCA1 and BRCA2 has been selected as a late breakin
Read more →BMRNBioMarin Provides BMN 673 Program Update
RECIST Response Rate Increases to 50% in gBRCA Breast Cancer; Study Ongoing Phase 3 Trial to Start in 3Q 2013 National Breast Cancer Coalition Announces Intention to Assist With Trial Recruitment SAN RAFAEL, Calif., July 25, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc
Read more →BMRNBioMarin Announces Second Quarter 2013 Financial Results
Total Revenue Growth Exceeds 10 Percent Phase 3 Trial to Start in 3Q 2013 Conference Call and Webcast to be Held Today at 5:00 p.m. ET Financial Highlights ($ in millions, except per share data, unaudited) Q2 2013 Q2 2012 Percent Change Total BioMarin Revenue $ 136.8 $ 124.0
Read more →BMRNBioMarin to Host Second Quarter 2013 Financial Results Conference Call and Webcast on Thursday, July 25 at 5:00 p.m. ET
SAN RAFAEL, Calif., July 3, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, July 25, at 5:00 p.m. ET to discuss second quarter
Read more →BMRNBioMarin to Present at the Goldman Sachs Global Healthcare Conference
SAN RAFAEL, Calif., June 6, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Joshua Grass, Senior Vice President of Corporate and Business Development at BioMarin, will present a company update at the Goldman Sachs Global Healthcare Confere
Read more →BMRNBioMarin Initiates Phase 3 Trial for PEG-PAL for the Treatment of PKU
SAN RAFAEL, Calif., June 5, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has initiated the Phase 3 program for PEG-PAL (PEGylated recombinant Phenylalanine Ammonia Lyase) for the treatment of phenylketonuria (PKU). "In the Phase 2 t
Read more →BMRNBioMarin Provides Preliminary Data on Ongoing Phase 1/2 Trial for BMN 673 for the Treatment of Solid Tumors at 2013 American Society of Clinical Oncology Annual Meeting
SAN RAFAEL, Calif., June 3, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced an update on the ongoing Phase 1/2 study for its poly ADP-ribose polymerase (PARP) inhibitor BMN 673 for the treatment of solid tumors. BMN 673 has exhibited substantia
Read more →BMRNBioMarin to Present at the Jefferies Global Healthcare Conference
SAN RAFAEL, Calif., May 30, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dan Spiegelman, Chief Financial Officer at BioMarin, will present a company update at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2013 at 8:30
Read more →BMRNBioMarin Announces BMN-673 Data in Breast and Ovarian Cancers to be Released at ASCO
SAN RAFAEL, Calif., May 16, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that data from its ongoing Phase 1/2 trial for BMN-673 for genetically-defined cancers will be released at the American Society of Clinical Oncology (ASCO) meeting in C
Read more →BMRNBioMarin to Present at the UBS Global Healthcare Conference
SAN RAFAEL, Calif., May 14, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dan Spiegelman, Chief Financial Officer at BioMarin, will present a company update at the UBS Global Healthcare Conference on Tuesday, May 21, 2013 at 9:00 a.m. ET
Read more →BMRNBioMarin to Present at the Baird Growth Stock Conference
SAN RAFAEL, Calif., May 2, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dan Maher, Senior Vice President of Product Development at BioMarin, will present a company update at the Baird Growth Stock Conference on Tuesday, May 7, 2013 at 9
Read more →BMRNBioMarin Announces First Quarter 2013 Financial Results
Total Revenue Continues Steady Growth of 10 Percent; Progress on All Aspects of the Business Conference Call and Webcast to Be Held Today at 5:00 p.m. ET Financial Highlights ($ in millions, except per share data, unaudited) Q1 2013 Q1 2012 Percent Change Total BioMarin Reven
Read more →BMRNBioMarin Submits Vimizim MAA to EMA for the Treatment of MPS IVA
SAN RAFAEL, Calif., April 24, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Vimizim (BMN-110, elosulfase alfa), an enzyme replacement the
Read more →BMRNBioMarin to Host First Quarter 2013 Financial Results Conference Call and Webcast on Thursday, April 25 at 5:00 p.m. ET
SAN RAFAEL, Calif., April 4, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 25, at 5:00 p.m. ET to discuss first quarte
Read more →BMRNBioMarin Submits CTA for BMN-190 for Batten Disease
SAN RAFAEL, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has submitted a Clinical Trial Application (CTA) with the Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. for BMN-190, a recombinant hum
Read more →BMRNBioMarin Submits Vimizim BLA to the U.S. FDA for the Treatment of MPS IVA
SAN RAFAEL, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Vimizim (BMN-110, elosulfase alfa), an enzyme replacement th
Read more →BMRNBioMarin Completes Additional Partial Exchange of Convertible Notes Due 2017 for Common Stock
SAN RAFAEL, Calif., March 25, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that an additional six holders of its 1.875% Convertible Senior Subordinated Notes due 2017 have agreed to exchange $75.8 million in aggregate principle amount of the
Read more →BMRNBioMarin to Advance BMN-701 for Pompe Disease to Next Phase of Development
BMN-701 Meaningfully Improves Respiratory Endpoints Phase 2/3 Switch Study Expected to Begin by December 2013 Conference Call and Webcast to Be Held Today at 5:00 p.m. ET SAN RAFAEL, Calif., March 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announce
Read more →BMRNBioMarin Completes Partial Exchange of Convertible Notes Due 2017 for Common Stock
SAN RAFAEL, Calif., March 18, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that seven holders of its 1.875% Convertible Senior Subordinated Notes due 2017 have agreed to exchange approximately $139.2 million in aggregate principal amount of
Read more →BMRNBioMarin to Attend Upcoming Conferences: Cowen Healthcare Conference, Credit Suisse Global Healthcare Conference and Barclays Global Healthcare Conference
SAN RAFAEL, Calif., Feb. 28, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that BioMarin will attend the Cowen Healthcare Conference in Boston on March 4th, the Credit Suisse Global Healthcare Conference in London on March 6th and the Barclay
Read more →BMRNBioMarin Announces Fourth Quarter and Full Year 2012 Financial Results
Total Revenue in 2012 Exceeds $500 Million PEG-PAL End of Phase 2 Meeting Completed, Phase 3 to Begin Next Quarter Conference Call and Webcast to Be Held Today at 5:00 p.m. ET Financial Highlights ($ in millions, except per share data, unaudited) FY 2012 FY 2011 Percent Chan
Read more →BMRNBioMarin Licenses Factor VIII Gene Therapy Program for Hemophilia A From University College London and St. Jude Children's Research Hospital
SAN RAFAEL, Calif., Feb. 21, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has licensed a Factor VIII gene therapy program for hemophilia A from University College London (UCL) and St. Jude Children's Research Hospital. The company ex
Read more →BMRNBioMarin to Attend Upcoming Conferences: Canaccord Genuity Orphan Drug Day, Citibank Global Healthcare Conference and RBC Capital Markets Healthcare Conference
SAN RAFAEL, Calif., Feb. 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that BioMarin will attend the Canaccord Genuity Orphan Drug Day on February 25th, the Citibank Global Healthcare Conference on February 26th and the RBC Capital Market
Read more →BMRNBioMarin Announces Kuvan Significantly Improves Inattentiveness in Kuvan Responding PKU Patients
SAN RAFAEL, Calif., Feb. 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today results from the PKU-016 ASCEND study, the largest randomized controlled trial evaluating neuropsychiatric outcomes in phenylketonuria (PKU) patients treated with the
Read more →BMRNBioMarin to Present at the BIO CEO & Investor Conference
SAN RAFAEL, Calif., Feb. 6, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer at BioMarin, will present a company update at the BIO CEO & Investor Conference in New York on Tuesday, February 12,
Read more →BMRNBioMarin to Host Fourth Quarter and Full Year 2012 Financial Results Conference Call and Webcast on Thursday, February 21 at 5:00 p.m. ET
SAN RAFAEL, Calif., Jan. 31, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 21, at 5:00 p.m. ET to discuss fourth qu
Read more →BMRNBioMarin Acquires Zacharon Pharmaceuticals
Lead Program Focused on the Oral Treatment of MPS III Acquisition Augments Existing Analytical Capabilities and Expertise in Glycobiology SAN RAFAEL, Calif., Jan. 7, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has acquired Zacharo
Read more →BMRNBioMarin to Host a Research and Development Day on December 6th
SAN RAFAEL, Calif., Nov. 27, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) will host a Research and Development Day for the investment community on Thursday, December 6, 2012 from 8:00 a.m. to 12:00 p.m. at The Plaza Hotel in New York City. Members of BioMar
Read more →BMRNBioMarin to Present at the Deutsche Bank BioFEST Conference
SAN RAFAEL, Calif., Nov. 27, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dan Spiegelman, Chief Financial Officer at BioMarin, will present a company update at the Deutsche Bank BioFEST Conference in Boston on Tuesday, December 4, 2012
Read more →BMRNBioMarin to Present at the Piper Jaffray Healthcare Conference
SAN RAFAEL, Calif., Nov. 20, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Joshua Grass, Senior Vice President of Corporate and Business Development at BioMarin, will present a company update at the Piper Jaffray Healthcare Conference in
Read more →BMRNBioMarin to Present at the Credit Suisse Healthcare Conference
SAN RAFAEL, Calif., Nov. 9, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dan Maher, Senior Vice President of Product Development at BioMarin, will present a company update at the Credit Suisse Healthcare Conference in Phoenix on Thursda
Read more →BMRNBioMarin to Present at the Lazard Capital Markets Healthcare Conference
SAN RAFAEL, Calif., Nov. 6, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer at BioMarin, will present a company update at the Lazard Capital Markets Healthcare Conference in New York on Tuesda
Read more →BMRNBioMarin Phase 3 Study of GALNS for the Treatment of MPS IVA Meets Primary Endpoint
Company Plans to Submit Marketing Applications Starting in 1Q 2013 Conference Call and Webcast to be Held Today at 8:30 a.m. ET SAN RAFAEL, Calif., Nov. 5, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the pivotal Phase 3 study of GALN
Read more →BMRNBioMarin Announces Third Quarter 2012 Financial Results
Steady Commercial Growth Supports Advancing Pipeline GALNS Phase 3 Results Expected in 4Q 2012 Conference Call and Webcast to Be Held Today at 5:00 p.m. ET Financial Highlights ($ in millions, except per share data, unaudited) Q3 2012 Q3 2011 Percent Change Total BioMarin Rev
Read more →BMRNBioMarin to Host Third Quarter 2012 Financial Results Conference Call and Webcast on Thursday, October 25 at 5:00 p.m. ET
NOVATO, Calif., Oct. 4, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 25, at 5:00 p.m. ET to discuss third quarter 2
Read more →BMRNBioMarin Announces Phase 1 Results for BMN-111 for Achondroplasia
NOVATO, Calif., Sept. 26, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the completion of a Phase 1 study for BMN-111, an analog of C-type Natriuretic Peptide (CNP), for achondroplasia. The company expects to initiate a Phase 2 trial in mid-2
Read more →BMRNBioMarin Announces Decision to Start Phase 3 Program for PEG-PAL in 2Q 2013
Preliminary Phase 2 Results Indicate Convenient and Accelerated Dosing Regimen Identified Conference Call and Webcast to be Held Today at 5:00 p.m. ET NOVATO, Calif., Sept. 26, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today preliminary resul
Read more →BMRNBioMarin Names Jeff Ajer Senior Vice President, Chief Commercial Officer
NOVATO, Calif., Sept. 5, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jeff Ajer, the current Vice President, Commercial Operations, the Americas, will be promoted to Senior Vice President, Chief Commercial Officer. Mr. Ajer has more tha
Read more →BMRNBioMarin to Present at the NewsMakers Conference
NOVATO, Calif., Aug. 23, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer at BioMarin, will present a company update at the NewsMakers Conference in New York on Friday, September 7, 2012 at 10:
Read more →BMRNBioMarin to Present at the Canaccord Genuity Growth Conference
NOVATO, Calif., Aug. 9, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dan Spiegelman, Chief Financial Officer at BioMarin, will present a company update at the Canaccord Genuity Growth Conference in Boston on Wednesday, August 15, 2012 a
Read more →BMRNBioMarin Announces Second Quarter 2012 Financial Results
Strong Commercial Performance Supporting Development of Five New Chemical Entities With Multiple Key Clinical Readouts by the End of 2012 Conference Call and Webcast to be Held Today at 5:00 p.m. ET Financial Highlights ($ in millions, except per share data, unaudited) Item Q2
Read more →BMRNBioMarin to Host Second Quarter 2012 Financial Results Conference Call and Webcast on Wednesday, August 1 at 5:00 p.m. ET
NOVATO, Calif., July 11, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, August 1, at 5:00 p.m. ET to discuss second quarter
Read more →BMRNBioMarin to Present at the NASDAQ OMX 28th Investor Program
NOVATO, Calif., June 19, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer at BioMarin, will present a company update at the NASDAQ OMX 28th Investor Program in London on Tuesday, June 26, 2012
Read more →BMRNBioMarin to Present at the William Blair Growth Stock Conference
NOVATO, Calif., June 7, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Steve Aselage, Chief Business Officer at BioMarin, will present a company update at the William Blair Growth Stock Conference in Chicago on Thursday, June 14, 2012 at
Read more →BMRNBioMarin Appoints Dan Spiegelman as Executive Vice President and Chief Financial Officer
NOVATO, Calif., May 8, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the appointment of Dan Spiegelman as Executive Vice President and Chief Financial Officer (CFO). Mr. Spiegelman will replace longtime BioMarin CFO, Jeffrey Cooper, at the en
Read more →BMRNBioMarin to Present at the Deutsche Bank Healthcare Conference
NOVATO, Calif., May 8, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Hank Fuchs, M.D., Chief Medical Officer at BioMarin, will present a company update at the Deutsche Bank Healthcare Conference in Boston on Wednesday, May 9, 2012 at 8:0
Read more →BMRNBioMarin Announces First Quarter 2012 Financial Results
Strong Commercial Performance Supporting Development of Five New Chemical Entities With Key Clinical Readouts by the End of 2012 Conference Call and Webcast to Be Held Today at 5:00 p.m. ET Financial Highlights ($ in millions, except per share data, unaudited) Item 1Q 2012 1Q
Read more →BMRNBioMarin to Host First Quarter 2012 Financial Results Conference Call and Webcast on Thursday, April 26 at 5:00 p.m. ET
NOVATO, Calif., April 5, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 26, at 5:00 p.m. ET to discuss first quarter 20
Read more →BMRNBioMarin Completes Enrollment for Phase 3 Trial for GALNS for the Treatment of MPS IVA
Largest Phase 3 ERT Study to Date in a Lysosomal Storage Disease Results Expected in the Fourth Quarter of 2012 NOVATO, Calif., March 8, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that enrollment is complete for the pivotal Phase 3 trial
Read more →BMRNBioMarin to Present at the Barclays Global Healthcare Conference
NOVATO, Calif., March 6, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Joshua Grass, Senior Vice President of Corporate and Business Development at BioMarin, will present a company update at the Barclays Global Healthcare Conference in M
Read more →BMRNBioMarin to Present at the RBC Global Healthcare Conference
NOVATO, Calif., Feb. 22, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer of BioMarin, will present a company update at the RBC Global Healthcare Conference in New York on Tuesday, February 28,
Read more →BMRNBioMarin to Present at the Citi Global Health Care Conference
NOVATO, Calif., Feb. 22, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer of BioMarin, will present a company update at the Citi Global Health Care Conference in New York on Tuesday, February 2
Read more →BMRNBioMarin Announces Chief Financial Officer Jeffrey Cooper to Leave the Company
NOVATO, Calif., Feb. 21, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that Jeffrey Cooper, Senior Vice President and Chief Financial Officer, plans to leave the company. He will stay in his current role through the middle of the year and the
Read more →BMRNBioMarin Initiates Phase 1 Trial for BMN-111 for the Treatment of Achondroplasia
NOVATO, Calif., Feb. 16, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the initiation of a Phase 1 study in healthy volunteers for BMN-111, an analog of C-type Natriuretic Peptide (CNP), for the treatment of achondroplasia. The company expect
Read more →BMRNBioMarin Announces Fourth Quarter and Full Year 2011 Financial Results
R&D Pipeline Advancing; Many Key Clinical Milestones in the Coming Year Net Product Revenue Growth of 18 Percent in 2011 Conference Call and Webcast to be Held Today at 5:00 p.m. ET Financial Highlights ($ in millions, except per share data, unaudited) Item FY 2011 FY 2010 Co
Read more →BMRNBioMarin to Host Fourth Quarter and Full Year 2011 Financial Results Conference Call and Webcast on Thursday, February 16 at 5:00 p.m. ET
NOVATO, Calif., Jan. 23, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaim , Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 16, at 5:00 p.m. ET to discuss fourth quarte
Read more →BMRNBioMarin to Present at the J.P. Morgan Healthcare Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company...
NOVATO, Calif. , Jan. 3, 2012 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime , Chief Executive Officer of BioMarin, will present a company update at the J.P. Morgan Healthcare Conference in San Francisco on Monday, January
Read more →BMRNBioMarin Announces IND for BMN-111 for Achondroplasia is Active BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Investigational New Drug (IND) application for BMN-111, an analog of C-type...
NOVATO, Calif. , Jan. 3, 2012 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that the Investigational New Drug (IND) application for BMN-111, an analog of C-type Natriuretic Peptide (CNP), for achondroplasia is active. The company expects to initiate
Read more →BMRNBioMarin Receives Positive Opinion from European Regulatory Authorities for Expanded Biologics Manufacturing Facility BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
NOVATO, Calif. , Dec. 19, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for the company's manufacturing facility expa
Read more →BMRNHighlights from BioMarin's Research & Development Day BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today hosted a Research and Development Day where members of the company's management team and industry...
NOVATO, Calif. , Dec. 8, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today hosted a Research and Development Day where members of the company's management team and industry experts provided an update on BioMarin's product portfolio and advancements in the re
Read more →BMRNBioMarin Announces Buy Back of Naglazyme Royalties From Adelaide Health Authority BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has completed the buy back of certain intellectual property from SA Pathology, a...
NOVATO, Calif. , Nov. 30, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that it has completed the buy back of certain intellectual property from SA Pathology, a unit of the Central Adelaide Local Health Network located in Adelaide, Australia fo
Read more →BMRNBioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 2 study for GALNS (N-acetylgalactosamine 6-sulfatase) in...
NOVATO, Calif. , Nov. 29, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced the initiation of a Phase 2 study for GALNS (N-acetylgalactosamine 6-sulfatase) in patients under five years of age with mucopolysaccharidosis IVA (MPS IVA). "We expect th
Read more →BMRNBioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the...
NOVATO, Calif. , Nov. 28, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the manufacturing facility expansion in Novato, CA. The facility will support up to $1.0
Read more →BMRNBioMarin to Host a Research and Development Day on December 8th BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) will host a Research and Development Day for the investment community on Thursday, December 8, 2011 from...
NOVATO, Calif. , Nov. 17, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) will host a Research and Development Day for the investment community on Thursday, December 8, 2011 from 8:00 a.m. to 12:00 p.m. at the Four Seasons Hotel in New York City . Members of Bio
Read more →BMRNBioMarin to Present at the Credit Suisse Healthcare Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development at BioMarin, will present a...
NOVATO, Calif. , Nov. 3, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Dan Maher , Senior Vice President of Product Development at BioMarin, will present a company update at the Credit Suisse Healthcare Conference in Phoenix on Thursday, N
Read more →BMRNBioMarin Announces Third Quarter 2011 Financial Results Financial Highlights ($ in millions, except per share data, unaudited) Item Q3 2011 Q3 2010 Comparison Total BioMarin Revenue $113.4 16.0% increase...
NOVATO, Calif. , Oct. 27, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced financial results for the third quarter of 2011. GAAP net loss was $17.7 million ( $0.16 per diluted share) for the third quarter of 2011, compared to GAAP net income of $
Read more →BMRNBioMarin to Host Third Quarter 2011 Financial Results Conference Call and Webcast on Thursday, October 27 at 5:00 p.m. ET BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference...
NOVATO, Calif. , Sept. 29, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime , Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 27 , at 5:00 p.m. ET to discuss third quarte
Read more →BMRNBioMarin to Present at the Jefferies Global Healthcare Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company...
NOVATO, Calif. , Sept. 20, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime , Chief Executive Officer of BioMarin, will present a company update at the Jefferies Global Healthcare Conference in London on Tuesday, Septemb
Read more →BMRNBioMarin to Present at the UBS Global Life Sciences Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Steve Aselage, Chief Business Officer of BioMarin, will present a company update at...
NOVATO, Calif. , Sept. 13, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Steve Aselage , Chief Business Officer of BioMarin, will present a company update at the UBS Global Life Sciences Conference in New York on Tuesday, September 20, 201
Read more →BMRNBioMarin to Present at the Morgan Stanley Global Healthcare Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Hank Fuchs, M.D., Chief Medical Officer of BioMarin, will present a company update...
NOVATO, Calif. , Sept. 7, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Hank Fuchs , M.D., Chief Medical Officer of BioMarin, will present a company update at the Morgan Stanley Global Healthcare Conference in New York on Wednesday, Septem
Read more →BMRNBioMarin to Present at the Baird Health Care Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update...
NOVATO, Calif. , Aug. 30, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Jeffrey Cooper , Chief Financial Officer of BioMarin, will present a company update at the Baird Health Care Conference in New York on Wednesday, September 7, 2011 at
Read more →BMRNBioMarin to Present at the Wedbush Life Sciences Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company...
NOVATO, Calif. , Aug. 9, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime , Chief Executive Officer of BioMarin, will present a company update at the Wedbush Life Sciences Conference in New York on Tuesday, August 16, 20
Read more →BMRNBioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100) BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced an update on the GALNS Phase 1/2 extension study (MOR-100) in which patients have...
NOVATO, Calif. , July 28, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced an update on the GALNS Phase 1/2 extension study (MOR-100) in which patients have continued treatment on an ongoing basis. Patients originally enrolled in the initial Phas
Read more →BMRNBioMarin Announces Second Quarter 2011 Financial Results Financial Highlights ($ in millions, except per share data, unaudited) Item Q2 2011 Q2 2010 Comparison Total BioMarin Revenue $110.6 20.2% increase...
NOVATO, Calif. , July 28, 2011 /PRNewswire/ -- * Net product transfer revenue had no impact on net Aldurazyme revenue to BioMarin in the second quarter of 2011 and a negative $0.2 million impact on net Aldurazyme revenue to BioMarin in the second quarter of 2010. BioMarin Pharm
Read more →BMRNBioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP)...
NOVATO, Calif. , July 14, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies. A Phas
Read more →BMRNBioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference...
NOVATO, Calif. , June 30, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime , Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, July 28 , at 5:00 p.m. ET to discuss second quarter 2
Read more →BMRNBioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has entered into a definitive agreement to acquire a bulk biologics manufacturing ...
NOVATO, Calif. , June 23, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that it has entered into a definitive agreement to acquire a bulk biologics manufacturing plant from Pfizer, located in Shanbally, Cork, Ireland . The plant, which was comp
Read more →BMRNBioMarin to Present at the William Blair Growth Stock Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a...
NOVATO, Calif. , June 8, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Dan Maher , Senior Vice President of Product Development of BioMarin, will present a company update at the William Blair Growth Stock Conference in Chicago on Wednesday
Read more →BMRNBioMarin Initiates Phase 3 Trial for Amifampridine Phosphate for the Treatment of LEMS BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the first patient has been dosed in the Phase 3 trial for amifampridine phosphate...
NOVATO, Calif. , June 7, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that the first patient has been dosed in the Phase 3 trial for amifampridine phosphate (3,4-diaminopyridine phosphate) for the treatment of patients with Lambert-Eaton Myast
Read more →BMRNBioMarin to Present at the Jefferies Global Healthcare Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update...
NOVATO, Calif. , May 31, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Jeffrey Cooper , Chief Financial Officer of BioMarin, will present a company update at the Jefferies Global Healthcare Conference in New York on Tuesday, June 7, 2011 a
Read more →BMRNBioMarin to Present at the UBS Global Specialty Pharmaceuticals Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company...
NOVATO, Calif. , May 18, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime , Chief Executive Officer of BioMarin, will present a company update at the UBS Global Specialty Pharmaceuticals Conference in London on Wednesday
Read more →BMRNBioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company...
NOVATO, Calif. , May 3, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime , Chief Executive Officer of BioMarin, will present a company update at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on Tue
Read more →BMRNBioMarin Announces First Quarter 2011 Financial Results Financial Highlights ($ in millions, except per share data, unaudited) Item Q1 2011 Q1 2010 Comparison Total BioMarin Revenue $109.5 28.8% increase...
NOVATO, Calif. , April 28, 2011 /PRNewswire/ -- Financial Highlights ($ in millions, except per share data, unaudited) BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced financial results for the first quarter of 2011. GAAP net loss was $4.4 million ( $0.04 per dilute
Read more →BMRNBioMarin to Present at the Deutsche Bank Healthcare Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Steve Aselage, Chief Business Officer of BioMarin, will present a company update at...
NOVATO, Calif. , April 26, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Steve Aselage , Chief Business Officer of BioMarin, will present a company update at the Deutsche Bank Healthcare Conference in Boston on Tuesday, May 3, 2011 at 3:30
Read more →BMRNBioMarin to Host First Quarter 2011 Financial Results Conference Call and Webcast on Thursday, April 28 at 5:00 p.m. ET BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference...
NOVATO, Calif. , March 28, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime , Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 28 , at 5:00 p.m. ET to discuss first quarter
Read more →BMRNFirst-of-Its-Kind Study Suggests Importance of Routine Mental Health Screening in the Care of Patients Suffering From Genetic Disease PKU BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract...
NOVATO, Calif. , March 18, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract (Abstract #91 , Mental Health Screening in Phenylketoniuria (PKU) Clinic ) present
Read more →BMRNBioMarin to Present at the Barclays Global Healthcare Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company...
NOVATO, Calif. , March 8, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime , Chief Executive Officer of BioMarin, will present a company update at the Barclays Global Healthcare Conference in Miami on Tuesday, March 15,
Read more →BMRNBioMarin to Present at the Cowen Health Care Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a...
NOVATO, Calif. , March 1, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Dan Maher , Senior Vice President of Product Development of BioMarin, will present a company update at the Cowen Health Care Conference in Boston on Tuesday, March 8,
Read more →BMRNBioMarin to Present at the Citi Global Healthcare Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Corporate and Business Development of BioMarin, will ...
NOVATO, Calif. , Feb. 22, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Joshua Grass , Vice President of Corporate and Business Development of BioMarin, will present a company update at the Citi Global Healthcare Conference in New York Cit
Read more →BMRNBioMarin Announces Fourth Quarter and Full Year 2010 Financial Results Financial Highlights ($ in millions, except per share data, unaudited) Item FY 2010 FY 2009 Comparison Total BioMarin Revenue $376.3 15.9% increase...
NOVATO, Calif. , Feb. 17, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced financial results for the fourth quarter and full year 2010. GAAP net loss was $12.2 million ( $0.11 per diluted share) for the fourth quarter of 2010, compared to GAAP ne
Read more →BMRNBioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has initiated a pivotal Phase 3 trial for N-acetylgalactosamine 6-sulfatase...
NOVATO, Calif. , Feb. 1, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that it has initiated a pivotal Phase 3 trial for N-acetylgalactosamine 6-sulfatase (GALNS or BMN 110), intended for the treatment of the lysosomal storage disorder Mucopoly
Read more →BMRNBioMarin to Host Fourth Quarter and Full Year 2010 Financial Results BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference...
NOVATO, Calif. , Jan. 24, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime , Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 17 , at 5:00 p.m. ET to discuss fourth quart
Read more →BMRNBioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has initiated a Phase 1/2 trial for BMN 701, a novel fusion protein of...
NOVATO, Calif. , Jan. 19, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that it has initiated a Phase 1/2 trial for BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA) in development for the tre
Read more →BMRNBioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 1/2 trial for BMN 673, a poly ADP-ribose polymerase (PARP)...
NOVATO, Calif. , Jan. 11, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced the initiation of a Phase 1/2 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor in development for the treatment of genetically-defined cancers. "PARP inihi
Read more →BMRNBioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company...
NOVATO, Calif. , Jan. 5, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime , Chief Executive Officer of BioMarin, will present a company update at the J.P. Morgan 29th Annual Healthcare Conference in San Francisco on Mond
Read more →BMRNMHRA Issues Notice of Acceptance for Phase 3 Trial of GALNS for the Treatment of MPS IVA BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has...
NOVATO, Calif. , Dec. 14, 2010 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of
Read more →BMRNBioMarin to Present at the Deutsche Bank 2010 BioFEST Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Corporate and Business Development of BioMarin, will ...
NOVATO, Calif. , Dec. 7, 2010 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Joshua Grass , Vice President of Corporate and Business Development of BioMarin, will present a company update at the Deutsche Bank 2010 BioFEST Conference in Boston on
Read more →BMRNMHRA Completes Review of CTA and Issues Notice of Acceptance for BMN 673 for Genetically-Defined Cancers BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has...
NOVATO, Calif. , Dec. 2, 2010 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and has issued a notice of accepta
Read more →BMRNBioMarin to Present at the Piper Jaffray Healthcare Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update...
NOVATO, Calif. , Nov. 29, 2010 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Jeffrey Cooper , Chief Financial Officer of BioMarin, will present a company update at the Piper Jaffray Healthcare Conference in New York City on Tuesday, November 30
Read more →BMRNBioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that six holders of its 2.50% Convertible Senior Subordinated Notes due 2013 have agreed...
NOVATO, Calif. , Nov. 9, 2010 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that six holders of its 2.50% Convertible Senior Subordinated Notes due 2013 have agreed to exchange $87.0 million in aggregate principal amount of the notes for a
Read more →BMRNBioMarin Announces Third Quarter 2010 Financial Results Financial Highlights ($ in millions, except per share data, unaudited) Item Q3 2010 Q3 2009 Comparison Total BioMarin Revenue $97.8 21.0% increase...
NOVATO, Calif. , Oct. 28 /PRNewswire-FirstCall/ -- Financial Highlights ($ in millions, except per share data, unaudited) BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced financial results for the third quarter of 2010. GAAP net income was $217.3 million ( $1.68 per
Read more →BMRNBioMarin Announces Program for BMN-111 for the Treatment of Achondroplasia BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced its program for BMN-111, a peptide therapeutic for the treatment of achondroplasia....
NOVATO, Calif. , Oct. 19 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced its program for BMN-111, a peptide therapeutic for the treatment of achondroplasia. BioMarin plans to file an IND in the fourth quarter of 2011 and to initiate a Phase
Read more →BMRNBioMarin to Host a Research and Development Day on October 19th BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) will host a Research and Development Day for the investment community on Tuesday, October 19, 2010 from...
NOVATO, Calif. , Oct. 14 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) will host a Research and Development Day for the investment community on Tuesday, October 19, 2010 from 8:00 a.m. to 12:00 p.m. at the St. Regis Hotel in New York City . Members of Bio
Read more →BMRNBioMarin to Host Third Quarter 2010 Financial Results Conference Call and Webcast on Thursday, October 28 at 5:00 p.m. ET BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference...
NOVATO, Calif. , Oct. 7 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime , Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 28 , at 5:00 p.m. ET to discuss third quar
Read more →BMRNBioMarin Appoints William Young and Kenneth Bate to Its Board of Directors BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today the appointment of William D. Young and Kenneth M. Bate to its Board of Directors. We...
NOVATO, Calif. , Sept. 23 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today the appointment of William D. Young and Kenneth M. Bate to its Board of Directors. "We are extremely pleased to welcome William Young and Kenneth Bate to our Board of
Read more →BMRNBioMarin to Present at the UBS Global Life Sciences Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President, Corporate and Business Development of BioMarin, will...
NOVATO, Calif. , Sept. 14 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Joshua Grass , Vice President, Corporate and Business Development of BioMarin, will present a company update at the UBS Global Life Sciences Conference in New Yor
Read more →BMRNBioMarin to Present at the Stifel Nicolaus Healthcare Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a...
NOVATO, Calif. , Sept. 9 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Dan Maher , Senior Vice President of Product Development of BioMarin, will present a company update at the Stifel Nicolaus Healthcare Conference in Boston on Frida
Read more →BMRNBioMarin to Present at the Robert W. Baird Healthcare Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company...
NOVATO, Calif. , Sept. 8 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime , Chief Executive Officer of BioMarin, will present a company update at the Robert W. Baird Healthcare Conference in New York City on Wednesd
Read more →BMRNBioMarin to Present at the Morgan Stanley Global Healthcare Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company...
NOVATO, Calif. , Sept. 7 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime , Chief Executive Officer of BioMarin, will present a company update at the Morgan Stanley Global Healthcare Conference in New York City on T
Read more →BMRNResults From Investigator-Sponsored Trials Presented at SSIEM Conference BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that results from investigator-sponsored studies on Kuvan (sapropterin dihydrochloride)...
NOVATO, Calif. , Sept. 1 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that results from investigator-sponsored studies on Kuvan (sapropterin dihydrochloride) are being presented at the 2010 Annual Symposium of the Society for The Study of
Read more →BMRNBioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has received orphan drug designation from the U.S. Food and Drug Administration...
NOVATO, Calif. , Aug. 30 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor 2 and alpha gluc
Read more →BMRNBioMarin Acquires ZyStor Therapeutics, Inc. BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has acquired ZyStor Therapeutics, Inc. (ZyStor), a privately-held biotechnology...
NOVATO, Calif. , Aug. 17 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that it has acquired ZyStor Therapeutics, Inc. (ZyStor), a privately-held biotechnology company developing enzyme replacement therapies (ERT) for the treatment of lysos
Read more →BMRNBioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the first subject has initiated treatment in a Phase 3b study (PKU-016) to evaluate...
NOVATO, Calif. , Aug. 17 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that the first subject has initiated treatment in a Phase 3b study (PKU-016) to evaluate the effects of Kuvan (sapropterin dihydrochloride) on neuropsychiatric symptoms
Read more →Competitive Position
How BMRN ranks across every disease it competes inCompetitive Position is a premium feature
See how BMRN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial